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5Abstract
Genotype 3 hepatitis C accounts for 35% of cases of chronic hepatitis C infection in the United
Kingdom. At the time this work was commenced there were limited treatment options for patients
with genotype 3 hepatitis C with advanced liver disease who had failed treatment with interferon
and ribavirin. Approximately 30% of patients with genotype 3 hepatitis C demonstrated a significant
virological response on a clinical trial with two weeks of treatment with telaprevir monotherapy.
A novel in vitro capture fusion assay had been developed by our group which enabled assessment of
in-vitro hepatitis C virus (HCV) sensitivity to antiviral drugs and indicated that sensitivity to telaprevir
could be pre-determined by viral phenotyping.
A multi-centre open label clinical trial was undertaken to evaluate whether the addition of twelve
weeks of treatment with telaprevir to standard treatment with 24 weeks interferon and ribavirin
was of benefit to patients with advanced liver disease who had previously failed treatment with
interferon and ribavirin and whether the ‘capture fusion’ assay could identify patients likely to
respond. In addition, we assessed the value of next generation sequencing as a predictor of clinical
response.
The main findings were that four out of fourteen patients (29%) achieved an SVR. The capture fusion
assay identified two of these four patients as having HCV that was sensitive to telaprevir in vitro. No
pre-treatment substitutions were identified on next generation sequencing that correlated with the
clinical outcome of treatment.
Trial recruitment was discontinued when sofosbuvir containing all oral regimens became available
for patients eligible to participate in the trial.  Although telaprevir may be of benefit to a proportion
of patients with genotype 3 hepatitis C, advances in the treatment of hepatitis C have resulted in
newer, more potent, direct acting antiviral drugs superseding telaprevir.
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Chapter 1: Introduction
1.1 Hepatitis C virus discovery
The hepatitis C virus (HCV) was first identified in 19891, and is a significant cause of chronic liver
disease worldwide. Up to 170 million people may be affected (approximately 2 to 3% of the global
population2). Most hepatitis C infected patients (85%) develop chronic infection, and 20% of these
individuals will develop liver cirrhosis after 20 years of infection. This can potentially lead to
significant morbidity and mortality, with decompensation of liver disease, hepatocellular carcinoma,
and the need for liver transplantation.
1.2 Viral structure and replication
Hepatitis C virus is a positive strand RNA virus in the flaviviridiae 3 family with a genome
approximately 10,000 nucleotides long4 . This encompasses an open reading frame (ORF) that is
translated via an internal ribosome entry site located in HCV 5’ untranslated region (UTR) resulting in
a polyprotein approximately 3000 amino acids long5. This polyprotein is processed by cellular
(signalase and signal peptidase)6,7 and viral proteases (NS2-NS3 and NS3-NS4A) into structural (core,
E1, and E2) and non-structural (p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B)  proteins8 (figure 1.1).
The core protein contains two domains. The first domain is involved in RNA binding and
nucleocapsid formation, while the second domain is thought to mediate the interaction between the
HCV core protein, lipid droplets and the endoplasmic reticulum9,10. The remaining structural proteins
encoded by the HCV genome are the envelope glycoproteins E1 and E2. Both E1 and E2 are
transmembrane proteins. They interact to facilitate HCV binding to cell surface proteins on
hepatocytes to enable viral entry into cells, and fusion of the viral lipid envelope with the host
endosomal membrane11,12. The p7 protein can form ion channels in membranes and is from a group
of viral proteins called viroporins.
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Figure 1.1 HCV genome and protein function
These proteins modulate membrane permeability to facilitate virus entry, assembly or release13. The
NS2 protein is involved in HCV polyprotein processing and particle formation. It comprises of a
membrane domain which is involved in viral particle formation and a protease domain14. The
protease domain is involved in the cleavage of the viral protein between NS2 and NS315. The HCV
NS3 protein is a 70kDa protein which comprises of an N terminal protease (with NS4A acting as a
cofactor) and a C terminal helicase. The NS3 protease is involved in viral polyprotein processing and
is needed for cleavage of the viral polyprotein at NS3/NS4, NS4/NS5 and NS5A/NS5B16,17. The
protease component of NS3 is a serine protease, which forms a chymotrypsin like fold with two β
barrel subunits. A zinc ion (Zn2+) stabilises the structure with a binding site comprising of Cys 97, Cys
99, Cys 145 and His 14918. The catalytic triad of the NS3 protein is formed by His 57, Asp 81 and Ser
13919 (figure 1.2). NS4A is involved as a co-factor for the NS3 protease by providing one of the β
strands for the N-terminal β barrels of the NS3 protease. The N terminal portion of NS4A is
hydrophobic and forms a transmembrane α helix which ensures that the NS3/4A complex is
membrane associated20. The NS3/4A protease binding site accommodates six amino acids (although
15
proteolytic activity is greatest when substrates include 10 amino acids). In addition to its role in
processing the HCV polyprotein, the NS3/4A protease also targets host substrates and is involved in
modulating the host immune response to HCV infection.
Figure 1.2 A) NS3 domains and catalytic triad B) NS3 crystal structure (amended from Morikawa
2011)
NS4B is an endoplasmic reticulum (ER) membrane associated protein which is involved in
remodelling of the ER to form a membranous web21, which is needed for viral replication. The NS5A
protein comprises of three domains and has multiple functions including RNA replication (domains I
and II) and viral packaging (domain III)22. It interacts with several host proteins to achieve these
functions, including cyclophilin A and phosphatidylinositol- 4 kinase IIIα23,24. The final non-structural
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protein is NS5B which is an RNA dependent RNA polymerase (RdRp). The NS5B is similar to other
viral RdRp enzymes and has finger, palm and thumb subdomains, with highly conserved RdRp motifs
in the palm region. The NS5B protein plays an integral role in RNA replication and therefore viral
replication25–27.
1.3 HCV life cycle
HCV virions are 50-80nm in diameter28, with E1 and E2 glycoproteins embedded in the viral
membrane surrounding a nucleocapsid composed of the core protein and the HCV RNA genome29.
HCV virions associate with low density and very low density lipoproteins in a lipoviral particle28. It is
notable that the HCV virion size and density is similar to that of very low-density lipoproteins and
this may be due to proteins involved in the processing of lipoproteins also being involved in HCV
infectivity, or the composition of HCV virions may enable the virus to evade the host immune
response.
1.3.1 HCV cell entry and replication
HCV entry into hepatocytes involves many cellular molecules (an overview of the HCV intracellular
lifecycle is shown in figure 1.3). The HCV envelope proteins E1 and E2 play an important part in HCV
entry. They are involved in the binding of HCV to cell surface receptors, followed by the fusion of the
HCV viral particle and the host cell endosomal membrane. The host cell surface proteins Scavenger
Receptor B130 (SR-B1), CD-8131, Claudin-132 and Occludin33 have been implicated in HCV cell entry.
Due to the close association between HCV and lipoproteins, the low density lipoprotein receptor
(LDLR) was thought to have been involved in HCV entry into cells, although this entry pathway does
not appear to be involved in HCV infection34. Similarly, the Niemann Pick C1-like protein 1
cholesterol transporter has been identified as being involved in viral entry although it’s role in HCV
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entry is unclear35. The E2 protein is thought to bind to CD-81, and interaction occurs between CD-81
and Claudin-136.
Figure 1.3 Overview of the intracellular lifecycle of HCV
Viral uptake into cells occurs via clathrin mediated endocytosis37, and virions are then transported to
early endosomes within cells38. The HCV virion then undergoes membrane fusion in the endosomes
and HCV RNA is translated at the endoplasmic reticulum. Following processing of the HCV
polyprotein by host proteins (e.g. signal peptidase) and viral proteins (NS2, NS3/4A), HCV proteins
associate with the endoplasmic reticulum. NS3/4A, NS4B, NS5A and NS5B form the viral replication
complex. NS4B mediated changes in the endoplasmic reticulum occur to create a complex
membranous web, and NS5A induces formation of double membrane vesicles21. Host proteins such
as phosphotidyl-inositol-4-kinase III, vesicle associated membrane associated proteins and
cyclophilin A interact with HCV viral proteins to modulate the structure and lipid composition of the
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membranous web. HCV affects the expression of host genes involved in intracellular lipid
metabolism, resulting in the intracellular accumulation of lipid39 to aid HCV viral replication. In
addition to the membranous web, lipid droplets (containing triglycerides and cholesterol esters) also
play an important role in viral replication and virion assembly40.
The HCV core protein interacts with the HCV genomic RNA to form the nucleocapsid. HCV core
protein then interacts with lipid drops and results in the recruitment of other viral proteins needed
for virion assembly (in particular NS2, NS3, and NS5A)40. NS2 acts a scaffold co-ordinating the
interaction between structural and non-structural proteins to lead to encapsidation of viral RNA41.
The production of viral particles is closely linked to the pathway used for production of VLDL42. Many
apolipoproteins are associated with the HCV viral particles (including apolipoprotein A, B, C and E),
although apolipoprotein E is thought to be the most important in affecting viral infectivity42.
Following formation of viral particles at the endoplasmic reticulum, virions are transported to the
Golgi apparatus and subsequently secreted (in a manner similar to VLDL secretion). Intracellular
vesicular trafficking involves proteins such as the Rab GTPases and vesicular associated membrane
protein 1 (VAMP1) which facilitate virion transport to the cell membrane and subsequent release of
viral particles43,44.
1.4 Epidemiology
The prevalence of hepatitis C infection worldwide is approximately 1.3-3.0%, corresponding to 92-
170 million infected individuals45,46. Historically, the major sources of HCV transmission were
exposure to contaminated blood or blood products (in particular affecting patients with inherited
bleeding conditions who received pooled blood products infected with hepatitis C), use of illicit
injectable drugs and nosocomial infections (due to re-use and inadequate sterilisation of needles,
particularly in countries such as Egypt and Pakistan), along with the risk of transmission between
patients who receive haemodialysis). In Egypt the use of unsterilised needles in the treatment of
19
endemic shistosomiasis has resulted in a HCV prevalence of over 14%45. In the United Kingdom an
estimated 215,000 individuals have chronic hepatitis C (approximately 0.4% of the UK population),
with genotype 1 and 3 accounting for the majority of cases (45% and 44% respectively)47. The
estimated prevalence of HCV infection in persons who inject drugs is 50%, and this accounts for the
majority of current HCV transmission in the UK48. Hepatitis C infection has an increased prevalence in
particular demographic groups, with people of Asian or British Asian origin having an HCV prevalence
of 2.2%, similarly people of Eastern European origin had a prevalence of 3.3% in the UK. Sexual and
perinatal transmission of HCV is rare. The routine testing of donated blood since 1991 in the United
Kingdom has almost eliminated the transmission of HCV via blood transfusion and products.
1.5 Natural history
The majority (approximately 85%) of patients who are infected with hepatitis C will develop chronic
infection. As a result of this, approximately 20-25% of patients with chronic HCV infection will
develop liver cirrhosis in the subsequent 20 years. In patients who have liver cirrhosis due to
hepatitis C, 4% will develop decompensated cirrhosis every year, and in patients with
decompensated cirrhosis annual mortality is approximately 15% without liver transplantation.
Hepatitis C accounted for 16% of liver transplants undertaken between 1996 and 201249 in the
United Kingdom. In addition to decompensation, 1.5-2.5% of patients with HCV related liver cirrhosis
will develop hepatocellular carcinoma each year50. Patients with concomitant steatohepatitis (both
alcohol and non-alcohol related) or hepatitis B or HIV co-infection are at increased risk of liver
disease progression. In addition to causing chronic liver disease, hepatitis C infection is also
associated with extrahepatic conditions. These include: haematological conditions such as
cryoglobulinaemia and non-Hodgkin’s lymphoma; general systemic symptoms including fatigue,
arthralgia and fibromyalgia as well as other rare conditions such as vasculitis and porphyria cutanea
tarda51.
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1.6 HCV genotypes
Six major genotypes of Hepatitis C have been identified (genotypes 1-6), and recently a seventh has
been proposed. The HCV RNA polymerase has a high error rate that results in error prone replication
and therefore a variety of Hepatitis C subtypes exist within each of these genotypes (figure 1.4).
Figure 1.4 Phylogenetic tree of the 6 major HCV genotypes and subtypes identified for each
genotype (adapted from Simmonds et al. 2005)
The sequence divergence between genotypes is approximately 30%, whilst sequence divergence
between subtypes can be up to 20%52. The distribution of each of these genotypes varies by
geographical regions53 (figure 1.5). Globally, genotype 1 hepatitis C accounts for the greatest
proportion of HCV infection (46%), followed by genotype 3 (22%), genotype 2 (13%), genotype 4
(13%), genotype 6 (2%), and genotype 5 (1%), with the remaining 3% comprising of patients with
undefined/combination infections. There are, however, significant regional variations with genotype
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1 accounting for 62-71% of infections in Europe and North America, whilst genotype 3 accounted for
a greater proportion of infections in South Asia (39%).
Figure 1.5 Prevalence of different HCV genotypes in different global regions (adapted from
Messina et al. 2015)
In the middle east genotype 4 hepatitis C accounted for 71% of infections, although this is in part
due to the high prevalence of genotype 4 hepatitis C infection in Egypt; once Egypt has been
excluded the proportion of genotype 4 hepatitis in the middle east is lower (34%)46.
1.7 Immune response to HCV infection
1.7.1 Innate immunity
Innate immune responses are the first line of defence against infection. Interferons (IFNs) are the
central cytokines in triggering an antiviral state in cells along with activating other immune cells
involved in the innate immune response. Type I IFNs (IFNα and IFNβ) and Type III IFNs (IFNλ1 (IL29),
λ2 (IL28A), and λ3 (IL28B)) are produced by cells infected by viruses and by macrophages and
dendritic cells. Macrophages and dendritic cells sample material from their surroundings and can
detect viral fragments or intact viral particles. Type II IFN (IFNγ) is produced by natural killer cells and
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natural killer T cells as part of the innate immune response and by antigen specific T cells (CD4+ Th1
and CD8+ cytotoxic T lymphocytes)54,55. Viral infections are sensed by the toll like receptor (TLR)
dependent pathway and by binding of viral RNA to retinoic acid inducible gene-1 (RIG-1) and
melanoma differentiation antigen 5 (MDA5)56,57. These pathways result in activation of nuclear
factor κβ (NF-κβ) and interferon regulatory factor (IRF) 3 and 7. IRF3 and NF-κβ result in transcription
of genes responsible for the Type I and Type III IFN response58,59 (figure 1.6).
Figure 1.6 Simplified overview of the innate immune response to HCV infection
The interferons produced bind to IFN receptors (comprising of interferon alpha/beta receptor
subunits 1 and 2 (IFNR1 and 2)) which connect to the Jak-STAT pathway and result in transcription of
IFN stimulated genes (ISGs). Signalling through the Jak-STAT pathway is regulated by inhibitors such
as suppressor of cytokine signalling (SOCS)60 and ubiquitin specific peptidase 18 (USP-18)61.
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Early on during HCV infection ISG induction is thought to be related to the HCV viral load62. In
patients with chronic HCV infection, however, ISG induction varies markedly and is unrelated to viral
load. Allelic variants near the IFNλ4 locus are associated with ISG induction63, and it is postulated
that the HCV NS3/4A protease cleaves mitochondrial anti-viral signalling protein (MAVS)64 and the
Toll-IL-1 receptor-domain containing adaptor-inducing IFNβ (TRIF)65. These molecules are involved in
the signalling pathways needed for activation of interferon stimulated genes, and by inactivating
them HCV manages to interfere with the host innate immune response. Interestingly patients with
chronic hepatitis C with an activated interferon system are poor responders to IFNα based
treatment. Treatment with IFN in these patients did not increase ISG expression in hepatocytes.
USP18 is thought to play an important role in this process66.
Genetic variants near the IFNλ3 and IFNλ4 gene have been identified which are associated with
response to interferon-based treatment. Paradoxically, the alleles resulting in increased IFNλ4
production are associated with decreased spontaneous clearance of HCV and a lower SVR to
treatment with pegylated IFN and ribavirin67,68. This may be a result of increased interferon
production exerting selection pressure resulting in the evolution of viral strains resistant to
interferon in these individuals.
1.7.2 Innate cellular response
Natural killer (NK) cells are granular lymphocytes which account for the majority of the innate
immune cells in the liver. They play an important role in the control of viral infections by either
direct cytolytic (e.g. TRAIL or perforin mediated) or non-cytolytic (e.g. IFN and TNFα mediated)
pathways69. In chronic hepatitis C, NK cells are activated but may display alterations in phenotype
with impaired anti-viral function70. Part of this may be due to a decreased ability of NK cells from
patients with chronic hepatitis C to secrete IFNγ.
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1.8 Adaptive immune response
1.8.1 T lymphocyte response
Successful immune responses to HCV target a wide range of viral epitopes, likely minimising viral
escape options, and are sustained until HCV clearance. In contrast, this broad T cell response often
wanes in infections that progress to chronicity. T cell exhaustion is thought to contribute to
persistent HCV infection55. Cytolytic activity of T cells is lost early in the development of T cell
exhaustion71. Additionally, in chronic HCV , HCV specific CD4+ cells express higher levels of inhibitory
co-receptors such as PD-1 which may impair CD8+ T cell function, resulting in impaired T cell
proliferation and thereby providing a further mechanism by which the spontaneous HCV clearance
rate is reduced72. The high HCV replication rate (up to 1012 viral particles per day) in an infected
individual, coupled with its error prone RNA polymerase generates a large pool of sequence
variation in an infected individual. T cell responses targeting specific epitopes exert selection
pressure, favouring variants lacking those epitopes. Viable mutations are those that maintain
replicative fitness whilst permitting immunological escape.
1.8.2 B cell and antibody response
Antibody responses to HCV occur several weeks after the onset of viraemia and target structural and
non-structural proteins. Neutralising antibodies targeting E1 and E2 develop in most infected
patients. Acutely infected patients who spontaneously clear the virus develop broad, cross reactive
neutralising antibodies73, while early neutralising antibody responses are weak in patients who
progress to chronic infection74. HCV escapes from sterilising humoral immunity by several methods,
such as rapid sequence variation, stimulating the production of interfering antibodies75, masking
neutralisation epitopes (e.g. by glycosylation) and by concealing itself within lipoviral particles76,77.
Many antibody responses towards HCV target the highly variable region near the amino terminus of
E2, which may act as a decoy, while conserved neutralisation epitopes may be concealed.
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Continuous generation of quasispecies furthermore enables viral escape from neutralising antibody
mediated immunity.
High HCV viral replication with the generation of multiple quasispecies along with the ability of the
virus to interfere with both the innate and adaptive immune response results in the majority of
individuals infected with HCV developing chronic infection. Similarly, these mechanisms affect the
response to treatments targeting the host immune response (e.g. IFN based treatment) and may
account for the poor success rate of host targeting treatment in certain populations.
1.9 HCV inhibition of host antiviral response
HCV inhibits the host antiviral response via several mechanisms. In addition to their role in viral
replication and packaging, many of the proteins that are encoded by the HCV genome also interfere
with the host immune response (as demonstrated in figure 1.7).
Figure 1.7 HCV inhibition of the host antiviral response
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1.9.1 HCV core protein
HCV core protein interferes with the interferon signalling pathway and attenuates the host
interferon response to HCV. STAT1 is involved in interferon signalling and leads to increased
transcription of interferon stimulated genes (ISGs). HCV core binds to STAT1 inhibiting STAT1
phosphorylation and nuclear translocation thereby decreasing the induction of ISGs78.
1.9.2 NS3/NS4A
Once HCV infection is detected, the host interferon response is induced by: pattern recognition
receptors, the retinoic acid inducible gene-I (RIG I) and toll like receptor (e.g. TLR-3) pathways. The
HCV NS3/4A protease cleaves host proteins such as mitochondrial antiviral signalling protein
(MAVS)79, and the toll/interleukin receptor domain containing adaptor inducing interferon β (TRIF)65.
TRIF is an adaptor protein for the RIG-I and TLR3 pathways that are stimulated by host interferons.
This leads to inhibition of the interferon mediated immune response. The HCV NS3/4A also inhibits
interferon regulatory factor 3 (IRF-3), a downstream component of the RIG-I and TLR3 signalling
pathways, thereby further downregulating the transcription of interferon stimulating genes80.
1.9.3 NS5A
HCV NS5A protein binds to and inactivates protein kinase R (PKR). This allows viral replication to
occur during interferon treatment81. NS5A also has inhibitory effects on the JAK-STAT signalling
pathway82. NS5A blocks the interferon stimulated response element (ISRE) promoter and STAT1
phosphorylation.
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1.10 History of HCV treatment
1.10.1 Interferon
Interferons are glycoproteins produced in vivo in response to viral infections. Interferons inhibit viral
replication through a variety of mechanisms. Interferons were initially noted to decrease serum
transaminase levels in the 1980s in patients with non-A, non-B hepatitis83. At that time a causative
agent hadn’t been identified, and once HCV had been identified it became clear the impact on HCV
viraemia was less pronounced than the improvement in liver biochemistry. Interferon monotherapy
(with interferon injections three times a week) was noted to normalise ALT levels in up to 40% of
patients with hepatitis C within the first three months of treatment. However, interferon
monotherapy only achieved sustained virological response rates (with no detectable HCV RNA six
months after treatment) of up to 15% with six months of interferon and 25% with 12 months of
treatment84,85. These studies led to the recognition that an early response to treatment (which
occurred in the majority of patients), did not always correlate with sustained treatment response.
This led to the concept of a sustained virological response (SVR) being developed to assess
treatment success. An SVR was initially defined as no detectable HCV in serum 24 weeks post
completion of treatment. More recently as it has become apparent that most patients who are non-
viraemic 12 weeks post treatment progress to achieve an SVR, SVR 12 has been used as an outcome
for more recent trials in the treatment of hepatitis C. As the success rates of treatment with
interferon monotherapy were poor, adjunctive and alternative treatments were explored from the
early 1990s.
1.10.2 Ribavirin
Ribavirin is a synthetic nucleoside analogue which resembles guanosine. It has in vitro activity
against several DNA and RNA viruses including flaviviridae86. The mechanism of action by which
ribavirin inhibits HCV has not been completely determined. Hypotheses that have been proposed
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regarding the mechanism of action of ribavirin include inhibition of RNA dependent RNA
polymerases (RdRp), inhibition of the 5’ cap structure of viral mRNA and inhibition of the
intracellular triphosphate pool. Treatment with ribavirin monotherapy resulted in normalisation of
ALT in 40% of patients with HCV but did not markedly lower serum HCV viral levels87. Secondly, once
treatment with ribavirin was discontinued transaminase levels gradually increased. Therefore, as
ribavirin monotherapy was not particularly effective, by the mid-1990s studies began evaluating the
efficacy of ribavirin in combination with interferon.
1.10.3 Interferon and ribavirin
The combination of interferon and ribavirin was noted to have a synergistic effect on antiviral
activity. Initial studies achieved an SVR rate of 40% in patients who received 12 months of
combination therapy. In these studies, it was noted that the SVR rate was much lower in genotype 1
patients (29% with 12 months of treatment) compared to genotypes 2 and 3 (66% and 65% for six
and 12 months of treatment)88,89. The presence of advanced liver disease was also noted to affect
virological response, with fewer patients achieving SVR following 24 and 48 weeks of treatment if
bridging fibrosis or cirrhosis was present. Additionally, in these trials of combined treatment with
interferon and ribavirin, early treatment response was also noted to predict treatment outcome
(with those patients who had a rapid virological response, with undetectable HCV DNA at week four,
being more likely to achieve an SVR)90. In patients who had relapsed following treatment (with
undetectable HCV RNA at the end of treatment), retreatment with interferon and ribavirin for six
months resulted in a sustained virological response (SVR) of 49% (compared to only 5% in an
interferon monotherapy group91). In patients who were non-responders to treatment with
interferon (with persistent Hepatitis C viraemia during treatment) retreatment with interferon α and
ribavirin resulted in SVR rates of 18%92.
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1.10.4 Pegylated interferon
The development of Pegylated interferon in 1999 further improved the efficacy of combined
interferon and ribavirin treatment. The bonding of polyethylene glycol to interferon increased the
half-life of interferon activity, enabling once weekly injections and increasing drug bioavailability.
When used as monotherapy, pegylated interferon did not result in markedly improved SVR rates
(23% after 48 weeks of treatment), although SVR rates were higher in patients with genotype 2 and
3 HCV with viral loads less than two million copies/mL serum93. The combination of pegylated
interferon (1.5µg/kg once weekly) and ribavirin (800mg daily) for 49 weeks resulted in a SVR of
54%94. In patients with genotype 1 or 4 hepatitis C treated with 48 weeks of peginterferon and
ribavirin, the SVR rate in non-cirrhotic patients was 60%, which dropped to 51% if bridging fibrosis
was present and down to 33% if patients were cirrhotic. For genotype 2 and 3 patients (treated with
24 weeks of peginterferon and ribavirin) the SVR rate was 75% if patients were non-cirrhotic, which
dropped to 61% if bridging fibrosis was present and down to 57% if patients were cirrhotic95. The
STEPS trial96 evaluated 24 versus 48 weeks of treatment with pegylated interferon and ribavirin in
patients with genotype 3 hepatitis C advanced fibrosis or cirrhosis. In this study SVR rates of 48 and
42% were achieved with 24 and 48 weeks of treatment. In cirrhotic patients this dropped to 46 and
40% respectively. Rapid virological response at week four was noted to be the only factor
significantly associated with SVR96.
For patients that did not achieve an SVR with initial treatment with pegylated interferon and
ribavirin retreatment with pegylated interferon and ribavirin was investigated. The EPIC study97
evaluated the response to retreatment with pegylated interferon and ribavirin in patients who had
previously failed treatment and who had evidence of liver fibrosis (METAVIR F2, F3 or F4). Patients
with hepatitis C who had previously relapsed following prior treatment had an overall SVR rate of
23% for genotype 1 and 57% for genotype 3. In patients who had previously been non-responders to
treatment, the SVR rates were 4% for genotype 1 and 36% for genotype 3. This study also identified
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that treatment response at week 12 in this population correlated with the likelihood of achieving
SVR. 56% of patients with undetectable HCV RNA at week 12 achieved an SVR while only 12% of
those patients with detectable HCV RNA proceeded to achieve an SVR. Further studies evaluating
retreatment of genotype 3 hepatitis C with pegylated interferon and ribavirin in patients who had
previously failed treatment with interferon and ribavirin, resulted in SVR rates of 32% in patients
with advanced liver fibrosis (METAVIR F3/F4), compared to 62% in patients with F0-F2 fibrosis98.
1.11 Factors affecting treatment response
From these early trials, it was evident that genotype 1 had a lower SVR than genotypes 2 and 3 when
treated with pegylated interferon α and ribavirin. High pre-treatment viral load (> 2 million), older
patient age and the presence of bridging fibrosis or cirrhosis also adversely affected the likelihood of
achieving an SVR94. In a retrospective analysis of patients with genotype 3 hepatitis who were
treated with pegylated interferon and ribavirin, factors that were associated with a failure to achieve
SVR were increased age, increased weight or body mass index, or the presence of diabetes. More
advanced fibrosis on biopsy, thrombocytopenia, or the presence of liver cirrhosis were also all
associated with a failure to achieve an SVR. Finally, treatment dose reduction or abbreviation of
treatment to less than 24 weeks was also associated with a failure to achieve an SVR99.
1.11.1 Genetic factors affecting treatment response
It was noted during the 2000s that patients with African ancestry had lower SVR rates than those of
European ancestry. Ge et al67 identified a polymorphism on chromosome 19 near the interleukin-
28B gene which encoded for interferon lambda 3 was associated with a difference in response to
treatment with pegylated interferon and ribavirin in patients with genotype 1 hepatitis C.
Polymorphisms at locus rs12979860 were associated with differences in treatment outcome.
Patients with the CC genotype had a twofold greater likelihood of achieving an SVR compared to
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patients with the TT genotype. Tanaka et al68 identified a further locus (rs8099917) 8 kilobases
downstream from the IL-28B gene which was associated with treatment outcome in Japanese
patients treated for genotype 1 hepatitis C. Patients homozygous for the major allele (TT) were more
likely to achieve an SVR than those heterozygous or homozygous for the minor allele (TG/GG).
Subsequent studies demonstrated that the CC genotype at rs12979860 was associated with an
increased likelihood of patients achieving a rapid virological response100.
Interferon lambda 3 (interleukin-28B) is a type III interferon101 and is produced in response to viral
infection. Like type I interferons its signalling pathway includes JAK and STATs and results in the
production of interferon stimulated genes (ISG). A key difference is that IFN-λ results in a more
gradual increase in expression of interferon stimulated genes but also inhibits HCV viral replication
independently102. Studies evaluating the effect of IL-28B genotype on interferon signalling identified
that patients with polymorphisms associated with positive treatment outcome had lower ISG
expression at the start of treatment, and also had a higher baseline viral load compared to those
patients with rs12979860 CT/TT or rs8099917 TG/GG63,103,104. This pre-existing upregulation of ISGs
had an adverse impact on the efficacy of exogenous interferon (such pegylated-interferon), resulting
in a decreased likelihood of achieving an SVR.
As these observations were noted in patients with genotype 1 hepatitis C, the significance of these
polymorphisms were evaluated in genotype 3 hepatitis C. A meta-analysis of trials where IL-28B
genotype data was available identified no clear correlation between IL-28B genotype and treatment
outcome in genotype 2 and 3 hepatitis C105. In a further prospective trial106, and in the STEPS trial96,
IL-28B genotype was not identified as a factor which significantly affected SVR in genotype 3. Holmes
et al107 identified that ISG expression was significantly greater in HCV genotype 1 patients with an IL-
28B genotype associated with an adverse outcome compared to HCV genotype 1 patients with the
positive IL-28B genotype. In genotype 3 this dichotomy was markedly attenuated, suggesting that
there may be HCV genotype dependent variations in ISG expression.
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1.12 Interferon and ribavirin side effects and tolerability
1.12.1 Interferon side effects
The broad spectrum of host antiviral mechanisms that are induced by synthetic interferons was also
reflected in the side effect profile that was reported from early studies88,91. Generalised symptoms
such as chills, fever, myalgia, asthenia, headache and arthralgia were reported in 40-85% of patients
treated. Gastrointestinal symptoms experienced by patients receiving interferon included nausea,
anorexia and less frequently diarrhoea. Neuropsychiatric side effects occurred in up to 30% of
patients; insomnia, irritability, decreased libido, decreased concentration and sleepiness were the
commonest symptoms reported. Depression was noted in up to 30% of patients during treatment,
and a rarer side effect was interferon triggered seizures108.
Thyroid disease was noted to occur in patients on interferon treatment, with hypothyroidism being
the most frequently reported abnormality. In some patients receiving interferon based treatment,
thyroid dysfunction that occurred on treatment persisted long-term even once the course of
treatment was discontinued or completed109. Dermatological side effects included alopecia, oral
lichen planus and flares of psoriasis were also described in individuals receiving treatment88,91.
Haematological side effects are common, with a fall in leukocyte or platelet count noted in over 50%
of patients treated with interferon. Usually these side effects could be monitored with dose
reduction of interferon if there was a progressive deterioration of cell counts110. Rare severe
thrombocytopenia (Platelet count <50x109/L) or neutropenia (<0.7x109/L) despite dose reduction
necessitated early treatment discontinuation.
1.12.2 Ribavirin side effects
Haemolytic anaemia is the commonest side effect of treatment with ribavirin with an average
decrease of approximately 2g/L in patients’ haemoglobin levels observed. In addition to generalised
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gastrointestinal symptoms (nausea, anorexia, weight loss and abdominal pain), pruritis, cough,
depression and dyspnoea have also been documented as commonly occurring side effects110–112. It is
of note that ribavirin is also teratogenic. Patients are therefore advised to use contraceptive
precautions during treatment and for seven months after the completion of treatment113.
1.13 Direct acting antiviral drugs
Following the identification of the hepatitis C non-structural proteins, research was undertaken to
identify their function and whether they were potential therapeutic targets. Despite the lack of a
robust in vitro viral replication model, the NS3 protein was identified as a serine protease and
predictions were made regarding its catalytic triad (based on the protease structure from other
flaviviruses)8,114. This led to the development of direct acting antiviral drugs. Following the
identification of the first effective hepatitis C NS 3/4A protease inhibitor (the macrocyclic inhibitor
BILN-2061 in 2003115), further inhibitors of the hepatitis C protease were developed, including
telaprevir (VX-950)116,117 and boceprevir118. At the time of trial conception and during patient
recruitment onto the pilot study: Telaprevir in Genotype 3 hepatitis C, telaprevir and boceprevir
were the only two direct acting antiviral drugs licenced for use in the treatment of hepatitis C.
1.14 Telaprevir
In early phase I trials in patients with genotype 1 hepatitis C, viral RNA initially dropped rapidly
during treatment with telaprevir monotherapy. Following this rapid drop in HCV RNA, a rebound in
viral RNA was noted between seven and 14 days due to virological breakthrough117. Subsequently,
trials using telaprevir in combination with pegylated interferon identified that combination therapy
achieved a greater drop in HCV RNA, with 50% of treatment naïve non-cirrhotic genotype 1 patients
having undetectable HCV RNA after two weeks of treatment119. Following this a further trial
evaluated combination treatment with telaprevir, pegylated interferon and ribavirin for 28 days in
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genotype 1 treatment naïve patients with hepatitis C120. This identified that treatment with all three
agents resulted in a greater virological response, with all trial participants having undetectable HCV
RNA after 28 days of treatment. Following this, trial participants then continued treatment with a
further 44 weeks of pegylated interferon and ribavirin, and 66% achieved an SVR. Even following
treatment with all three drugs, two patients experienced virological breakthrough during treatment.
These findings, together with the subsequent PROVE-2 study121, where treatment with telaprevir,
pegylated interferon and ribavirin resulted in an improved SVR (62% with telaprevir, pegylated
interferon and ribavirin, compared to 36% for telaprevir and pegylated interferon alone), identified
that despite the advent of direct acting antiviral drugs, first generation protease inhibitors would still
need to be administered with interferon and ribavirin.
The subsequent ADVANCE, ILLUMINATE and REALIZE122–124 trials were the three major phase 3 trials
performed evaluating telaprevir in the treatment of genotype 1 hepatitis C. SVR24 rates were 69%
and 75% in treatment naïve patients with 24 or 48 weeks in the ADVANCE study compared to 44%
with placebo and Peg IFN and ribavirin. ILLUMINATE showed the non-inferiority of 24 weeks of
treatment. REALIZE included treatment experienced patients, with higher SVR24 rates in previous
relapsers (83-88%) compared with null responders (29-33%) and cirrhotic patients (25-27%). These
trials also confirmed that patients with prior non-response to treatment, high pre-treatment viral
load or advanced fibrosis had a lower SVR rate.
1.15 Telaprevir in genotype 3 hepatitis C
Following the initial promising results for treatment of genotype 1 hepatitis C, telaprevir was
evaluated in the treatment of genotypes 2 and 3125. This trial demonstrated a more rapid decline in
HCV viral load in a small cohort of patients with genotype 2 hepatitis C treated with telaprevir
monotherapy or triple therapy (telaprevir, pegylated interferon and ribavirin) compared to those
treated with pegylated interferon and ribavirin alone. In genotype 3 hepatitis C, early virological
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response to telaprevir was attenuated. Only two of eight patients in the telaprevir monotherapy arm
had a virological response with a greater than 2 log drop in HCV RNA within the first three days of
treatment. The median decline in HCV RNA at day three was -0.54 log. At the end of 24 weeks
treatment (24 weeks of pegylated interferon/ribavirin or two weeks telaprevir/pegylated interferon/
plus 22 weeks pegylated interferon/ribavirin or two weeks telaprevir followed by 24 weeks of
pegylated interferon/ribavirin), SVR rates were 44% (4 of 9), 67% (6 of 9) and 50% (4 of 8)
respectively. This preliminary study suggested that telaprevir may be of benefit to some patients,
although there were no pre-treatment factors identified in this small cohort which predicted
response to telaprevir.
1.16 Adverse events with telaprevir treatment
The commonest side effects from adding telaprevir to interferon and ribavirin were increased rates
of fatigue, gastrointestinal side effects (nausea and diarrhoea), pruritis, skin rashes and anaemia.
The increase in side effects experienced resulted in an increased number of patients in the telaprevir
containing arms discontinuing treatment early (with an 8-12% increase in treatment discontinuation
compared to patients in the control arm receiving treatment with pegylated interferon and
ribavirin)122–125. In addition to adverse events, drug-drug interactions were also noted for telaprevir,
as drug metabolism is via the CYP3A pathway. Therefore, concomitant administration of medications
which induced or inhibited CYP3A enzymes could result in lower telaprevir plasma concentration,
and decreased efficacy or increased plasma concentration and risk of toxicity.
Summary
The results from these landmark trials with telaprevir demonstrated that it is an effective direct
acting antiviral drug for patients with genotype 1 hepatitis C (in particular those who were treatment
naïve and did not have advanced liver disease). With regards to other genotypes, in particular
genotype 3, the preliminary trials suggested that a cohort of patients with genotype 3 HCV may be
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telaprevir sensitive, and therefore could potentially benefit from the addition of telaprevir to their
treatment regimen. One of the challenges would be identifying which subgroup of patients with
genotype 3 hepatitis C were most likely to benefit from treatment with telaprevir. If the addition of
telaprevir could be targeted to those patients most likely to respond to treatment, this could
improve their treatment outcome whilst minimising drug exposure and risk of adverse events to
those patients who would be unlikely to have any benefit from telaprevir being added to their
treatment regimen.
1.17 Boceprevir
In addition to telaprevir, boceprevir is another protease inhibitor developed for the treatment of
hepatitis C. SPRINT-2 and RESPOND-2126,127 were the key studies relating to boceprevir in the
treatment of genotype 1 hepatitis C. In SPRINT-2 a four-week lead-in of pegylated interferon
(PegIFN) and ribavirin was followed by either 24 weeks of boceprevir, PegIFN and ribavirin; or 44
weeks of all three medications depending on treatment response between weeks eight and 24. The
SVR24 rates were 67% and 68% in these groups compared to 40% in the placebo arm. RESPOND-2
involved treatment experienced patients, also with a four-week lead in, followed by 32 or 44 weeks
of treatment with all three drugs. Patients in the arm that received 32 weeks of treatment were
given an additional 12 weeks of PegIFN and ribavirin if HCV RNA was detectable at week 8 on
treatment. The SVR rates were 59% and 66% respectively. Prior relapsers had better SVR rates (69%
and 75% respectively) compared to null responders (40% and 52% respectively). As with telaprevir,
patients with advanced fibrosis had worse SVR rates (50% for treatment naïve patients with
METAVIR F3-4), as did black patients (SVR 42%-53%). The commonest side effects encountered with
boceprevir were anaemia and dysgeusia, followed by nausea, diarrhoea and neutropenia.
Subsequently, boceprevir was also evaluated in the treatment of genotype 2 and 3 hepatitis C128.
Boceprevir monotherapy achieved a modest drop in HCV RNA after 14 days of treatment (1.7 log
37
decrease in genotype 3 hepatitis C) in a small cohort of patients. This further supported the
possibility that protease inhibitors may be of use in the treatment of some patients with genotype 3
hepatitis C.
1.18 NS3 resistant variants
From the earliest studies into first generation protease inhibitors (in the treatment of genotype 1
hepatitis C), resistance associated substitutions were identified. Many of these (e.g. V36A, T54A,
R155Q, A156V/T, D168V/A)129 were noted to confer resistance to multiple different protease
inhibitors. In exploratory studies evaluating telaprevir in patients with genotypes 2 and 3130
resistance associated substitutions were investigated. Patients with genotype 3 HCV had no
mutations at baseline associated with decreased telaprevir susceptibility. Patients who developed
virological breakthrough on telaprevir monotherapy were noted to have the T54A and R155K
variants (which conferred resistance to telaprevir in patients with genotype 1 HCV). Despite this,
following treatment with pegylated interferon and ribavirin, all three patients had undetectable HCV
RNA at the end of treatment and one patient achieved an SVR. Additional variants were also
identified in patients at the end of the telaprevir monotherapy phase of the trial or at virological
breakthrough. These included T47A/T, A67A/V, K92K/N, A98A/T, S101A/T and P146S, although none
of these had a significant correlation with treatment outcome. Similarly, it was noted that at position
36 of the NS3 protein, which is a site for G1 resistance associated variants, wild-type genotype 3
Hepatitis C virus contained leucine, compared to valine in genotype 1, although the impact of this
substitution on telaprevir sensitivity was unclear.
1.19 Other direct acting antiviral drugs
During the work described in this thesis several new direct acting antiviral drugs were being
evaluated in clinical trials. The key drugs in development at that time were sofosbuvir, ledipasvir,
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daclatasvir and simeprevir, and these drugs have since completed their evaluation and have become
key components of current antiviral regimes for hepatitis C.
1.19.1 NS5B inhibitors
The NS5B inhibitor sofosbuvir was one of several new direct acting antiviral drugs that were
evaluated in clinical trials from 2010 onwards. Sofosbuvir was relatively unique in being a nucleotide
polymerase inhibitor which conferred an improved side effect burden compared to interferon and
protease inhibitors131. Initially sofosbuvir was tested in combination with pegylated interferon and
ribavirin. In the NEUTRINO study patients with treatment naive genotype 1 hepatitis C received 12
weeks of sofosbuvir, interferon and ribavirin and achieved a sustained virological response rate of
89%132. The ELECTRON study131 suggested that in treatment naïve patients with genotype 2 or 3
hepatitis C, the addition of pegylated interferon did not confer any treatment advantage to 12 weeks
of sofosbuvir and ribavirin (with an SVR24 of 100% in all groups), similarly all patients with genotype
2 or 3 hepatitis C who received eight weeks of sofosbuvir, PegIFN and ribavirin achieved an SVR12.
These findings suggested that interferon free treatment regimens would potentially be possible. In
the subsequent FISSION study, patients with treatment naïve genotype 2 or 3 hepatitis C received 12
weeks of sofosbuvir and ribavirin (which was demonstrated to being non-inferior to pegylated
interferon and ribavirin) and achieved an SVR of 56% in genotype 3132. The FUSION study133 explored
treatment with sofosbuvir and ribavirin for 12 or 16 weeks in patients who had previously failed
treatment with interferon. The SVR rates were only 37 and 63% respectively in patients with
genotype 3 hepatitis C. In those with cirrhosis these rates dropped further (19% vs 61%) with 12 and
16 weeks of sofosbuvir and ribavirin.
Despite the paradigm shift in treatment of hepatitis C that the development of sofosbuvir heralded,
by early 2014 there were still limited interferon free treatment options available for patients with
genotype 3 hepatitis C who had failed previous treatment with interferon and had liver cirrhosis. At
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this time the BOSON study134 was underway to evaluate the efficacy of sofosbuvir, PegIFN, and
ribavirin in the treatment of patients with genotype 2 and 3 hepatitis C who had failed previous
treatment, including patients with cirrhosis. The work described in this thesis took place against a
background of relatively few treatment options for patients with genotype 3 hepatitis C with
advanced liver disease following previously unsuccessful treatment with interferon and ribavirin.
1.19.2 NS5A inhibitors
Following the clinical trials investigating sofosbuvir, two NSA inhibitors were developed in quick
succession: daclatasvir and ledipasvir
Daclatasvir was initially investigated in the treatment of patients with genotype 1 hepatitis C. In
initial preliminary studies in patients with genotype 1 hepatitis C without cirrhosis, SVR rates of 83%
were achieved with 48 weeks of treatment along with pegylated interferon and ribavirin135. A further
study in treatment naïve genotype 1 patients achieved SVR rates of 90% following 24 weeks of
treatment with daclatasvir, pegylated interferon and ribavirin. For patients with genotype 3 hepatitis
C, 16 weeks of daclatasvir, pegylated interferon and ribavirin achieved an SVR of 69%136. This further
confirmed that interferon-based treatment for patients with genotype 3 hepatitis C could potentially
be abbreviated.
Due to the rapid speed at which new direct acting antiviral drugs were being developed,
combinations involving all oral direct acting antiviral drugs were also explored, to avoid exposure to
interferon (along with the associated side effects this conferred). The combination of sofosbuvir and
daclatasvir was evaluated in non-cirrhotic patients with HCV genotypes 1-3. For previously untreated
patients SVR 24 rates were 92% in genotype 2 and 89% in genotype 3 hepatitis C with 24 weeks of
treatment with sofosbuvir and daclatasvir (with or without ribavirin). In genotype 1 patients
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(including patients who had previously failed treatment with interferon/ribavirin and a protease
inhibitor) SVR rates of 98% were achieved137.
While studies evaluating the all oral combination of sofosbuvir and daclatasvir were underway, trials
evaluating sofosbuvir and another NS5A inhibitor, ledipasvir, were being performed. In the
LONESTAR trial138, treatment naïve non-cirrhotic genotype 1 patients achieved SVR rates of 95% with
8 or 12 weeks of sofosbuvir and ledipasvir, and the addition of ribavirin resulted in an SVR of 100%
following eight weeks of treatment. Of 22 patients with liver cirrhosis and genotype 1 infection, 21
(95%) achieved an SVR12 following 12 weeks of treatment with sofosbuvir and ledipasvir with or
without ribavirin. The ION 1, 2 and 3 studies confirmed the efficacy of this regimen in larger cohorts
of patients, achieving SVR rates of 95% and 99% in genotype 1 patients with 12 and 24 weeks of
treatment139–141. By mid-2014, trials were underway evaluating the efficacy of sofosbuvir with
ledipasvir in patients with genotype 3 hepatitis C142. Treatment naïve patients only achieved an SVR
of 64%, whilst treatment experienced patient achieved an SVR of 82%.
Despite the advent of high potency direct acting antiviral drugs which enabled SVR rates of 95% to
be achieved in patients with genotype 1 hepatitis C (including those with cirrhosis and patients who
had previously failed treatment with interferon and/or protease inhibitors), these findings had not
been replicated in patients with genotype 3 hepatitis C by 2014.
1.19.3 NS3 inhibitors
Simeprevir was another NS3/4A protease inhibitor that was being developed. Twelve weeks of
simeprevir, pegylated interferon and ribavirin followed by a further 12 or 36 weeks of pegylated
interferon and ribavirin was effective in the treatment of genotype 1 hepatitis C, achieving SVR rates
of up to 86% in treatment naïve patients143. The subsequent QUEST-1 and QUEST-2144,145 trials
further evaluated this treatment regimen in treatment naïve patients, achieving SVR rates of 80%
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and 81%. Trials were undertaken to evaluate the efficacy of simeprevir in genotype 3 hepatitis C, but
no significant drop in HCV RNA was noted in any trial participants (n=8) treated with simeprevir
monotherapy for one week146. Sequence analysis of trial patients with genotype 3 hepatitis
identified amino acid substitutions (V36L and D168Q) which conferred a 1 and 100 fold decrease in
sensitivity to simeprevir in vitro147.
1.20 Summary of Hepatitis C treatment in 2013
At the time this work was commenced, the standard of care treatment for patients with genotype 1
and 4 hepatitis C was either telaprevir or boceprevir with pegylated interferon and ribavirin. The
standard of care treatment for patients with genotype 2 and 3 hepatitis C remained pegylated
interferon and ribavirin. All oral treatments were being developed at this time, but none had been
licenced for use. During the course of the work described here, the treatment options available for
patients with hepatitis C advanced rapidly. By the time this work was completed, many of the
treatments described above had been superseded and replaced by newer and more effective
treatment regimens. The impact of these newer treatments will be reviewed in further detail in the
discussion.
1.21 Hepatitis C replication models
1.21.1 Cell lines permitting HCV replication
The Human hepatoma cell line Huh 7 was discovered in 1982148 and has been used extensively in the
development of in vitro HCV replication assays. Yoo et al.149 created a putative full length clone of
the Hepatitis C virus in 1995. This strategy was adopted after failed attempts to create a cell line that
permitted direct viral replication from HCV patient plasma. HCV RNA was transcribed from a cDNA
clone of HCV3. The transcribed RNA was transfected into Huh 7 cells. HCV RNA levels in the cell
culture supernatant were variable and transient, with factors including the addition of foetal bovine
serum to cell culture media and the cell cycle phase of the Huh 7 cells affecting HCV replication.
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Theilmann et al.150 evaluated infection of Huh 7 cells and Hep G2 cells with serum from HCV infected
patients and noted minimal viral replication, even with modifications of the cell culture media used
(including the addition of polyethylene glycol (PEG) and dimethyl sulfoxide (DMSO), both of which
increased the efficiency of in-vitro infection with other viruses, and modestly increased HCV
infection in the short term). For the first decade following identification of the hepatitis C virus, the
lack of an efficient in vitro HCV replicon system hampered further research into the understanding of
the HCV life cycle and the development of effective direct acting antiviral drugs.  Several
developments at the turn of the twenty-first century allowed substantial progress to be made on
both those fronts.
1.21.2 Huh 7.5 cells
Blight et al.151 developed the pre-existing Huh 7 cell line further in 2002. In order to select cells that
were more permissive to HCV replication, Huh 7 cell clones that permitted subgenomic HCV RNA
replication without adaptive mutations were treated with IFN-α. Of these clones, the Huh 7.5 cell
line permitted much greater viral replication, resulting in a 33-fold increase in the number of
neomycin resistant colonies formed.
1.22 Replicons
1.22.1 Con-1
Viral replicons are self-replicating viral RNAs that do not form complete virions but which can be
stably expressed in cell culture systems using selectable markers. A number of groups attempted to
generate HCV replicons that could be used to model HCV replication in tissue culture models.
Lohmann et al.152 were the first to successfully create a subgenomic replicon system in 1999 which
allowed the propagation of modified HCV genomes (replicons) in vitro. The replicon they developed
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was derived from the consensus sequence of genotype 1b HCV cloned from the liver of a patient
with chronic HCV infection. This genome was modified by replacing the HCV genome from the core
to NS2, or from the core to p7 with the neomycin phosphotransferase gene (neo), and the IRES of
the encephalomyocarditis virus, which would direct translation of HCV sequences from NS2 or NS3
up to NS5B (figure 1.8).
Once transfected into the human hepatoma (Huh) cell line, HCV RNA replication occurred and was
maintained, although the number of Huh 7 cells infected was small (only 1 in 106 cells demonstrated
HCV replication in vitro). It was subsequently noted that the efficiency of the replicon system
depended on the development of cell culture adaptive mutations in the HCV replicon sequence, in
particular in the NS5A region153, and by engineering specific variants (e.g. replacing a serine residue
at position 2204 in the NS5A protein with isoleucine) the percentage of Huh 7 cells infected rose to
10%. Huh 7 cell lines which permitted in vitro replication of subgenomic HCV were then treated with
interferon α to ‘cure‘ them of HCV. A higher proportion of these cured cells were able to support
HCV replication in vitro151 (Blight 2002).
1.22.2 JFH-1
A genotype 2a replicon was created by Kato et al.154 in 2003 where the HCV genome was recovered
from a patient with fulminant hepatitis. The initial subgenomic replicon was created following a
method similar to that used in the development of the Con-1 replicon. The JFH-1 subgenomic
replicon was noted to have a greater colony forming efficacy than Con-1, and was able to replicate in
vitro without adaptive mutations (although adaptive mutations which enhanced in vitro replication
were noted in NS5A and NS5B).
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Figure 1.8 In vitro HCV replication models
Subsequently Zhong et al.155 evaluated HCV replication when Huh 7 cells were transfected with the
full length JFH-1 genome (in contrast to the subgenomic replicons previously used). They identified
that 70-80% of cells demonstrated JFH-1 replication 72 hours post transfection. JFH-1 secretion from
transfected cells increased rapidly five days post transfection, and secretion continued at a high level
for the following 7 days before gradually decreasing. When naïve Huh 7 cells were inoculated with
supernatant from JFH-1 transfected cells, JFH-1 was noted to infect these cells 48 hours after
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incubation. Infectivity of cell culture derived JFH-1 was evaluated by inoculating a chimpanzee with
supernatant from JFH-1 transfected cells. HCV RNA was detected in the chimpanzee’s serum two
weeks after inoculation, and remained detectable until five weeks post inoculation. When HCV RNA
from the infected chimpanzee was sequenced, it was identical to the JFH-1 strain. The ability for JFH-
1 to replicate in vitro and produce infectious viral particles was a key breakthrough, as it facilitated
research into the HCV life cycle from viral entry to replication and viral particle formation (figure
1.8).
1.23 Capture fusion assay
The in vitro HCV replication systems described above proved useful in understanding the HCV
lifecycle and paved the way for the development of the direct acting antiviral drugs discussed earlier
in this chapter. As direct acting antiviral drugs (DAAs) became available (initially NS3 protease
inhibitors) these replicons were used to identify drug resistant variants. Although they provided an
invaluable tool, there were limitations to this replicon system. The process of identifying drug
resistance was laborious as it involved the cloning of every variant HCV sequence from patients who
did not respond to drug treatment into the replicon to identify drug resistance. Secondly, the
replicon systems were only representative of genotype 1 and 2 hepatitis C, with no stable replicon
model for genotype 3 HCV. As a result, in vitro phenotyping of viral resistance to HCV was limited.
A ‘capture fusion’ model of HCV replication was therefore developed by the Foster laboratory in
2013156 (figure 1.9). This was based on the observation that HCV was present in peripheral blood
mononuclear cells (PBMCs)157, although there is uncertainty as to whether HCV replicates in PBMCs
in vitro158.
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Figure 1.9 Schematic of capture fusion assay
Dendritic cells had been implicated in cell-cell infection with HIV159, therefore a model where HCV
infected PBMCs were fused with human hepatoma cell lines was developed to assess whether HCV
replication occurred in vitro156.  This demonstrated in vitro replication of patient derived HCV,
including in patients with genotype 3 HCV. Patients infected with direct acting antiviral drug (DAA)
resistant HCV were also correctly identified. This provided a useful tool in evaluating the in vitro
sensitivity of patient derived HCV to DAA drugs. In particular the capture fusion assay was accurate
in predicting which patients with genotype 3 HCV infection were likely to experience a >2log drop in
HCV viral load on treatment with telaprevir monotherapy, despite no resistance associated
substitutions having been identified in genotype 3 HCV to protease inhibitors125,156. These data
suggested that it might be possible to identify drug sensitive genotype 3 variants that might be
effectively treated with the available direct acting antiviral drugs (e.g. telaprevir).
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1.24 Work leading up to this thesis
By late 2013 there were still limited treatment options available for patients with genotype 3
hepatitis C and advanced liver disease, who had previously failed treatment with interferon and
ribavirin. At that time the only direct acting antiviral drugs licenced for treatment of hepatitis C in
the UK were telaprevir and boceprevir. As the preliminary in vitro and clinical studies with telaprevir
in genotype 3 hepatitis C suggested that a proportion of patients may benefit from treatment, the
telaprevir in genotype 3 hepatitis C trial was formulated to provide these patients with an alternate
treatment option that might benefit a subset of patients. Given the previous work showing that
patients with genotype 3 HCV who responded to telaprevir did not contain obvious sequence motifs
that predicted the outcome of therapy, we speculated that viral sequencing was unlikely to predict
treatment outcome. Since the capture fusion assay had correctly predicted the response to
telaprevir in a limited clinical study we speculated that the use of this assay would correctly identify
patients with genotype 3 HCV who were likely to respond to treatment with telaprevir. The purpose
of this work was to examine these hypotheses.
1.25 Hypotheses
1) A subset of patients with genotype 3 HCV and cirrhosis will benefit from treatment with pegylated
interferon, ribavirin and telaprevir.
2) Differences in sensitivity to telaprevir can be detected by viral phenotyping using the capture-
fusion assay.
3) Differences in sensitivity to telaprevir identified by viral phenotyping may be used to identify
patients with genotype 3 HCV who are likely to benefit from treatment with telaprevir.
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1.25.1 Experimental approach
To investigate these hypotheses a clinical trial of pegylated interferon, ribavirin and telaprevir in
patients with genotype 3 HCV and cirrhosis who had failed to respond to a course of pegylated
interferon and ribavirin was devised, initiated and managed. The trial included an evaluation of viral
sensitivity to telaprevir using the capture fusion assay.
During recruitment to the trial, alternative treatment regimens for patients with genotype 3 HCV
were developed and licensed (chiefly sofosbuvir) and given the side effects associated with
telaprevir treatment it was decided that it was unethical to proceed with the trial to completion. The
study was therefore terminated early to protect patients from harm.
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Chapter 2: Laboratory Methods
The laboratory methods used in the thesis are described below, in particular the methods related to
the capture/monocyte fusion assay and the laboratory methods used in assay optimisation.
2.1 PBMC collection and CD 14 separation
1. Collect 30-50 ml blood in 9ml heparinised tubes.
2. Add 15ml Ficoll Paque to 50ml Falcon tube.
3. Add 15-25ml ml of blood to two 50ml Falcon tubes and dilute with RPMI to 35mls total volume.
4. Carefully layer RPMI/blood mix on top of Ficoll.
5. Centrifuge at 1500rpm for 20mins with brakes off.
6. After centrifugation carefully aspirate PBMC layer.
7. Add PBS to make up to 30mls then spin for 5mins at 1500rpm with brakes on.
8. Dilute to 5mls with RPMI/PBS and count cells with haemocytometer.
9. Spin cells for 5mins at 1500rpm with brakes on.
10. Add Freezing media (FBS and 20% DMSO) to make up a concentration to 1x107cells/ml.
11. Place cells in cryotube and place in Cryofreezing container and place in -80oC freezer.
12. After 24 hours transfer to Liquid nitrogen storage.
CD 14 separation
As per Miltenyi Biotec protocol for CD14 microbeads.
1. Defrost PBMCs if necessary.
2. Add RPMI to make PBMCs up to 10ml.
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3. Centrifuge at 200g for 5mins.
4. Discard supernatant.
5. Add 80µl MACS buffer to PBMCs.
6. Add 20µl CD14 MACS beads to PBMCs.
7. Incubate in fridge for 15mins.
8. Prepare MACS column on magnet, on MACS stand.
9. Add 500µl MACS buffer to column.
10. Once PBMC incubation complete, make up to 500µl with MACS buffer.
11. Add PBMC mix to MACS column and collect effluent (containing CD14- cells).
12. Add 3 sets of 500µl MACS buffer to column and continue to collect CD14- effluent.
13. Remove MACS column from magnet and place in new 15ml Falcon tube.
14. Move magnet away from hood.
15. Flush though with 3x 500µl MACS buffer with plunger and collect effluent (containing CD 14+ve
cells).
Proceed to step 9 of HCV infection and fusion of monocytes protocol.
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2.2 Cell Fusion Protocol
Start from step 1 for THP-1 Capture fusion or from step 9 for PBMC fusion.
Day 1
1.Plate THP-1 cells at density of 1x106cells/mL in RPMI/adds.
2.Add PMA to final concentration 200ng/ml and IFNγ to 10ng/ml, swirl mix.
3. Incubate at 37OC for 18-24 hours.
Day 2
4. Majority of cells will be adherent. Remove supernatant/non-adherent cells, gently wash adherent
cells x 3 with RPMI and replace medium with RPMI + 2% FCS.
5. Add HCV serum of known viral load at ratio of 1 HCV copy/cell.
6. Incubate at 37oC overnight.
Day 3- Fusion
7. Remove supernatant, wash cells x 3 with RPMI.
8. Remove adherent cells into fresh RPMI using cell scraper (x2, washing with RPMI after each
scrape).
9. Add equal number of Huh 7.5 cells (to monocytes or PBMCs) and pellet the cells together in a
15ml Falcon tube (3min at 1500rpm usually adequate).
10. Remove supernatant completely and fuse with pre-warmed PEG 1500- add PEG (100µl per
million total cells) over 1 min, with gentle stirring. Transfer to 37oC for 90 secs. Remove from
incubator and slowly dilute out the PEG in 10ml pre-warmed DMEM/adds. Add the first 1ml over 1
minute, the second 2ml over a further minute and the remainder dropwise.
11. Incubate at 37oC for 5 minutes.
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12. Pellet the fused cells (5min at 1000 rpm) and resuspend in an appropriate volume of
DMEM/adds to plate at a density of 105cells/ml (e.g. 1x105 cells/well of 6 well plate in 1ml
medium/well). Leave to settle at 37oC overnight.
Day 4- Drug inhibition
13. Add inhibitory drugs at appropriate concentrations per well (drug dilution mix containing
DMEM/2%FCS/0.05% added to “no drug” wells).
Day 6- 3 days post- fusion
14. Aspirate medium from each well and replace with fresh medium and drug.
Day 8- 5 days post- fusion
15. Aspirate medium from each well. Dissolve adherent cells in 1ml TRIzol reagent per well or 350µl
Buffer RLT.
2.3 RNA extraction
Follow steps below or alternatively Qiagen RNeasy Mini-kit protocol (enclosed).
RNA extraction
TRIzol step
1. Remove supernatant from 6 well plates.
2. Wash each well with 1ml PBS.
3. Aspirate PBS.
4. Add 1ml TRIzol per well.
5. Aspirate contents of well into 1.5ml Eppendorf tube.
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RNA precipitation and extraction
1. Add 200µl chloroform per Eppendorf tube.
2. Shake well for 15 seconds.
3. Incubate at room temperature for 2-3 mins.
4. Centrifuge for 15 minutes at 12,000g at 4oC.
5. Remove 400µl from aqueous (upper) phase and transfer to new 1.5ml Eppendorf.
6. Add 500µl isopropanol to each sample.
7. Incubate at room temperature for 10 mins.
8. Centrifuge for 10minutes at 12,000g at 4oC.
9. Remove supernatant from Eppendorf tubes.
10. Add 1ml 70% Ethanol to each sample.
11. Briefly vortex each sample.
12. Centrifuge for 5mins at 7500g at 4oC.
13. Discard wash.
14. Air dry pellet for 5-10mins.
15. Resuspend RNA in 50µl water.
16. Place in heat block at 55-60oC for 10-15 mins.
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2.4 RNA quantification:
Omit steps 1-4 of following protocol if on column DNase reaction performed when using RNeasy spin
columns. Proceed to add 2µl RNA sample to 200µl TE buffer and aliquot 100µl duplicates to 96 well
plate and proceed from step 5.
1. DNase treatment. 2µl RNA in 10µl DNase reaction with 1µl DNase, 1µl 10x buffer and 6µl water
(Promega).
2. Incubate at 37oC for 30 minutes.
3. Quantification of DNase-treated RNA using the RiboGreen assay (Invitrogen) according to
manufacturer’s instructions for high range protocol:
4. Dilute 5µl of each DNase treated RNA sample (in duplicate) in 100µl TE buffer in 96well white
plates, dilute high range standards according to protocol and add to plate.
5. Dilute RiboGreen reagent in 1 in 200 TE buffer and add 100µl to each well.
6. Incubate 2-5mins at room temperature in the dark.
7. Read on fluorescence plate reader (standard fluorescence settings).
8. Use standard results to construct standard curve then interpolate sample concentrations. Back
calculate to account for dilution steps (if dilutions are done as above then interpolated value=
Yng/mL; corrected value= Yx410ng/ml. Then divide by 1000 to give ng/µl).
2.5 Real time quantitative polymerase chain reaction (RT-qPCR)
Set up RT-qPCR reaction using Quantitect Viral Nucleic Acid Detection Kit (Qiagen) according to
manufacturer’s recommendations in 20µl volumes. Commercial HCV primer/probe (Taqman, Applied
Biosystems) is used at 1µl per reaction. Each RNA sample is measured in triplicate in RT-qPCR. Aim to
use 100-200ng/RNA per reaction.
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1. Create mix for samples with 4µl 5x Mastermix, 1µl Primer probe, 0.2µl 100x Quantitect Viral RT
Mix, Sample volume (to enable 100-200ng RNA per reaction) and water to make up to 20µl.
2. Create mix for two blanks (with 5µl water instead of sample).
3. Make serial dilutions of RNA standard (stock is quantified JFH-1 RNA at 2x105 copies/µl). Include
standards in duplicate 10 copies/reaction- 105 copies/reaction. Dilute 2µl of 2x105 JFH-1 in 18µl
water, and perform serial 1 in 10 dilutions to obtain JFH-1 standards at 2x104, 2x103, 2x102, 20, and
2copies. Use 5µl per reaction.
4. Run on RotorGene at recommended cycling conditions (50⁰C for 20 mins, followed by 95⁰C for 5
mins then 35 cycles of 95⁰C for 15 seconds, and 60⁰C for 45 seconds).
2.5.1 PCR Data analysis
1. Select data file on RotorGene thermocycler.
2. Click on autoscale (below graph).
3. Click analysis (on tabs along top).
4. Choose quantitation (Cycling A green) and click show.
5. Click auto-find threshold on menu bar on bottom right.
6. Review that blanks are negative.
7. Right clinic on Quantitative Cycling A green table on bottom left and select export to Excel.
8. In Microsoft Excel divide the calculated copies of RNA by the total RNA at the start of the reaction
to give RNA concentration in copies of HCV per nanogram of RNA.
9. Multiply by 1000 to calculate copies per microgram of RNA.
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10. Calculate the average copies of HCV RNA per sample (as each sample was performed in
triplicate).
11. Calculate HCV RNA per sample as a percentage of average value for no drug inhibition samples.
2.6 Laboratory serum viral load quantification
As per QIAamp Viral RNA Handbook: Purification of Viral RNA (Spin Protocol).
1. Pipette 560µl of prepared buffer AVL containing carrier RNA into a 1.5ml microcentrifuge tube.
2. Add 140µl plasma to the microcentrifuge tube. Mix by pulse vortexing for 15 secs.
3. Incubate at room temperature for 10 mins.
4. Briefly centrifuge.
5. Add 560µl 100% ethanol to the sample and mix by pulse vortexing for 15 secs. After mixing, briefly
centrifuge the tube to remove drops from the lid.
6. Add 630µl of the solution from step 5 to the QIAamp mini column (in a 2ml collection tube)
without wetting the rim. Close the cap, and centrifuge at 6000g (8000rpm) for 1 minute. Place the
QIAamp into a clean 2ml collection tube, and discard the tube containing the filtrate.
7. Carefully open the mini-column and repeat step 6.
8. Open the QIAamp mini column and add 500µl of buffer AW1. Close the cap and centrifuge at
6000g (8000rpm) for 1 min. Place the QIAamp mini column in a clean 2ml collection tube and discard
the tube containing the filtrate.
9. Carefully open the QIAamp mini column and add 500µl of buffer AW2. Close the cap and
centrifuge at full speed (20,000g/14,000rpm) for 3 mins.
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10. Place the QIAamp mini column in a new 2ml collection tube and discard the old collection tube
with the filtrate. Centrifuge at full speed for 1 min.
11. Place the QIAamp mini column in a clean 1.5ml microcentrifuge tube. Discard the old collection
tube containing the filtrate. Open the column and add 60µl of buffer AVE equilibrated to room
temperature. Close the cap and incubate at room temperature for 1 min. Centrifuge at 6000g
(8000rpm) for 1 min.
12. Proceed to RNA quantification and QPCR subsequently, or store RNA at -20⁰C or -70⁰C.
2.7 Capture fusion assay optimisation methods
2.7.1 Cell Colouring Protocol
Reagent Preparation
 DMSO (dimethylsulfoxide)
 PBS
 Cell tracker dyes need to be reconstituted to a final concentration of 10mM in
DMSO and diluted to a working concentration of 0.5-25µM in serum free medium
(Use at 10µM). Warm to 37˚C.
Colouring Controls:
 1 no-colour control for each cell line (negative control).
 1 no-colour control for each cell line for fusion.
Procedure- Colouring
1. For adherent cells aspirate media and replace with 1ml of the pre-warmed CellTracker dye
working solution and incubate for 30 mins at 37˚C. (For Huh7.5 cells this will be the BODIPY
Green Dye solution, for THP1 cells this will be the Orange dye solution).
58
a. For Cells in suspension: harvest by centrifugation, pour off supernatant and gently
re-suspend ~106 cells in dye working solution, incubate cells as above.
2. Replace dye-working solution with fresh pre-warmed medium and incubate for 30mins at
37˚C.
a. Centrifuge and re-suspend in fresh medium if in solution.
3. Wash with PBS and replace with medium (RPMI for THP-1, DMEM for huh7.5).
4. Carry out Fusion as per protocol (step 9). (Keep at least 1 well of each coloured cell line to
act as a control).
5. After fusion fix cells in 2% paraformaldehyde.
Controls for FACs
 Un-coloured for huh7.5 and THP-1 (2 wells).
 Non-fused coloured huh7.5 and THP1 (2 wells).
 Fusion with un-coloured cells.
 Fusion with coloured cells (1 well).
Dye reconstitution
BODIPY (279.55 g/mol)
 Reconstituted to 10mM therefore need to dilute 10µM.
Orange (Mw = 550.44 g/mol)
 Come in 50 ug aliquots and need to be reconstituted to 10mM see below:
 i.e. Vol= 50 µg/(0.01 M[10 mM] x 550.44 g/mol) = 9.08 µl
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2.7.2 Preparation of samples for Flow Cytometry
1. Aim for 1x105-5x105 cells per sample.
2. For adherent cells, wash with 1mls PBS, then repeat, following this add 1ml PBS to well on tissue
culture plate.
3. Scrape cells from well and transfer to 15ml Falcon, wash both sides of scraper and well with 1ml
PBS each then add 1ml PBS to well.
4. Repeat 3.
5. Centrifuge sample at 1700 rpm for 5 mins.
6. Discard supernatant.
7. Resuspend samples in 1ml PBS.
8. Divide sample into 500µl aliquots and place in FACS tube.
9. Centrifuge at 1500 rpm for 5 minutes.
10. Discard supernatant.
11. Add 100µl of FACS buffer and antibody.
12. Incubate on ice in the dark for 1 hour.
13. Add 1ml FACS buffer to each tube.
14. Centrifuge at 1500 rpm for 5 minutes.
15. Discard supernatant.
16. Add 500µl 4% PFA and resuspend for 10 mins.
17. Centrifuge at 1500 rpm for 5 minutes.
18. Resuspend in 500µl PBS.
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2.7.3 Transfection protocol
1. Prepare 5x105 cells per well on 6 well plate.
2. Use 5 or 10µg plasmid DNA and dilute in 100µl Optimem.
3. Add 5µl Fugene to 95µl Optimem.
4. Leave mixtures in 3 and 4 got 40 minutes at room temperature, then mix together and leave for
15 minutes.
5. Wash cells (culture plate) with optimum twice.
6. Add 600µl Optimem to each well.
7. Add transfection mixes and incubate at 37⁰C for 1.5 hours.
8. Add 3ml DMEM (10% FBS) and incubate for 24 hours.
9. Add media containing antibiotic to select transfected cells after 24 hours.
10. Leave cells to grow for 4-6 weeks, changing antibody selection media every 2-3 days.
2.7.4 RNA extraction from tissue cultured cells
1. If under 1x107 cells harvest with RLT buffer (350µl per well).
2. Add 350µl 70% ethanol to lysate and mix well.
3. Transfer 700µl of sample to a RNeasy mini spin column placed inside a 2ml collection tube and
centrifuge for 15 secs at >8000g. Discard the flow through.
4. Add 700µl buffer RW1 to spin column. Centrifuge for 15 secs at >8000g. Discard flow through.
5. Add 500µl buffer RPE to spin column. Centrifuge at >8000g for 15 secs. Discard flow through.
6. Add 500µl buffer RPE to spin column, centrifuge at >8000g for 2 mins.
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7. Place spin column in a new collection tube. Centrifuge at full power for 1 min.
8. Place spin column in a new 1.5ml microcentrifuge tube. Add 30-50µl RNase-free water directly to
spin column membrane. Close the lid and centrifuge for 1min at >8000g to elute the RNA.
9. Calculate RNA concentration using nanodrop.
2.7.5 Protocol to create cDNA from cellular RNA
1. Use 1µg mRNA per reaction.
2. Add 0.5µg of primer (random primer) per 1µg of mRNA in <14µl of H2O.
3. Heat for 5 mins at 70⁰C to melt secondary structure. Cool immediately on ice the spin briefly.
4. Add 10µl of each dTP (dATP, dTTP, dCTP and dGTP) at 10mM concentration to 60µl H2O.
5. Add the following components to the primer/mRNA mixture to create a reaction volume of 25µl:
M-MLV 5x buffer 5µl
DTP mix (from 4) 5 µl
200 Units M-MLV RT 1µl
Sample (1µg RNA) and primer
H2O to make up to 25µl
6. Mix and incubate at 37⁰C for 60 mins.
7. Calculate cDNA concentration using nanodrop.
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2.7.6 SYBR green protocol to assess relative expression of cellular genes
1. Create primer mixture (20µl each of forward and reverse primer for gene) and 160µl H2O.
2. Add the following components to the primer/mRNA mixture to create a reaction volume of 25µl:
2µl primer mix
12.5µl SYBR green reagent
250ng cDNA per reaction
H2O to make up-to 25µl
3. Run samples on rotor-gene:
95⁰C for 10 mins
40 cycles at 95⁰C for 10 secs, 58⁰C for 15 secs, and 72⁰C for 5 secs
72⁰C for 90 secs
Ramp temperature from 72⁰C to 95⁰C by 1⁰C every 5 secs
4. Calculate relative expression of gene of interest using 2-ΔΔCT (2-(Cycle threshold housekeeping gene - cycling threshold
gene of interest)).
2.7.7 Immunohistochemistry protocols
1. Place coverslips in 24 plate.
2. Plate 5x104 cells in each well.
3. Remove culture medium from well.
4. Add 350µl 10mM NH4Cl (incubate for 10 mins at room temperature).
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5. Remove NH4Cl then add 350µl Triton X-100 0.05% and incubate for 5 mins on ice.
6. Remove Triton then add 350µl 5% V/V goat serum in PBS 0.1% Triton.
7. Prepare parafilm for incubation with primary antibody (label and tape down to lab bench).
8. Add primary antibody in 1:100 dilution (dilute with PBS 0.1% Triton and 5% Goat serum), 40µl per
slide and place coverslip face down on parafilm.
9. Incubate for 1 hour at room temperature.
10. Wash x 2 with PBS.
11. Add secondary antibody 1:1000 dilution 40µl per coverslip and incubate for 1 hour at room
temperature.
12. Wash x 2 with PBS.
13. Dip briefly in H20 then 70% ethanol.
14. Mount with Prolong Gold and DAPI.
15. Leave in dark for 12 hours.
2.7.8 50% Tissue culture infective dose (TCID 50) Assay
Day 1 – seed cells
Plate Huh7 cells in a density of 3000 cells/100µl/well in a 96 well plate.
Day 2 – infection
Take cells to BSL3.
Collect the supernatant of cells containing viral particles and centrifuge (6 well plates containing
electroporated Huh7 cells).
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Add 50µl supernatant (containing JFH-1) per well (1 condition is tested in 12 different wells).
Make 8 serial dilutions of 1/3.
Incubate for 3 days.
Day 5 – immunofluorescence
Discard the cell medium.
Submerge the plate and the lid in methanol.
Transfer to plastic box, spray with ethanol.
Immunofluorescence:
 Wash 3 times with PBS A
 Incubate with primary antibody for 1 hour at RT (sheep NS5A 1/1000 in PBS A with 1% FCS),
the antibody is already diluted 1:10
 Wash 3 times with PBS A
 Incubate with secondary antibody for 30 to 40 minutes at RT (AlexaFluor 488 donkey anti-
sheep 1/1000 in PBS/FCS)
 Wash 3 times with PBS A
 Counterstain with DAPI (1:1000) for 5 min
 Wash 3 times in PBS and store in PBS, read and score positive cells on time-lapse microscope
2.7.9 Western Blot
Protein extraction
1. Initial part of protocol is as per RNAeasy mini kit (steps 1 & 2).
2. Add 700µl of sample to spin column placed within a collecting tube.
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3. Centrifuge for 15 secs at >8000g.
4. Collect the flow through (as this contains protein).
5. Place 900µl acetone in an empty 1.5ml microcentrifuge tube.
6. Add 300µl flow through to each tube.
7. Set centrifuge to 4⁰C (Can store at 20⁰C if RNA extraction needs to be completed (as per
protocol)).
8. Centrifuge protein sample at 14,0000rpm for 15 min at 4⁰C.
9. Aspirate supernatant.
10. Add 100µl 100% ethanol to pellet.
11. Spin at 14,000rpm for 5mins at 4⁰C.
12. Aspirate 100µl supernatant.
13. Resuspend in 100µl WCL buffer (1ml Whole cell lysis buffer + 10µl PMSF (100mM) + 40µl
protease inhibitor (25x)).
14. Perform BCA assay to calculate protein concentration.
Bicinchoninic acid assay (BCA assay)
1. The BCA is used to calculate protein concentration.
2. Dilute standards (Bovine serum albumin) BSA in PBS at 1mg/ml, 0.5mg/ml, 0.25mg/ml,
0.125mg.ml, 0.0625mg/ml and use a negative control (PBS only).
3. Create reagent for BCA. Mix Pierce BCA protein assay kit reagent A with copper sulphate in a ratio
of 50:1.
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4. Will need total of 12 wells in 96 well plate for standards then, duplicates for each protein
concentration (usually do: undiluted, 1:10, 1:100).
5. Add 200µl of mixture in 3 to each well in 96 well plate and add 25µl of sample or standard to each
well.
6. Incubate at 37⁰C for 30mins.
7. Read on plate reader (on absorbance setting at 570nm).
8. Create standard curve and calculate concentration of samples.
Protein electrophoresis
1. Aim for 5µg protein per lane.
2. Make up protein and WCL to 22.5µl per lane in Eppendorf.
3. Add 2.5µl DTT (1M) and 5µl loading buffer (6x laemmli) per lane (total 30µl per lane).
4. Heat to 70⁰C for 5 mins.
5. Assemble electrophoresis kit.
6. Remove gel cassette from packaging and wash cassette with tap water, remove tap strip at
bottom of gel.
7. Place gel cassette and spare cassette holder in tank with text facing outwards and clamp in place.
8. Add MOPS-SDS 1x running buffer to space between both cassettes to above lip on cassette.
9. Remove comb from gel and wash wells with running buffer.
10. If no leak to remainder of tank add running buffer (MOPS-SDS 1x) to halfway up tank.
11. Add 3µl ladder to first well of gel and 28µl of samples to subsequent wells.
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12. Run gel at 200V for 35 mins.
Gel transfer
1.Add transfer buffer (TRIS/glycine and 10% methanol) to wadding and blotting paper (cut to size).
2. Unpack nitrocellulose membrane and add to kit above to soak in transfer buffer.
3. Place several sheets of wadding and blotting paper to solid gel holder (for gel transfer) with black
side (negative) of gel holder facing down.
4. Dismantle gel casing, keep gel with side towards text on casing facing down.
5. Cut off bottom right corner of gel (opposite side to ladder).
6. Remove bottom of gel with loading reagent, and top of gel with wells and stacking gel using a
palette knife.
7. Place membrane on top of gel.
8. Transfer gel and membrane to gel holder and place on top of wadding/blotting paper. Add further
layer of blotting paper on top of membrane and several layers of wadding, and place lid for gel
holder.
9. Recycle running buffer in tank (MOPS-SDS 1x).
10. Rinse tank with water.
11. Place gel holder (with wadding, blotting paper, membrane and gel) in tank and clamp in place.
12. Ensure gel holder has sufficient transfer buffer.
13. Place water in outer segment of tank.
14. Place tank in bucket of ice.
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15. Run at 25V for 1 hour.
Western blot
1. Place membrane in shallow container and add Ponceau’s solution (this will highlight the protein
bands on membrane).
2. Cut membrane into strips (in pairs/groups of control vs test conditions).
3. Place strips in 50ml falcon tube and wash with 1x TBS.
4. Add 5ml blocking solution (39ml 5% PVP in PBS and 1ml FBS) and place on roller to block for 1
hour at 4⁰C.
5. Add primary antibody at 2µl per falcon tube and incubate overnight at 4⁰C.
6. Wash membrane with 1x TBS and 0.2% Tween 20mls and repeat 3x.
7. Prepare secondary antibody 1µl to 10mls blocking solution (see step 4), and add 5ml after 3rd
wash.
8. Incubate for 1 hour.
9. Wash as per step 6.
10. Prepare enhanced luminescence (ECL) kit. Add 2mls of Pierce ECL mixture A to 2mls of mixture B.
11. Add mixture in 10 to gel facing side membrane and incubate for 5 mins.
12. Turn face down onto cling film and wrap in clingfilm.
13. Take to dark room and place on photographic paper.
14. Run paper through developer.
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Chapter 3: Capture fusion assay optimisation
Background
One of the aims of the telaprevir in genotype 3 trial, was to prospectively assess in-vitro sensitivity of
patient derived HCV from trial participants to telaprevir. As the trial was designed to evaluate
treatment in patients with advanced fibrosis or cirrhosis, it was anticipated that HCV viral loads in
these patients would be lower than previously used in the capture fusion assay. Furthermore the
capture fusion assay was only successful with 80% of patient serum samples which was regarded as
suboptimal for a clinical assay. In order to overcome the challenges posed by using patient serum
samples with low HCV viral load, and to improve the proportion of patient samples that could be
accurately phenotyped using the capture fusion assay, a number of modifications of the Huh 7.5 cell
line were evaluated to determine whether viral replication in the assay could be improved.
3.1 Huh 7.5 Cells cultured in Human serum
Steenbergen et al.160 hypothesised that HCV infection was not only dependent on the presence of
human hepatocytes but also required human serum factors. Their group identified that
humanisation of mouse lipoprotein profiles enabled successful HCV infection of chimeric mouse
livers (which had been transplanted with human hepatocytes). Huh 7.5 cells were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) with either 10% Foetal Bovine serum (standard Huh 7.5
cell culture conditions) or DMEM with 2% Human Serum. Cells cultured in Human serum
demonstrated a change in morphology with increased expression of hepatocyte tight junction
proteins and HCV entry receptors, and also a marked increase in JFH-1 replication, and increased
infectivity of virus produced in cells grown under the new culture conditions. We therefore
hypothesised that Huh7.5 cells grown in human serum would increase viral replication in the capture
fusion assay.
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3.1.1 Methods:
Huh 7.5 cells cultured in DMEM with 10% FBS and penicillin/streptomycin were trypsinised, the
trypsin was inactivated with DMEM. The cells were then centrifuged at 300g for 5 minutes. The cells
were then resuspended in PBS and counted. Cells were divided into 1x106 cell aliquots and placed in
separate 15 ml falcon tubes. Cells were centrifuged again at 300g for 5 minutes then resuspended in
either DMEM with 10% FBS or DMEM 2% HS (with penicillin/streptomycin) and plated in T75 culture
flasks with 20mls media. Media was changed every 72 hours and cells were passaged once they
approached confluence. Huh 7.5 cells in DMEM and 10% FBS were passaged every 72 hours. The
Huh 7.5 cells cultured in 2% HS took longer to approach confluence and were first passaged after 10
days, and then every 72 hours. After at least 21 days of culture in 2% Human serum cells were used
in experiments.
3.1.2 Results
3.1.2.1 Cell RNA and protein expression
After cells had been passaged in DMEM with Human Serum for 21 days, cells were plated out in six
well plates at 1x106 per well and harvested after 24 hours and genomic RNA was extracted. PCR was
performed with SYBR green to evaluate the relative expression of mRNA for HCV cell entry proteins.
The fold change of mRNA expression was calculated by the Pfaffl method161, and the results shown
are relative to cells cultured in FBS (figure 3.1). These experiments demonstrated that culturing Huh
7.5 cells in human serum resulted in (non-significant) increased expression of occludin and claudin
(as previously observed by Steenbergen et al), but also resulted in a non-significant increase in CD 81
expression whilst a rise in SR-B1 mRNA levels was not observed (which was in contrast with the
Steenbergen paper).
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Figure 3.1 Relative expression of mRNA for cell surface proteins between Huh 7.5 cells cultured
in FBS and Human serum
3.1.2.2 Immunohistochemistry
In order evaluate whether increases in mRNA resulted in translated protein, immunohistochemistry
was performed to evaluate the expression of cell surface proteins involved in HCV cell entry. 5x10^4
cells (cultured in either 10% FBS or 2% HS) were seeded onto coverslips in 24 well plates, and
incubated for 24 hours. These cells were fixed with 4% PFA, and immunohistochemical analysis was
performed (as described in Methods). Image J software was used to calculate the relative
immunofluorescence of tissue staining.
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Figure 3.2: Immunohistochemistry of Huh 7.5 cells cultured in standard conditions (10% FBS) (l)
or 2% HS (r), A) Albumin B) CD81 C) Claudin D) E cadherin
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Immunohistochemistry (figure 3.2) suggested increased expression of CD-81 and E-cadherin in cells
passaged in DMEM with 2% Human serum (as noted in the original paper). Having identified
potential differences in the expression of cell surface proteins involved in HCV cell entry,
experiments assessing JFH replication were performed to evaluate whether the noted increase in
these proteins resulted in increased HCV replication.
3.1.2.3 HCV replication in vitro- JFH
Huh 7.5 cells cultured in 10% FBS and 2% HS were seeded onto a 12 well plate at a concentration of
1x105 cells per well. JFH-1 from a common stock was added at an MOI of 0.01, and the cell culture
media for these cells was replaced after 4 hours with fresh media (containing 10% FBS or 2% HS
respectively). Cells were cultured initially for 3 or 5 days and harvested with 500 microlitres of
TRIZOL. JFH-1 RNA was extracted from these samples (as described in Methods) and HCV RNA was
quantified. Initial experiments (figure 3.3) demonstrated non-significant increased JFH replication by
approximately 1 log both at day 3 and day 5 post infection. Subsequently a time-course experiment
was performed to evaluate the rate of increase in JFH RNA. This demonstrated that JFH-1 replication
in Human serum cells occurred at a lower rate over the first 24 hours then increased by day 6. This
may be a result of a lower rate of cell division (as noted by Steenbergen) affecting viral replication
over the first 24 hours, with increased JFH-1 replication subsequently noted at days 3 and 6. The
findings from these experiments suggested that there may be a marginal increment in JFH-1
replication when using Huh 7.5 cells cultured in 2% Human serum.
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Figure 3.3 JFH titres in Huh 7.5 cells cultured in FBS and HS (at different timepoints post
infection)
3.1.2.4 Infectivity of JFH-1 produced in Huh7.5 cells cultured with 2% Human Serum
The infectivity of JFH-1 produced in Huh7.5 cells cultured in FBS or HS was evaluated by a Tissue
Culture infectious dose assay (TCID 50). This evaluated the infectivity of serial dilutions of JFH-1
produced under the two different tissue culture conditions, and enabled calculation of the number
of 50% infectious doses of virus contained per ml of viral supernatant. The TCID50 results for the cells
cultured in FBS and HS are demonstrated below (figure 3.4), with an example of the NS5A
immunohistochemistry used to calculate the TCID50 value. These data confirm the observation that
Huh 7.5 cells grown in human serum are more permissive to HCV replication. It is unclear whether
this is due to increased internal cellular replication or changes in viral entry
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Figure 3.4 TCID50/ml for Huh 7.5 cells cultured with FBS and HS (l) and example of NS5A (green)
and nuclear (DAPI) immunohistochemistry in cells cultured with FBS (top) and HS (bottom) (r)
3.1.2.5 Colour fusion data
In order to evaluate whether there was any effect of the phenotypic changes in Huh 7.5 cells
cultured in 2% Human Serum on the efficiency of PEG mediated cell fusion, experiments were
performed to assess if there was any difference in cell fusion between Huh 7.5 cells cultured in FBS
and those cultured in Human serum. Huh 7.5 cells (cultured in FBS or Human Serum) were labelled
with CellTracker orange CMRA, and THP-1 cells were labelled with CellTracker violet. The figure
below (figure 3.5) demonstrates the effective cell labelling of both Huh 7.5 and THP-1 cells. As the
THP-1 cells had been stimulated prior to co-culture a population of THP-1 cells adherent to Huh 7.5
cells was noted with both the cells cultured in FBS and those cultured in HS. This made quantification
of effective cell fusion challenging.  Given the difficulties in interpreting these experiments and as
cell fusion alone is not an accurate surrogate marker of viral replication in the capture fusion assay
further experiments were performed to evaluate if Huh 7.5 cells cultured in Human Serum permitted
greater viral replication in the capture fusion assay.
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Figure 3.5. Flow cytometry data. A) Huh 7.5 cells cultured with 10% FBS: negative control (l),
with CellTracker orange (r) B) Huh 7.5 cells cultured with 2% HS: negative control (l), with
CellTracker orange (r) C) THP-1 cells: negative control (l), with CellTracker violet (r) D) Huh 7.5
FBS cells fused with THP-1 cells: uncoloured cells (l), with Huh 7.5 FBS cells labelled with
CellTracker orange and THP-1 cells labelled with CellTracker violet E) Huh 7.5 HS cells fused
with THP-1 cells: uncoloured cells (l), with Huh 7.5 FBS cells labelled with CellTracker orange
and THP-1 cells labelled with CellTracker violet.
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3.1.2.6 Capture fusion data
As the objective of using new and modified cell lines was improved HCV replication in the capture
fusion assay, paired capture fusions were performed using Huh 7.5 cells cultured in FBS and HS and
THP-1 cells infected with HCV infected serum (figure 3.6). Serum from three Genotype 3 HCV
patients was used and drug inhibition was assessed by evaluating sensitivity to a single
concentration of telaprevir. Telaprevir was used as this would be the drug of interest in the
telaprevir in genotype 3 clinical trial.
Figure 3.6. Capture fusion data comparing Huh 7.5 cells cultured in FBS or Human serum. 3
different HCV containing serum samples were used and sensitivity to drug inhibition was
assessed using telaprevir
Whilst Huh 7.5 cells cultured in human serum demonstrated a marked increase in viral replication in
the capture fusion assay for one HCV serum sample (SD029), the HCV copy number per microgram
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of RNA was similar for both the Huh 7.5 cells cultured in FBS and those cultured in 2% HS for the
remaining two HCV serum samples.
3.1.3 Conclusions
Huh 7.5 cells cultured in 2% Human serum demonstrate phenotypic changes compared to those
cultured in 10% FBS. They demonstrate altered expression of cell surface proteins involved in tight
junction formation (some of which are also involved in HCV cell entry). The replication of JFH-1 virus
is greater in Huh 7.5 cells cultured in Human serum compared to those cultured in FBS. Viral
replication in the capture fusion assay was greater in one patient serum sample containing HCV, with
no difference between the cell lines when another two different HCV containing patient serum
samples were used. These data suggested that culturing Huh7.5 cells in human serum alone would
not consistently augment HCV viral replication in the capture fusion assay. Therefore Huh7.5 cells
cultured in Human Serum would be unlikely to provide a solution enabling HCV replication (in the
capture fusion assay) from low viral copy number samples. Alternative strategies were subsequently
pursued to optimise in vitro viral replication.
3.2 SEC14 L2
3.2.1 Background
One of the limitations in evaluating hepatitis C in-vitro was the need for sub-genomic replicons to
acquire or contain adaptive mutations in order to replicate in cell culture conditions. This was
thought to represent a lack of essential host factors or presence of inhibitory factors in the cell lines
used (such as Huh 7 derived cells). In order to overcome this block Saeed et al.162 transduced Huh 7.5
cells with lentivirus libraries containing a range of human cDNA. These transduced cells were
electroporated with G418 selectable HCV sub-genomic replicons, which usually require at least 2
adaptive mutations for replication. Multiple colonies harboured replicons with parental sequence.
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cDNA sequence analysis from these colonies identified the same gene product, SEC14L2 (tocopherol
associated protein 1 (TAP-1), supernatant protein factor 1 (SPF1)).
Huh 7.5 cells stably expressing SEC14L2 were transfected with wild type replicons from genotypes
1a, 1b, 2a, 3a, 4a, and 5a, and stably expressed wild type viral sequence. Patient derived HCV had
not previously resulted in persistent and productive infection in cultured hepatoma cells. When
SEC14L2 cells were inoculated with 1a, 1b and 3a patient sera with high viral titres viral replication
was detected in vitro.
3.2.2 SEC14L2 mechanism of action
SEC14L2 is a cytosolic lipid binding protein family member, which is ubiquitously expressed in human
tissues. SEC14L2 has 3 domains, an N terminal CRAL-TRIO domain that binds to small lipophilic
molecules, a SEC 14 like domain that contains a hydrophobic ligand binding pocket, and a C-terminal
GOLD domain that facilitates protein-protein interactions. All 3 domains were needed for HCV
replication. The functions of SEC14L2 include regulation of the PI3K/Akt signalling pathway,
cholesterol synthesis, and vitamin E metabolism. Neither the PI3K/Akt pathway nor cholesterol
synthesis related roles of SEC14L2 affected HCV replication.
SEC14L2 acts as a Vitamin E (tocopherol) binding protein. Vitamin E acts as a lipid soluble
antioxidant, inhibiting lipid peroxidation and enhanced HCV replication. HCV isolates resistant to
lipid peroxidation (e.g. JFH-1) showed no change in viral replication irrespective of SEC14L2
expression. When SEC14L2 cells were cultured in medium containing lipid depleted FBS (including
vitamin E) HCV replication was no longer supported.  This effect was reversed by vitamin E
supplementation
3.2.3 Results
SEC14L2 cells were kindly provided by Professor Peter Simmonds (Oxford). A Western blot was
performed to confirm the presence of SEC14L2 (figure 3.7). Following on from the previous work
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with Huh 7.5 cells cultured in Human serum, SEC14L2 cells were cultured in 10% FBS and 2% HS.
Viral replication in the SEC14L2 cells was then assessed.
Figure 3.7 Western blot confirming the presence of
SEC14 in SEC14L2 cells
As HCV replication had been shown in SEC14L2 cells using patient serum samples containing HCV
from genotypes 1 and 3 (by Saeed et al.) the cells were evaluated to assess if viral replication was
observed with serum from patients infected with Genotype 3 HCV with a range of viral loads, and at
different Magnitudes of infection (MOI). SEC14L2 cells were seeded at 1x105 per well in 6 well plates
and after 24 hours were incubated with patient serum containing HCV for 4 hours. The cell culture
medium was removed after 4 hours and fresh medium was added. Samples were harvested at Day 0
(4 hours post incubation with HCV), Day 1, Day 3, Day 5 and Day 7 post infection. Although HCV
replication did occur over 5 days with one patient serum sample containing HCV (see figure 3.8), no
viral replication was seen in SEC14L2 cells (cultured in either FBS or in human serum) with any other
patient serum samples containing HCV.  This may potentially be as a result of either the viral titres
used, be due to the lipid profile and vitamin E levels of patient derived HCV, or alternatively reflect
the need for replication enabling mutations when HCV from patient sera is used.
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Figure 3.8. Time course of in vitro HCV replication in SEC14L2 cells cultured with 10% Foetal
bovine serum or 2% Human serum following incubation with patient serum containing HCV
As robust viral replication from patient serum containing HCV was not observed following direct
incubation with the SEC14L2 cells further experiments were undertaken to evaluate the utility of the
SEC14L2 cells (cultured with 10% FBS) in the monocyte fusion assay. Four HCV genotype 3 patient
monocyte samples were chosen from patients with serum viral loads of 1x106-6x106. 1x106 patient
monocytes were fused with 1x106 Huh7.5 cells and a further 1x106 monocytes were fused with 1x106
SEC14L2 cells (figure 3.9). These experiments demonstrate that SEC14L2 cells facilitate a non-
significant increase in HCV viral replication in the monocyte fusion assay in samples with high serum
viral loads including patients with liver cirrhosis. Therefore, SEC14L2 cells were used alongside Huh
7.5 cells in subsequent experiments designed to optimise HCV replication in the monocyte/capture
fusion assay.
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Figure 3.9. A-D) HCV replication 5 days after fusion of monocytes from 4 different HCV patients with
Huh 7.5 and SEC14L2 cells E) Pooled data from all 4 monocyte fusion experiments
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3.3 Transfection of Huh 7.5 and SEC14L2 cells with a construct expressing ICAM bound
Protective Antigen Domain 4
In addition to evaluating modifications to Human hepatoma cells and their effect on viral replication,
experiments were undertaken to optimise monocyte-hepatocyte fusion. One of the limitations of
the capture fusion assay/monocyte fusion assay is the indiscriminate fusion of hepatocytes and
monocytes. The hypothesis that increased monocyte-hepatocyte fusion would increase viral
replication was tested by further modifying Huh 7.5 and SEC14L2 cells. Previous work undertaken by
our group in collaboration with Dr Angray Kang involved transfecting Huh 7.5 cells with plasmids
expressing anti-HCV E2 antibodies, anti-LDL antibodies, and LDLR fused to ICAM and assessing their
effect on HCV infection in Huh 7.5 cells. None of these synthetic receptors increased JFH or Con-1
infection of Huh7.5 cells.  In addition to these synthetic receptors a further plasmid had been
developed by Dr Kang to potentially increase hepatocyte/monocyte fusion. The pEGFP-C3 plasmid
was used with the EGFP cut out from the Nhel to the Xbal restriction sites. The EGFP sequence was
replaced by a leader sequence, Haemagglutinin tag, and Protective Antigen Domain 4 (PAd4)
Figure 3.10. pEGFP-C3 plasmid with EGFP cut out from Nhel to Xbal and replaced with ICAM
leader sequence followed by HA tag, and PAd4-ICAM sequence
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(from Bacillus anthracis) fused to ICAM (figure 3.10). Protective antigen domain 4 was selected as it
is a ligand for capillary morphogenesis gene 2 (CMG-2) which is expressed in monocytes (with
increased expression of CMG-2 upon differentiation of monocyte cell lines into macrophages using
PMA)163. We speculated that overexpression of this gene would enhance approximation of
monocytes and Huh7.5 cells leading to improved cell fusion and thereby enhanced viral replication
in the capture-fusion assay. Huh 7.5 cells and SEC14L2 cells were transfected with the plasmid (as
described in the methods section) and placed under G418 selection. Expression of PAd4-ICAM was
assessed by immunohistochemistry with a Tumour endothelial marker 8 (TEM-8) –Red fluorescent
protein (RFP) labelled antibody (see figure 3.11). TEM-8 is an alternative receptor for PAd4 (which is
predominantly expressed by vascular endothelial cells). Expression of PAd4-ICAM was confirmed by
flow cytometry and cell sorting (using a mouse anti haemagglutinin tag primary antibody and 488
goat anti mouse secondary antibody), cells from the highest decile of PAd4-ICAM expression were
selected to form stable cell stocks of Huh7.5 PAd4 and SEC14 PAd4 cells (figure 3.12).
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Figure 3.11. Huh 7 and Huh 7 SEC14 cells transfected with PAd4. Immunohistochemistry with
RFP labelled TEM8 A. Huh 7.5 PAd4 0.5µg B. Huh 7.5 PAd4 1µg C. Huh 7 SEC14 PAd4 1µg (G418)
D. Huh7 SEC14 PAd 4 1µg (G418/puro) E. Huh 7.5 (negative control)
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Figure 3.12. Flow cytometry data of A) Huh 7.5 cells (negative control) B) Huh 7.5 cells with
anti-HA primary and Alexa Fluor 488 secondary antibody C) Huh 7.5 PAd4 cells (negative
control) D) Huh 7.5 PAd4 cells with anti-HA primary and Alexa Fluor 488 secondary antibody.
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Huh 7.5 PAd4 cells were then evaluated in the monocyte fusion assay and compared to Huh 7.5 cells
to assess if transfection with PAd4 improved viral replication following monocyte fusion (using 6
samples from genotype 3 HCV patients with high serum viral loads 1x106-6x106). HCV replication
occurred with all 6 samples in Huh 7.5 PAd4 cells, and only in 4 samples in with Huh 7.5 cells. Data
from the four samples where replication occurred with both cell lines comparing viral replication is
shown in figure 3.13.
Figure 3.13. A-D) Monocyte fusion data for 4 different HCV patient monocyte samples E) Pooled
data from all 4 experiments
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Huh 7.5 cells transfected with PAd4 demonstrated a non-significant increase in HCV replication in
vitro in the monocyte fusion assay. Although the increase in HCV replication seen with Huh 7.5 PAd4
cells was non-significant, this increase in viral replication combined with the more consistent viral
replication observed in Huh 7.5 PAd4 (6/6 samples compared to 4/6 with Huh 7.5 cells) justified
evaluating these cells in additional assay optimisation experiments.
Further experiments evaluating HCV replication in vitro were undertaken using monocytes from HCV
infected patients with low serum HCV viral load. The three cell lines used for these experiments
Figure 3.14. A-D) Comparison between SEC and SEC14 PAd4 cells with 4 different HCV patient
monocyte samples (with low serum viral load) E) Pooled data from all four samples
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were SEC14L2 cells, Huh 7.5 PAd4 cells and SEC14L2 PAd4 cells. 4 monocyte samples from genotype
3 HCV patients with cirrhosis were used. The serum HCV viral loads of the samples used ranged from
2x104 to 1x106 IU/ml. SEC14 L2 cells were initially compared with SEC14L2 PAd4 cells (figure 3.14).
HCV viral replication was non-significantly increased in monocyte fusion experiments using SEC14
PAd4 cells compared to SEC14 cells, Huh 7.5 PAd4 and SEC14 PAd4 cells were also compared (figure
3.15) in the monocyte fusion assay to determine which cell line would be most effective to be used
in the monocyte fusion assay with samples from the TIG3 trial which included several patients with
low serum HCV viral loads.
Figure 3.15. A-D) Comparison between Huh7.5 PAd4 and SEC14 PAd4 cells with 4 different
HCV patient monocyte samples (with low serum viral load) E) Pooled data from all four
samples
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The SEC14 PAd4 cells demonstrated significantly greater HCV replication than Huh 7.5 PAd4 cells,
and increased viral replication compared to SEC14 cells. Therefore, SEC14 PAd4 cells were used for
subsequent monocyte and capture fusion experiments related to the TIG3 trial.
3.4 Conclusions
The optimisation experiments that were undertaken highlighted the challenges faced in achieving a
robust in-vitro HCV replication system. As one of the aims of the telaprevir in genotype 3 trial was to
evaluate in vitro sensitivity of patient derived HCV to telaprevir, assay optimisation could only focus
on adaptations to the hepatoma cell lines used. Three different adaptations were evaluated,
culturing hepatoma cells in human serum, using hepatoma cells transfected with SEC14L2 cDNA, and
using cells transfected with PAd4. The first two adaptations attempted to address potential factors
which inhibited replication of patient derived HCV in vitro, whilst the final adaptation was more
specifically targeted at potentially improving the efficacy of monocyte-hepatoma cell fusion in the
capture fusion assay. Although modest changes were noted with the use of human serum and
SEC14L2 cells these adaptations alone did not result in a marked increase in patient derived HCV
replication in vitro.  The SEC14L2 cells transfected with PAd4 demonstrated increased HCV
replication in the capture fusion assay, including in patient samples with lower viral loads. These
cells were therefore also used in the telaprevir in genotype 3 trial to assess in-vitro telaprevir
sensitivity.
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Chapter 4: Telaprevir in patients with Genotype 3 Hepatitis C:
Pilot clinical study to evaluate efficacy and predictability of therapy
in patients who have failed to respond to pegylated interferon and
ribavirin.
4.1 Background
Genotype 3 hepatitis C is the second commonest genotype of HCV in the United Kingdom accounting
for 44% of HCV in England48. The majority of treatment naïve, non-cirrhotic patients respond to
treatment with Pegylated Interferon and Ribavirin. In Genotype 3 HCV patients with cirrhosis the
success rates are less than 60%96 and patients that fail to eradicate the virus are at risk of
complications of chronic liver disease, and at the time of trial inception (prior to sofosbuvir
becoming available) there were no alternative treatments for these Genotype 3 cirrhotic patients
who had previously failed treatment with interferon and ribavirin.
Telaprevir formed the standard of care treatment for patients with genotype 1 HCV, achieving SVR
rates of >75%122,124. Telaprevir is given with pegylated interferon and ribavirin for a total duration of
12 weeks and the interferon-based therapy is then continued for a further 12 or 36 weeks,
depending upon pre-treatment characteristics. Telaprevir in combination with pegylated interferon
and ribavirin was shown to be effective even in patients who had previously failed to respond to
therapy with pegylated interferon and ribavirin.  Patients who demonstrated an early virological
response were more likely to achieve an SVR, as no patients with a HCV viral load of >1000 at week 4
on treatment achieved a SVR. Similarly, only 25% of patients with a HCV viral load between 100 and
1000 at week 4 achieved a SVR164.
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Clinical trials with telaprevir monotherapy in patients with Genotype 3 HCV demonstrated that most
patients had a very modest decline in HCV viral load (0.5log), but a minority (~30%) had a drop in
HCV RNA >2log125. Previous work from our group156 showed that patients with Genotype 3 HCV who
responded to telaprevir monotherapy had demonstrable sensitivity to telaprevir in our ‘capture-
fusion’ assay. This led to the hypothesis that for patients with Genotype 3 HCV who had no
reasonable alternative treatment options therapy with pegylated interferon, ribavirin and telaprevir
may allow some patients to respond to treatment. We further hypothesised that patients likely to
respond to triple therapy with pegylated interferon, ribavirin and telaprevir could be identified by
pre-treatment assessment of sensitivity to telaprevir using the ‘capture-fusion’ assay. At the time
this trial was conceived and initiated there were no available treatment alternatives to pegylated
interferon and ribavirin for patients with Genotype 3 HCV and for patients with cirrhosis who had
failed to respond to this medication the standard of care was ‘no treatment’. During the course of
this trial alternative medications for the treatment of Genotype 3 HCV became available and at that
time we determined that it was no longer appropriate to enrol patients to the trial, which was
therefore discontinued early.
4.2 Trial objectives and outcomes
Primary objective: To determine whether patients with genotype 3 HCV and cirrhosis who have
relapsed following therapy with PegIFN and RBV will achieve a sustained virological response (SVR) if
treated with telaprevir, PegIFN and RBV.
Secondary objective: To determine whether pre-treatment viral phenotyping predicts the response
to therapy with telaprevir in patients with G3 HCV and cirrhosis.
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Primary outcome: The proportion of patients with a sustained virological response (SVR) 12 weeks
after end of treatment (SVR12). SVR 12 is defined as undetectable HCV RNA on a blood sample taken
between 12 and 18 weeks after the end of treatment measured using a sensitive, validated
polymerase chain reaction (PCR) assay with a lower limit of quantification of at least 30 IU/ml. End of
treatment is defined as date of final dose of any IMP (whichever is the latest date).
Secondary outcomes:
 The proportion of patients who are phenotypically poorly responsive to telaprevir (defined as virus
with a poor response to telaprevir in vitro i.e. an IC50of >10 μMol in an in vitro assay) who achieve
early and late virological clearance.
 The proportion of patients with a sustained virological response 24 weeks after the last dose of
PegIFN and RBV (SVR24). SVR 24 is defined as undetectable HCV RNA on a blood sample taken
between 24 and 30 weeks after the final dose of PegIFN and ribavirin measured using a sensitive,
validated polymerase chain reaction (PCR) assay with a lower limit of quantification of at least 30
IU/ml.
 The proportion of patients who have undetectable HCV RNA (measured using a sensitive, validated
polymerase chain reaction (PCR) assay with a lower limit of quantification of at least 30IU/ml) after
1,2,3 and 4 weeks of therapy with PegIFN, RBV and telaprevir.
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4.3 Contributions
I co-authored the study protocol (with assistance from Professor Graham Foster and Ailsa
Wetherall), and subsequently managed the research and ethics committee and Medicines and
Health Regulatory Authority submissions. I devised the study laboratory protocols and standard
operating procedures to ensure the laboratory-based component of the trial was compliant with
good clinical practice principles. I initiated the different trial sites (with assistance from Ailsa
Wetherall) and then monitored trial progress at all the participating sites (with assistance from
Adrienne Richards). I uploaded case report forms onto the Discovere database which was used for
data collection from the trial. At the Royal London site, I was involved in patient identification and
recruitment, along with the management of patients on the clinical trial. I was responsible for data
collection, data management and analysis of the trial outcomes. I performed and analysed all of the
‘capture-fusion’ analyses.
4.4 Study Design
Patients who fulfilled the study inclusion and exclusion criteria received open label treatment with
12 weeks of Telaprevir 1125mg twice daily, PegIFN alfa 2a 180 µg once weekly and ribavirin 400mg
twice daily followed by 12 weeks of PegIFN alfa 2a 180 µg once weekly and ribavirin 400mg twice
daily. Samples were taken for viral phenotyping prior to treatment commencing and at 8 weeks on
treatment (figure 4.1). Strict ‘stopping rules’ were included in the trial to ensure that futile therapy
was identified and therapy discontinued as soon as it was clear that therapy was ineffective.
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Figure 4.1 Schematic of Study Protocol with treatment stopping rules based on virological response
and samples collected for in-vitro drug sensitivity phenotyping
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4.5 Study patient selection
Patients attending outpatient clinic at study sites who were deemed suitable for this study were
identified by their consultant and were contacted to ascertain if they wished to participate in the
study. Those who were willing to participate were provided with a patient information sheet about
the study. After study subjects had reviewed the information (for at least 24 hours after receiving
the information sheet) those that still wished to participate were consented and enrolled onto the
study.
The inclusion criteria for the study included patients with low haemoglobin levels, low neutrophil
counts and low platelet counts who were excluded from treatment with telaprevir according to the
drug license. However, since licensing of telaprevir substantial real-world experience had shown that
such patients could be treated safely and as such patients had very limited treatment options (and
therefore an urgent unmet need for treatment) at the time of study recruitment they were deemed
suitable candidates for the study and approval from the MHRA for their inclusion in this study was
requested and given. Hence the study involved ‘off label’ use of telaprevir in genotype 3 HCV in
patients who had characteristics that excluded their treatment according to the telaprevir license
(which was only for patients with genotype 1 HCV).
The study aimed to recruit 30 patients, with competitive recruitment across all study sites. This
number trial participants would enable further evaluation of the findings noted in the previous
telaprevir monotherapy trial and the preliminary capture fusion findings (as described in the primary
and secondary outcomes for the trial). The sample size of 30 was calculated based on guidance from
the National Institute for Health Research, Research Design Service (as there was only limited data
for the efficacy of pegylated interferon and ribavirin in the retreatment of genotype 3 hepatitis C in
patients with cirrhosis). The inclusion and exclusion criteria for trial participants were designed to
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ensure that treatment with telaprevir, PegIFN and ribavirin was appropriate (i.e. the patient had
limited treatment options and a delay in treatment was likely to have harmful effects), and that the
risk of serious adverse events was minimised by early discontinuation of therapy in patients where a
response to treatment was thought improbable based on the early virological response.
4.6 Inclusion criteria
• Age ≥18 years of age and ≤70 years old.
• Advanced fibrosis - defined as a liver biopsy within 2 years showing an Ishak fibrosis score of >4 OR
radiological evidence of cirrhosis (ultrasound scan or fibroscan reading >10.6kPa).
• Previous therapy with pegylated interferon and ribavirin for at least 24 weeks with undetectable
HCV RNA at the end of therapy and detectable HCV RNA six months after treatment cessation.
• Chronic genotype 3 HCV infection, RNA positivity with genotype 3 infection confirmed at a local
laboratory.
• HBsAg negative and no clinical evidence of co-infection with HIV.
• Platelet count >50,000 cells/mm3 (support with eltrombopag is permitted).
• Neutrophil count > 600 cells/mm3.
• All female patients of childbearing potential and all males with female partners of childbearing
potential must be prepared to use two forms of effective contraception (combined) during
treatment and 6 months after treatment end.
• Able and willing to give informed consent and able to comply with study.
4.7 Exclusion Criteria
• Evidence of other cause of significant liver disease – serum ferritin > 1000, biochemical evidence of
Wilson’s disease, autoantibody titres in excess of 1:160.
• Poorly controlled diabetes that, in the investigators opinion, precludes therapy.
• Severe retinopathy that, in the opinion of the investigator, precludes therapy.
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• Evidence of ascites seen on previous liver ultrasound.
• Haemoglobin concentration <11 g/dL in females or <12 g/dL in males or any patient with an
increased risk for anaemia (e.g., thalassemia, sickle cell anaemia, spherocytosis, history of
gastrointestinal bleeding) or for whom anaemia would be medically problematic.
• Albumin levels <35 G/L.
• Females who are pregnant or breast-feeding.
• History of severe psychiatric disease, including psychosis and/or depression, characterized by a
suicide attempt, hospitalization for psychiatric disease, or a period of disability as a result of
psychiatric disease within the last 2 years.
• History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic
thrombocytopenic purpura, lupus erythematosus, autoimmune haemolytic anaemia, scleroderma,
severe psoriasis (defined as affecting >10% of the body, where the palm of one hand equals 1%, or if
the hands and feet are affected), rheumatoid arthritis requiring more than intermittent nonsteroidal
anti-inflammatory medications for management.
• Other on-going serious medical condition in the opinion of the investigator that would prohibit
treatment.
• Poorly controlled thyroid dysfunction that, in the investigators opinion, precludes therapy.
• History of major organ transplantation with an existing functional graft.
• History of severe pre-existing cardiac disease, including unstable or uncontrolled cardiac disease in
the previous 6 months.
• History or laboratory testing showing evidence of a haemoglobinopathy.
• Concomitant administration with active substances that are highly dependent on CYP3A for
clearance and for which elevated plasma concentrations are associated with serious and/or life-
threatening events. These active substances include alfuzosin, amiodarone, bepridil, quinidine,
astemizole, terfenadine, cisapride, pimozide, ergot derivatives (dihydroergotamine, ergonovine,
ergotamine, methylergonovine), lovastatin, simvastatin, atorvastatin, sildenafil or tadalafil (only
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when used for treatment of pulmonary arterial hypertension) and orally administered midazolam or
triazolam.
• Concomitant administration with Class Ia or III antiarrhythmics, except for intravenous lidocaine.
• Concomitant administration of INCIVO with active substances that strongly induce CYP3A e.g.
rifampicin, St John's wort (Hypericum perforatum), carbamazepine, phenytoin and phenobarbital
and thus may lead to lower exposure and loss of efficacy of INCIVO (telaprevir).
For patients that were enrolled onto the trial stringent ‘stopping rules’ were applied to minimise
exposure to trial medication in patients who were unlikely to benefit from treatment. These
stopping rules were based on data from clinical trials evaluating telaprevir in genotype 1 HCV.
Virological response at week 4 was predictive of treatment outcome in these trials so similar criteria
were applied to this trial. The virological stopping criteria were as follows (figure 4.1):
• If the viral load after 4 weeks of therapy with PegIFN, Ribavirin and telaprevir was
>1000 IU/ml, therapy would be abandoned and the patient would be deemed a non-responder to
therapy.
• If the viral load at week 8 was greater than 1000 IU/ml OR the viral load had not declined by more
than 3 logs from the pre-treatment viral load, therapy would be abandoned and the patient deemed
a non-responder to therapy.
In addition to virological criteria determining whether treatment should be discontinued, patient
safety criteria were also included which would result in treatment discontinuation. These criteria
were:
1. Patients would be withdrawn from the study if there was evidence of systemic drug toxicity which,
in the opinion of the investigator, modified the risk: benefit ratio in favour of harm.
2. Request of the participant or discretion of the investigator.
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3. Inability or participant’s failure to comply with the protocol requirements.
4. Pregnancy in a trial participant or their partner.
The trial protocol received approval from North East London Research Ethics Committee in
November 2013, with Medicines and Healthcare Products Regulatory Agency approval in June 2014.
The first trial participant was screened on the 7th of July 2014. Fourteen patients were recruited at
the four participating sites (The Royal London Hospital; Queen’s Medical Centre, Nottingham; St
George’s Hospital, London; and the Bradford Royal Infirmary), with the final trial participant enrolled
on the 6th of November 2014. Trial recruitment was terminated early as sofosbuvir based all oral
regimens became available on the early access programme in England and it was expected that
patients with compensated cirrhosis would eligible for those treatments in the subsequent 12
months.
4.8 Results
Trial Participant demographic data
Fourteen patients were recruited onto the trial. There were ten male patients and four female
patients. The median age of trial participants was 49 years (range 32-63 years). Seven patients were
Asian, six were Caucasian and one patient described their ethnicity as other (table 4.1).  All patients
had advanced liver fibrosis or cirrhosis secondary to Hepatitis C, and all had relapsed following
previous treatment with interferon and ribavirin. Thirteen out of the fourteen patients had
additional co-morbidities; diabetes was the commonest co-morbidity (n=7), followed by
hypertension (n=4), dyspepsia (n=4), skin conditions (n=3), depression (n=3), hypothyroidism (n=2),
previous hysterectomy (n=2), insomnia (n=1), hay fever (n=1). The co-morbidities for each individual
trial participant are listed in table 4.2, with medications they were taking shown in table 4.3. The
medications taken by trial participants at screening correlated with their medical history.
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Demographic data (at
screening)
n=14
Age (years) 47 (32-63)
Gender
Male 10 (71%)
Female 4 (29%)
Ethnicity
Caucasian 6 (43%)
Asian 7 (50%)
Other 1 (7%)
Comorbidities
Diabetes 7 (50%)
Hypertension 3 (21%)
Skin Conditions 3 (21%)
Hypothyroidism 2 (14%)
Depression 2 (14%)
Dyspepsia 2 (14%)
Previous hysterectomy 2 (14%)
Insomnia 1 (7%)
Hay fever 1 (7%)
Table 4.1. Demographic characteristics of Study participants at screening
Table 4.2 Co-morbidities for each trial participant
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Table 4.3 Medications taken by trial participants at their baseline visit
Five diabetic patients were on medication (metformin), of these five two were also on a second
diabetic medication (glimepiride (n=1) and gliclazide (n=1)). Four patients with hypertension were on
antihypertensive medications (ramipril n=3 and losartan n=1). The mean blood pressure for trial
participants at their baseline visit was 131/79 mmHg (range 110-165/59-107), along with a pulse
rate of 83 beats per minute (range 67-98). The four patients with dyspepsia were on medication for
this (lansoprazole n=3, omeprazole n=1, and gaviscon n=1). One patient was on both lansoprazole
and gaviscon. Mean results (and range) at baseline (as demonstrated in figure 4.2) were: HCV viral
load 2.5x106 IU/L (1x105-1x107); alanine transaminase levels of 104.5 IU/L (33-366), bilirubin 10
µmol/L (6-20), sodium 138 mmol/L (133-142), creatinine 62 µmol/L (35-78), haemoglobin 145.6 g/L
(104-167) and platelet count 139 x109/L (53-243).
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Figure 4.2. Baseline results: a) HCV viral load b) ALT c) Bilirubin d) Sodium e) Creatinine f)
Haemoglobin g) Platelets
4.9 Patient Outcomes
Of the 14 patients that commenced treatment, 13 completed the trial (until they met one of the
predetermined trial endpoints). Three patients did not achieve a sufficient virological response at
week 4 so their treatment was discontinued. All 10 of the remaining trial participants achieved the
virological response necessary at week 8 to continue on treatment. One participant had virological
breakthrough on treatment at week 12. Nine patients completed 24 weeks of treatment, of these
four achieved an SVR 24 and five relapsed. One patient withdrew from the trial after two weeks of
treatment due to adverse events. An overview of the overall outcomes for trial participants is shown
in figure 4.3. The baseline demographics and laboratory results of patients with each trial outcome
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(SVR, relapse, treatment stopped at week 4, virological breakthrough and withdrawal from the trial)
are listed in table 4.4, and figure 4.4
Figure 4.3. Overview of trial participant outcomes
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Table 4.4 Baseline demographics of patients with different trial outcomes
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Figure 4.4 Demographic and Laboratory results at baseline for patients in different treatment
outcome groups a) Age b) HCV RNA c) ALT d) Sodium e) Haemoglobin f) Platelets
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4.9.1 Results from Baseline to Week 4 on treatment
After one week on treatment the viral loads of trial participants had declined by a mean of 2.05
log10 IU to 88,596 IU, the virological decline seen in groups of patients with different outcomes is
shown in figure 4.5. The alanine transaminase (ALT) levels of trial participants had improved to a
mean of 40.4 IU/L (SD 13.6), with different changes in each group of patient outcomes (figure 4.5).
Haemoglobin and platelet counts remained stable (figure 4.5) at a mean value of 131 g/L. Only one
trial participant reported adverse events in the first week of treatment (headaches, fatigue, difficulty
sleeping, itchy skin and decreased appetite). Two patients were commenced on high energy dietary
supplements, one was commenced on paracetamol, and one patient was commenced on saxagliptin
for diabetes (in addition to metformin).
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Figure 4.5 Week 1 on treatment biochemistry results (l) and change from baseline (r) a) HCV RNA
b) ALT, c) Bilirubin d) Haemoglobin e) Platelets
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At week two a further decline in viral load was noted to a mean of 37,598 IU (a drop of 3.16 log from
baseline) (figure 4.6) with ALT levels had changed to a mean of 89.3 IU/L (SD 129.9), with a median
value of 38 IU/L, which represented a mean drop in ALT of 13.6 IU (figure 3.6). At this point a
decrease in haemoglobin was noted in some trial participants (figure 4.6) to a mean of 131.9 g/L (SD
15.9) which was a mean drop of 13.6 g/L (SD 17.14) and one participant withdrew from the trial at
this point due to adverse events (abdominal pain, nausea and pruritis). Five other trial participants
had also reported adverse events (flu symptoms, lethargy, low mood, maculopapular rash, nausea,
and palpitations) by week 2 on treatment. By week two on treatment one further patient had been
commenced on paracetamol as needed and calogen.
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Figure 4.6 Week 2 on treatment biochemistry results (l) and change from baseline (r) a) HCV RNA
b) ALT, c) Bilirubin d) Haemoglobin e) Platelets
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At week 4, the mean viral load of all trial participants had dropped further to a mean of 648.5 IU (a
mean of drop in HCV viral load of log 3.39). The four patients who achieved an SVR had a mean viral
load of 130 IU/ml, the 5 patients who relapsed had a mean viral load of 332 IU/ml while three
patients (mean HCV RNA 2078 IU/ml) did not achieve a sufficient virological response (HCV RNA
<1000) and had their treatment discontinued (figure 4.7). There was a significant difference in the
viral loads of patients who achieved an SVR or relapse compared to those that stopped treatment at
week 4 (p=0.03 and p=0.05 respectively). Mean ALT levels remained at 95 IU/ml (median 35.5 IU/ml,
SD 123 IU/ml) although the majority of patients were noted to have an improvement in ALT from
baseline. A further drop in haemoglobin was also noted to a mean of 129 g/L (SD 16) with the
haemoglobin levels and changes from baseline shown for each different patient outcome group.
(figure 4.7).
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Figure 4.7. Week 4 on treatment biochemistry results (l) and change from baseline (r) a) HCV
RNA b) ALT, c) Bilirubin d) Haemoglobin e) Platelets
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The trends for HCV viral load and serum biochemistry from baseline to week 4 on treatment are
shown in figure 4.8. This shows that all groups of patients irrespective of trial outcome
Figure 4.8 Trend of HCV viral load and biochemistry in trial participants from baseline visit to
week 4 on treatment: a) HCV viral load b) Haemoglobin c) Platelets d) ALT e) Bilirubin
had a progressive drop in HCV viral load from their baseline visit to week 4 on treatment. The
haemoglobin and platelet levels of trial participants also dropped from baseline visit to week 4 on
treatment (by a mean of 20.2 g/l haemoglobin and 49 giga/l platelets). Liver biochemistry changes
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were also noted over the first 4 weeks of treatment, with the mean ALT of trial participants
decreasing by 15 IU/L and bilirubin rising by 4.7 µmol/L. Trial participants had experienced further
adverse events by week 4 (nausea, musculoskeletal pain, skin symptoms (rash/itching) (n=5), flu like
symptoms (n=4), Sore throat, dyspnoea, irritability (n=3), lethargy, headaches (n=2), proctalgia,
insomnia, altered taste (n=1)). The patient that withdrew from the trial was commenced on
metoclopramide, cyclizine, and esomeprazole for their symptoms between week 2 and 4 on the trial.
Four patients received treatment for pruritis and rash: loratidine and betnovate (n=1), E45 cream
(n=1), oilatum (n=1), diprobase and chlorpheniramine (n=1). Patients were also commenced on
ferrous sulphate for anaemia (n=1), lansoprazole for dyspepsia (n=1), paracetamol for leg pain (n=1),
and ondansetron for nausea (n=1).
4.9.2 Results from week 4 to week 12 on treatment
The HCV viral load of trial participants who achieved a viral load of <1000 IU at week four (and
therefore continued treatment) declined further from week 4 to week 8 to a mean of 10 IU/ml (with
all trial participants having a viral load <30) figure 4.9. As all remaining trial participants had a viral
load of <100 IU at week 8, all 10 continued on treatment. Haemoglobin and platelet counts had
stabilised at the levels seen at week 4 with only small changes from week 4 to week 8 (a mean of 7.7
g/L rise in haemoglobin and 15.1 giga/L rise in platelets were noted). ALT levels had improved
further (mean drop 37 IU/L (although SD was 92 IU/L) and bilirubin levels remained stable with only
a mean of 2.78 µmmol/L increase noted. From week four to eight all trial participants experienced
further adverse events. These included gastrointestinal symptoms (vomiting/nausea n=6, decreased
appetite n=2, altered taste n=2, proctalgia n=1, constipation n=1), musculoskeletal symptoms
(muscular pain n=3, abdominal pain n=1, cramps n=1), respiratory symptoms (cough n=3, dyspnoea
n=1), neuropsychiatric symptoms (insomnia n=2, dizziness n=2, headache n=1, paraesthesia n=1,
visual disturbance n=1, irritability n=1, anxiety n=1, depression n=1),
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Figure 4.9 Week 8 on treatment HCV RNA (l) and change from week 4 (r)
skin symptoms (rash n=4, itching n=2, and hair loss n=1) and other symptoms (lethargy n=4, dysuria
n=2, flu like symptoms n=2, weakness n=1, temperature n=1, sweats n=1, sore throat n=1). One
patient was noted to have biochemical abnormalities (anaemia and thrombocytopenia which were
identified between weeks 4 to 8). Trial participants commenced additional medication for certain
adverse events: three patients with nausea needed medication (ondansetron n=2, cyclizine n=1);
three patients with rashes/pruritis commenced treatment (cetirizine n=2, topical cream n=3); two
patients commenced medication for musculoskeletal pain (paracetamol n=1, and co-codamol n=1);
two patients with a cough/sore throat were given antibiotics (amoxicillin n=1, clarithromycin n=1)
and one commenced simple linctus; one patient commenced omeprazole for dyspepsia; one patient
commenced anusol for proctalgia; and one patient commenced darbopoetin for anaemia.
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At week 12 ten trial participants had completed 12 weeks of treatment with Telaprevir, pegylated
interferon and ribavirin. Only three of the 10 trial participants had detectable RNA at this point
(figure 4.10). Two participants had HCV RNA <15 IU/ml, and one <30 IU/ml. One of the trial
participants was noted to have HCV RNA <15, having previously had undetectable HCV RNA levels.
On repeat testing this individual was noted to have virologic breakthrough and their treatment was
discontinued. Haemoglobin, platelet counts and liver biochemistry of trial participants remained
stable from week 4 to 12 (figure 4.10) with only a mean 3 g/L change in haemoglobin, a mean 11.9
giga/L change in platelets, an ongoing improvement in ALT (mean decrease of 53 IU/L) and mean 3.4
µmol/l change in bilirubin. At week 12 further patients had experienced adverse events: rash (n=5),
nausea (n=2), poor concentration (n=2), insomnia (n=1), and diarrhoea (n=1). Four patients
commenced additional treatment for rashes (cetirizine n=1, chlorpheniramine n=1, sudacrem n=1,
and cetraben n=1); one patient commenced cyclizine and gaviscon for nausea; and one patient
started corsodyl mouth wash for mouth ulcers.
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Figure 4.10. Week 12 on treatment biochemistry results (l) and change from week 4 (r) a) HCV
RNA b) haemoglobin, c) platelets d) ALT e) bilirubin
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4.9.3 Week 12-24 on treatment
The remaining nine trial participants continued on the trial with a further 12 weeks of Pegylated
Interferon and Ribavirin. At week 16 all trial participants bar one had undetectable HCV RNA. This
patient subsequently relapsed post treatment. Trial participants’ biochemistry remained stable from
week 12 to week 16 on treatment. Mean haemoglobin was 129 g/L, platelet count was 80 giga/L,
ALT was 90.7 IU/L and bilirubin was 10.7 µmmol/L. Between weeks 12 and 16, patients experienced
several more adverse events: two developed a rash, one developed a dental abscess, one developed
thrush, and one patient developed an elevated GGT (attributed to alcohol consumption). Two
patients commenced treatment for their rash (one patient started cetirizine and diprobase, and one
commenced betnovate cream); the patient with thrush commenced on canesten; and the patient
with a dental abscess was treated with metronidazole.
At week 20 all participants bar the one that had detectable HCV RNA at week 16 had undetectable
HCV RNA. Trial participants’ biochemistry remained stable from week 16-20. Haemoglobin remained
at 129 g/L, platelet count was 86 giga/L, ALT was 106.6 IU/L and bilirubin 11 µmmol/L. Two patients
had developed further adverse events: One developed a rash, and one developed paraesthesia. Two
patients commenced treatment for rashes (chlorpheniramine n=1, and E45 cream n=1).
At the end of treatment all patients who achieved an SVR had an undetectable HCV viral load, while
2 of the 5 patients who relapsed had detectable HCV RNA (figure 4.11). Mean haemoglobin at this
point was 128 g/L, platelet count was 76 giga/L, ALT 88.9 IU/L and bilirubin 11 µmmol/L. Adverse
events occurred between weeks 20 and 24: one trial participant developed chest pain and a rash,
one developed a cough, one developed a urinary tract infection, one developed insomnia, and
another developed muscular back pain. Treatment was commenced with trimethoprim for the
patient with a UTI, and benylin for the patient with a cough.
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Figure 4.11 End of treatment biochemistry results (l) and change from week 12 (r) a) HCV RNA b)
ALT c) bilirubin d) haemoglobin e) platelets
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4.9.4 Post treatment
At week 12 post treatment four of nine patients had a detectable viral load (figure 4.12), with a
mean HCV viral RNA of log 5.6 IU/ml. Mean haemoglobin had increased to 145.9 g/L, as had the
mean platelet count which was now 141 giga/L. Mean ALT had risen to 128.9 IU/L and mean bilirubin
was 8.3 µmol/l.  Two further adverse events were noted: rectal bleeding (n=1), and dysuria (n=1).
At week 24 post treatment only the 4 patients who achieved an SVR and one patient who relapsed
(HCV viral load log 5.9 IU/ml) remained on the trial (figure 4.13). Mean haemoglobin had remained
at 149.6 g/L, mean platelets remained at 135 giga/L, mean ALT was 48 IU/L and mean bilirubin was
10.  Post treatment further trial participants experienced adverse events: one had developed
muscular back pain and sciatica, one developed eczema on both shins, one developed increased
urinary frequency and rectal bleeding, one developed cramps, and one developed a coryzal illness.
The patient with eczema was commenced on hydrocortisone cream, and the patient with sciatica
was commenced on co-codamol and gabapentin.
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Figure 4.12. Post treatment week 12 biochemistry results (l) and change from end of treatment
(r) a) HCV RNA b) ALT c) bilirubin d) haemoglobin e) platelets
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Figure 4.13. Post treatment week 24 HCV RNA
4.10 Adverse events
There was only one serious adverse event during the trial. This occurred after one of the trial
participants had been screened but prior to their baseline visit. The patient was admitted for under
24 hours with confusion, agitation and aggression. This was thought to be secondary to alcohol and
substance misuse, and resolved spontaneously. That individual subsequently tolerated treatment as
per trial protocol and completed 24 weeks of treatment. Treatment on the trial was tolerated
relatively well with only one patient withdrawing from the trial due to treatment side effects. This
may be because the trial participants had previously tolerated treatment with interferon and
ribavirin. Despite all patients except one reaching a trial endpoint for treatment, the combination of
telaprevir, interferon and ribavirin resulted in all patients experiencing adverse events during
treatment (table 4.5). The most frequently reported adverse events were skin related (n=28),
followed by gastrointestinal (n=24), neuropsychiatric (n=24), general/systemic (n=22),
musculoskeletal (n=12), respiratory (n=6), urological/gynaecological (n=6), biochemical
abnormalities (n=4), oral (n=3), and other categories (n=2). The breakdown of each of those
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Table 4.5 Adverse events experienced by trial participants
categories is shown in table 4.6.  Skin related side effects were: rash (n=21), pruritis (n=5), with
periorbital oedema and hair loss each experienced by one trial participant. Gastrointestinal adverse
events were: nausea (n=10), vomiting (n=3), loss of appetite (n=3), dyspepsia/reflux (n=3),
constipation (n=1), diarrhoea (n=1), proctalgia (n=1), rectal bleeding (n=1), and abdominal pain
(n=1). Neuropsychiatric adverse events were: insomnia (n=6), dizziness (n=4), paraesthesia (n=3),
memory impairment (n=2), visual disturbance (n=2), dysgeusia (n=2), depression (n=2), irritability
(n=1), ear pain (n=1), and anxiety (n=1). General/systemic adverse events experienced were: fatigue
(n=7), coryzal symptoms (n=6), pyrexia (n=4), headache (n=3), and weakness (n=2). Musculoskeletal
adverse events were: musculoskeletal pain (n=12). This was divided into: generalised
musculoskeletal pain (n=5), lower limb pain (n=3), back pain (n=3), and chest pain (n=1). Respiratory
adverse events were: cough (n=5), dyspnoea (n=1). Urological/gynaecological adverse events were:
dysuria (n=3), urinary tract infection (n=1), vaginal discomfort (n=1), vaginal thrush (n=1).
Biochemical abnormalities noted were: raised bilirubin (n=1), raised gamma GT (n=1), anaemia
(n=1), and thrombocytopenia (n=1).
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Table 4.6 Adverse events episodes by body system
Oral/dental adverse events were: dental abscess (n=1), mouth ulcers (n=1), and sore mouth (n=1).
The remaining adverse events were: foot injury after treading on a nail (n=1), and injection site
reaction (n=1).
The majority of these adverse events occurred early during treatment, of a total of one hundred and
thirty-one adverse effects noted, thirty-eight were recorded during the first 4 weeks of treatment
(with nineteen of these occurring during the first fortnight of treatment). A further fifty-eight
adverse events occurred by week eight on treatment, and only a further thirteen adverse events
were recorded by week twelve on treatment. Fourteen further adverse events were recorded from
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weeks twelve to twenty-four on treatment. Eight adverse events commenced after patients
completed treatment.
The majority of the adverse events experienced were mild (n=98, 75%), 32 were moderate (24%)
and only one adverse event was graded as severe. The severe adverse event was for a patient who
had chest pain at week twenty on treatment. That patient attended their local emergency
department and was discharged after having blood tests taken and an ECG performed. This was not
thought to be due to the trial medications, and the patient was not commenced on any additional
regular medication. Unfortunately, their symptoms persisted until the end of follow up although
they did not need any additional medications or treatment. The majority of adverse events (n=94,
72%) experienced by trial participants resolved by the end of the trial follow up period (twenty-four
weeks post treatment). The median duration of adverse events experienced was three weeks
(standard deviation 8.1 weeks). Thirty-seven (28%) of adverse events experienced were still ongoing
at the end of treatment. Six of these were adverse events experienced after patients had completed
treatment. The adverse events still experienced at the end of trial follow up were gastrointestinal
(n=9, (dyspepsia n=3, loss of appetite n=2, nausea n=2, rectal bleeding n=1 and diarrhoea n=1)),
neuropsychiatric (n=8, (insomnia n=3, depression n=1, dizziness n=1, irritability n=1, paraesthesia
n=1, ear pain n=1)), skin (n=7, (pruritis n=4, rash n=3)), musculoskeletal pain (n=5),
general/constitutional side effects (n=4, (fatigue n=2, coryzal symptoms n=1, pyrexia n=1),
biochemical abnormalities (n=3,   (anaemia n=1, thrombocytopenia n=1, abnormal liver biochemistry
n=1)) and urogynaecological (n=1, (dysuria n=1).
Two of the adverse events experienced (low haemoglobin and coryzal symptoms) were thought to
be definitely due to the IMP. Eighteen adverse events were thought to be probably related to the
IMP (rash n=5, fatigue n=3, nausea n=2, insomnia n=2, coryzal symptoms n=1, pyrexia n=1, dyspepsia
n=1, irritability n=1, poor concentration n=1, pruritis n=1). Of the remaining adverse events
experienced 47 were possibly related to the IMP, and 61 were unlikely to be, or were not related to
the IMP. With regards to action taken for adverse events, one patient temporarily discontinued all
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three IMPs due to nausea, and one patient had both their ribavirin and interferon dose decreased
for anaemia and thrombocytopenia respectively. Twenty-seven adverse events resulted in the
patient receiving an additional medication, these were (rash n=8, dyspepsia n=3, pruritis n=2,
musculoskeletal pain n=2, insomnia n=2, vomiting n=2, urinary tract infection n=1, vaginal
discomfort n=1, cough n=1, proctalgia n=1, pyrexia n=1, coryzal symptoms n=1). Fourteen adverse
events needed additional action taken: six patients were monitored by their local HCV nurses and
needed a prescription (these were for headache n=2, nausea n=1, mouth ulcers n=1, rash n=1,
vaginal candidiasis n=1); four adverse events were monitored by the local HCV nurses. One referral
was made the local dermatologists for assessment of a rash. One patient had an additional ECG
during the trial. One patient was seen in the emergency department for chest pain then discharged
(without needing admission). One final patient had their dose of interferon and ribavirin reduced
due to thrombocytopenia and anaemia (as described above).
Twelve patients needed additional medication for treatment of adverse events experienced during
the trial. A total of 59 additional medications were taken by trial participants (see table 4.7). The
most frequent indication for additional medication was skin symptoms (n=22: rash n=14, pruritis
n=7, general skin care n=1), this was followed by gastrointestinal symptoms (n=12: nausea n=8,
dyspepsia n=3, proctalgia n=1), musculoskeletal pain (n=5), dietary supplementation as an adjunct to
treatment (n=4), general symptoms (n=3: coryzal symptoms n=1, headache n=1, sore throat n=1),
respiratory symptoms (n=3: cough n=3), glycaemic control (n=2), oral symptoms (n=2: mouth ulcer
n=1, dental abscess n=1), urological/gynaecological symptoms (n=2: vaginal candidiasis n=1, urinary
tract infection n=1), anaemia (n=2), insomnia (n=1), injection site reaction (n=1). The medications
prescribed were topical creams (n=15), antihistamines (n=8), antiemetics (n=7), analgesia (n=7),
dietary supplements (n=4), antibiotics (n=4), antacids (n=4), anaemia (n=2), medication for glycaemic
control (n=2), cough medicine (n=2), mouthwash (n=1), anal cream (n=1), sleeping tablets (n=1) and
antifungal medication (n=1). The majority of medications (55/59) were commenced while patients
127
Table 4.7 Additional medication commenced during trial
were on treatment with trial medication (the median time point at which trial participants
commenced additional medications was 5 weeks after baseline visit (standard deviation 9.8 weeks)).
The mean duration of treatment was 5 weeks, and 44% (24/55) of additional medications that were
commenced during the trial were stopped by the end of trial follow up. Of the total of 59
medications commenced during the trial 35 were still being taken at the end of trial follow up. Just
under half of these were for skin complaints (n=15, and included 10 topical moisturising/barrier
creams, 4 antihistamines were also still being taken at the end of the trial, and one trial participant
was still on hydrocortisone cream), nine medications were still being taken for gastrointestinal side
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effects (5 were antiemetics and 4 were antacids), four patients were still needing analgesia for
musculoskeletal symptoms at the end of the trial, and two patients were on additional diabetic
medication. Two trial participants remained on nutritional supplements at the end of the trial, one
patient was still using topical cream for an injection site reaction, another was still taking
paracetamol for coryzal symptoms, and a final patient was still needing zopiclone for insomnia.
Although there were no serious adverse events whilst patients were receiving treatment as part of
the trial, the adverse event profile was consistent with previous data on treatment with telaprevir,
interferon and ribavirin. This treatment combination resulted in a range of previously documented
symptoms, and resulted in almost all the trial participants needing medication to alleviate at least
some of their symptoms. As would be expected with this treatment combination, skin related side
effects, general/constitutional adverse events, and gastrointestinal adverse events were frequently
experienced. Despite the frequency of symptoms, all trial participants except one, completed
treatment as per the trial protocol.
4.11 Discussion
All patients bar one completed participation on the trial until a virological endpoint was achieved.
The overall SVR rate in this population who had failed to respond to pegylated interferon and
ribavirin was 29% (four patients). Three patients did not achieve a sufficient viral response at week 4
to continue treatment and one patient withdrew before week four due to adverse events. Of the
remaining patients on one patient had virological breakthrough before the end of treatment (this
was between weeks 12 and 24 on treatment, after they had completed twelve weeks of treatment
with telaprevir).  The number of patients achieving an SVR was comparable to previous trials
evaluating retreatment with pegylated interferon in patients with genotype 3 hepatitis C and
advanced fibrosis or cirrhosis who had previously failed treatment with interferon and ribavirin98,165.
As the number of patients enrolled onto the trial was lower than expected and the overall number
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that achieved an SVR was only 4 patients, it is hard to determine the impact of adding telaprevir to
pegylated interferon and ribavirin. Furthermore, the absence of an untreated control arm (treated
with pegylated interferon and ribavirin alone) makes assessment of the additional value of telaprevir
problematic. During the course of the clinical trial, many other treatment regimens were
concurrently being evaluated in clinical trials, including several all oral treatment regimens. The
prospect of all oral treatment regimens becoming available in the next few years undoubtably
affected recruitment onto the trial. It is of note that none of the trial participants were initially
eligible for the early access programme, therefore the trial provided a treatment option with
possible additive benefit to pegylated interferon and ribavirin to a group of patients who had a
limited range of treatment readily accessible at the time of trial recruitment.
The development of sofosbuvir, and first generation NS5A inhibitors revolutionised the treatment of
hepatitis C, providing all oral regimens which had excellent efficacy in treating genotype 1 hepatitis
C. Further protease inhibitors (grazoprevir and paritaprevir) were also developed, although early
trials with the combination of grazoprevir, elbasvir and ribavirin only resulted in SVR rate of 45 and
57% in non-cirrhotic genotype 3 patients166.
Subsequent newer protease inhibitors glecaprevir167 and voxilaprevir168 demonstrated pan-genotypic
activity rendering first generation protease inhibitors (such as telaprevir and boceprevir) obsolete.
The rapid improvements in this field render the use of telaprevir obsolete and it is unlikely that the
approach outlined here will be pursued further.
Treatment was tolerated well despite the side effects experienced by trial participants. This was
consistent with the side effect profile from treatment with telaprevir, interferon and ribavirin. No
serious adverse events occurred on treatment and only one patient withdrew from the trial due to
treatment related side effects. It should be noted that the patient cohort included in this trial were
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highly ‘self-selected’. They had all undergone previous treatment with pegylated interferon and
ribavirin and were therefore aware of the adverse events this treatment entailed and were willing to
tolerate these. It is unclear whether a group of treatment naïve patients would have tolerated
treatment in a similar manner.
Although the findings of this trial have been superseded by the availability newer all oral direct
acting antiviral drug regimens, protease inhibitors are now are a mainstay in the standard of care
treatment of patients with genotype 3 hepatitis C in the United Kingdom, but given the high
incidence of side effects in this study we would not recommend further studies in this population
with telaprevir based regimens.
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Chapter 5: Telaprevir in Genotype 3 Hepatitis C: Capture fusion
results
5.1 Methods
Initial capture fusion experiments were performed (as described inMethods) using THP-1
monocytes. 1x106 THP-1 cells were aliquoted onto 6 well plates and stimulated with phorbol
myristate acetate (PMA) and interferon γ for 24 hours. Patient serum containing hepatitis C (taken at
the baseline visit during the trial) was added to the THP-1 cells at a magnitude of infection of one
(i.e. one IU of virus per THP-1 cell). Patient serum was blinded using an independent laboratory
scientist prior to addition to THP-1 monocytes to eliminate bias in the interpretation of capture
fusion data. Cells were incubated with patient serum for 24 hours. These cells were then fused with
1x106 Huh 7.5 hepatocytes as described in Methods. The fused cells were divided into 20 aliquots
and plated out in 6 well plates with 1ml of culture medium (DMEM with 10% FBS). 24 hours post
fusion telaprevir was added at four different concentrations (10µM, 1µM, 0.1µM, 0.01µM and no
drug). The dose range was selected based on previous work by Cunningham et al.156 which enabled
identification of HCV from patient serum which was sensitive or insensitive to telaprevir in vitro.
Samples which were telaprevir sensitive had an IC50 of less than 1mM while insensitive samples had
an IC50 of >10mM. Cell culture medium was changed four days post fusion, and telaprevir was added
to the new medium. Experiments were harvested five days post fusion in 1 ml of TRIzol reagent. RNA
extraction was performed as previously described, with total RNA quantified using RiboGreen
reagent, and viral RNA calculated by real time quantitative PCR. Drug inhibition of HCV viral
replication from each serum sample was quantified by representing HCV RNA detected for each drug
concentration as a percentage of hepatitis C in the sample without drug. Dose response curves and
the half maximal inhibitory concentrations (IC50) were calculated by using GraphPad software.
Statistical analysis was performed using unpaired t-tests for pooled samples and IC50 values. Mann
Whitney U tests were used for statistical analysis of HCV viral load and telaprevir sensitivity in vitro.
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5.2 Capture Fusion results
The capture fusion results for the patients in the TIG 3 trial are shown in figures 5.1-5.2. Capture
fusion data was obtained for 10 samples and dose response curves and IC50 values were calculated
using GraphPad software. Insufficient HCV viral RNA was detected in four samples (including in the
aliquots without drug inhibition) to calculate dose response curves. Three samples were telaprevir
sensitive in vitro with IC50 values of 0.13, 0.03 and 8x10-9 µM (figure 5.1), albeit with wide confidence
intervals. Repeated analysis of samples was precluded by a limited amount of patient serum, which
may have allowed more robust data to be generated.
Figure 5.1 Samples from patients on the telaprevir in genotype 3 HCV trial that are sensitive to
telaprevir in the capture fusion assay.
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For seven patients no clear response to telaprevir could be seen (figure 5.2). The increase in HCV
RNA seen in some patients at the highest concentrations of drug may reflect cell death due to
toxicity and we regard this as artefactual. The lack of any clear dose response curve led us to
conclude that these patients were telaprevir ‘insensitive’ and the failure to demonstrate reduction
of HCV RNA at drug concentrations that were non-toxic precluded an accurate assessment of the
IC50.
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Figure 5.2. Samples from patients on the telaprevir in genotype 3 HCV trial that are insensitive to
telaprevir in the capture fusion assay.
The pooled telaprevir inhibition curves for samples that were sensitive (n=3) and insensitive (n=7)
were calculated. There was a significant difference (p=0.009, p=0.01) between the pooled sensitive
and pooled insensitive samples at telaprevir doses of 1µM and 10µM (figure 5.3). The IC50 values
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obtained for telaprevir sensitive samples were significantly different (p<0.001) to those from
telaprevir insensitive samples (figure 5.4).
Figure 5.3. Pooled dose response curves
for samples sensitive to telaprevir in the
capture fusion assay, and those samples
insensitive to telaprevir in the capture
fusion assay.
Figure 5.4. IC50 values for samples
sensitive or insensitive to telaprevir in
the capture fusion assay
Having identified telaprevir sensitive and insensitive samples, the serum samples were unblinded to
enable correlation with clinical outcome (figure 5.5). Of the three patients with serum HCV that was
sensitive to telaprevir in vitro, two achieved an SVR, whilst one stopped therapy at week 4 due to
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Figure 5.5. Correlation between in vitro telaprevir sensitivity and clinical outcomes of trial
participants
insufficient virological response. Seven patients had serum HCV that was insensitive to telaprevir in
vitro. One of the patients achieved an SVR, one stopped at week 4 on treatment, 4 relapsed post
treatment, and one withdrew from the trial at week 2. The sensitivity and specificity of the capture
fusion assay in predicting clinical outcome for patients on the TIG 3 assay is shown in table 5.1. The
capture fusion assay had a sensitivity of 67% and a specificity of 86%. The corresponding positive
predictive value was 67%, with a negative predictive value of 86%. The correlation between in vitro
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Table 5.1. The sensitivity and specificity of the capture fusion assay in predicting clinical
outcome in the Telaprevir in Genotype 3 clinical trial
SVR No SVR
Sensitive 2 1 Positive predictive value
(67%)
Insensitive 1 6 Negative predictive value
(86%)
Sensitivity
(67%)
Specificity
(86%)
telaprevir sensitivity and viral load at baseline, week 2 and week 4 visits are shown (figure 5.6) along
with the log drop in HCV RNA from baseline to week 2 and 4, and the log drop in HCV RNA from
week 2 to 4. There was no significant difference in baseline HCV RNA between those patients who
were sensitive to telaprevir and those that were insensitive (p=0.25). Similarly, there was no
significant difference between in vitro serum HCV sensitivity and viral load at weeks 2 and 4 (p=0.50,
p=0.39). The change in HCV viral load from baseline to week 2 and from baseline to week 4 on
treatment was not significantly different (p=0.39, p=0.47). The change in HCV RNA from weeks 2 to 4
on treatment was also not significantly different between patients with serum HCV which was
sensitive to telaprevir compared to those with serum HCV insensitive to telaprevir (p=0.19).
The initial capture fusion data demonstrated that three of 10 HCV serum samples were sensitive to
telaprevir in vitro. This data is consistent with previous data evaluating genotype 3 HCV sensitivity to
telaprevir in vitro. Interestingly two out of three patients who had telaprevir sensitive HCV in vitro
achieved an SVR however there was no significant difference in virological response between the
patients who had HCV sensitive to telaprevir in vitro and those who had HCV insensitive to telaprevir
in vitro.
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Figure 5.6. Telaprevir sensitivity in vitro and HCV viral load and change in viral load on
treatment: a) Telaprevir sensitivity and baseline HCV RNA b) Telaprevir sensitivity and HCV
RNA at week 2 on treatment c) Telaprevir sensitivity and change in HCV RNA from baseline
to week 2 on treatment d) Telaprevir sensitivity and HCV RNA at week 4 on treatment e)
Telaprevir sensitivity and change in HCV RNA from baseline to week 4 on treatment f)
Telaprevir sensitivity and change in HCV RNA from week 2 to week 4 on treatment.
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5.3 Monocyte fusion assay data
The data using THP1 cell fusions did not allow an accurate differentiation of responder and non-
responder patients. However, four samples did not generate meaningful data and we therefore
examined alternative ‘capture-fusion’ approaches to increase the sensitivity of the model and to
increase the proportion of samples that generated useful data. As described in Results Chapter 1
(Capture fusion assay optimisation). Huh 7.5 cells were developed to permit greater viral replication
in vitro. Once stable cell lines transfected with both SEC14L2 and PAd4 were established these were
used for preliminary monocyte fusion experiments which identified increased HCV replication in
vitro when this cell line was used. Subsequently the Huh 7.5 SEC14L2 PAd4 cells were used in fusion
experiments with monocytes obtained from TIG 3 trial participants at their baseline visit. The
rationale behind using monocytes from trial participants was that due to the low baseline serum
HCV viral load in several of the patients the serum ‘capture-fusion’ assay data was suboptimal and
we speculated that the use of patient monocytes would improve on the quality of the data and
perhaps allow patients with very low viral loads to be studied. Once again patient monocytes were
blinded by laboratory co-workers prior to fusion to avoid bias during results analysis. The same
range of Telaprevir doses as used in the capture fusion assay was evaluated using the method
described in Chapter 2. 1x106 patient monocytes were fused with an equivalent number of Huh 7.5
SEC14L2 PAd4 hepatocytes. Telaprevir was added at days one and 4 post fusion with samples
harvested at day 5 and in-vitro telaprevir sensitivity was calculated (GraphPad). Statistical analysis of
the monocyte fusion data was performed using unpaired t-tests for pooled dose response curve
analysis, and IC50 analysis. Mann Whitney U tests were used for statistical analysis of HCV viral load
and telaprevir sensitivity in vitro.
Telaprevir dose response curves were obtained for 13 of the 14 samples. There was insufficient HCV
viral replication with monocytes from one patient in the fusion assay. Three samples were sensitive
to telaprevir in vitro with IC50 values of 0.14, 0.005, and 0.003 µM (fig 5.7). The remaining 10 samples
were insensitive to telaprevir in vitro (with IC50 values greater than 10µM) (fig 5.8 a-b). Pooled dose
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Figure 5.7. Samples sensitive to telaprevir in the monocyte fusion assay
Figure 5.8a. Samples insensitive to telaprevir in the monocyte fusion assay.
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Figure 5.8b. Samples insensitive to telaprevir in the monocyte fusion assay.
response curves were calculated for monocyte samples that had telaprevir sensitive HCV in vitro and
those monocyte samples that were insensitive to telaprevir in vitro (fig 5.9). Pooled HCV replication
in vitro was significantly different in patients with monocyte derived HCV sensitive to telaprevir
compared to those who were telaprevir insensitive at 1 and 10µM concentrations of telaprevir (p=
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0.04, p=0.01). The IC50 values obtained were significantly different for monocyte samples sensitive to
telaprevir (p=<0.001) compared to those insensitive to telaprevir (figure 5.10).
Figure 5.9. Pooled dose response curves for
samples sensitive to telaprevir in the
monocyte fusion assay, and samples
insensitive to telaprevir in the monocyte
fusion assay
Figure 5.10. IC50 values for samples
sensitive or insensitive to telaprevir in the
monocyte fusion assay
The monocyte samples were unblinded to enable correlation of the in vitro results with clinical
outcome (figure 5.11). Monocyte fusion data was obtained from thirteen of the fourteen patient
samples used. Three samples were identified as being telaprevir sensitive. Of these patients one
achieved SVR, one relapsed, and one stopped treatment at week 4 due to insufficient virological
response. Ten samples were insensitive to telaprevir in vitro. The clinical outcomes for these
patients are as follows: three achieved an SVR, four relapsed post treatment, one patient
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experienced virological breakthrough on treatment, and two patients stopped treatment at week 4
due to insufficient virological response. This resulted in the monocyte fusion assay having a
sensitivity of 25%, a specificity of 78%, a positive predictive value of 33%, and a negative predictive
value of 70% (table 5.2).
Figure 5.11. Correlation between in vitro telaprevir sensitivity in the monocyte fusion assay and
clinical outcome.
SVR No SVR
Sensitive 1 2 Positive predictive value
(33%)
Insensitive 3 7 Negative predictive value
(70%)
Sensitivity
(25%)
Specificity
(78%)
Table 5.2. The sensitivity and specificity of in vitro telaprevir sensitivity in the monocyte fusion
assay predicting clinical outcome
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The correlation between in vitro telaprevir sensitivity in the monocyte fusion assay and viral load at
baseline, week 2 and week 4 visits are shown (figure 5.12) along with the log drop in HCV RNA from
Figure 5.12. Telaprevir sensitivity in vitro in the monocyte fusion assay and its correlation with
HCV viral load and change in viral load on treatment. a) Telaprevir sensitivity and baseline HCV
RNA b) Telaprevir sensitivity and HCV RNA at week 2 on treatment c) Telaprevir sensitivity and
change in HCV RNA from baseline to week 2 on treatment d) Telaprevir sensitivity and HCV RNA
at week 4 on treatment e) Telaprevir sensitivity and change in HCV RNA from baseline to week
4 on treatment f) Telaprevir sensitivity and change in HCV RNA from week 2 to week 4.
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baseline to week 2 and 4, and the log drop in HCV RNA from week 2 to 4. There was no significant
difference in baseline HCV RNA between those patients who were sensitive to telaprevir and those
that were insensitive (p=0.29). Similarly, there was no significant difference between in vitro serum
HCV sensitivity and viral load at weeks 2 and 4 (p=0.41, p=0.34). The change in HCV viral load from
baseline to week 2 and from baseline to week 4 on treatment was not significantly different either
(p=0.23, p=0.34). The change in HCV RNA from weeks 2 to 4 on treatment was also not significantly
different between patients with serum HCV which was sensitive to telaprevir compared to those
with serum HCV insensitive to telaprevir (p=0.23).
The correlation between the capture fusion results and monocyte fusion results is shown in figure
5.13. Results from both assays were only available for nine of the 14 patients.
Figure 5.13. In vitro sensitivity to telaprevir in both the capture and monocyte fusion assays and
its correlation with patients’ clinical outcomes on the telaprevir on genotype 3 HCV trial
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Three patients were insensitive in both the capture fusion and monocyte fusion assay. All three of
these patients did not achieve an SVR. Of the remaining six, three had HCV sensitive to telaprevir in
the capture fusion assay, but not in the monocyte fusion assay. Two of these patients achieved an
SVR, while one was stopped at week 4 due to insufficient virological response. The final three
patients had HCV sensitive to telaprevir in the monocyte fusion assay, but not in the capture fusion
assay. One of these patients achieved an SVR, while one relapsed, and one stopped treatment at
week 4 due to insufficient virological response.
The dose response curves for the samples where there was a discrepancy between the capture
fusion assay (using patient serum) and the monocyte fusion (using patient monocytes) were
compared figure 5.14.
Figure 5.14. Samples with a discrepancy in telaprevir sensitivity between capture fusion and
monocyte fusion
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Figure 5.14 continued. Samples with a discrepancy in telaprevir sensitivity between capture
fusion and monocyte fusion.
Of the six samples where there was a discrepancy a dose response curve could not be calculated in
four of these samples A, D-F. In the remaining two samples, B and C (where HCV from patient serum
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was sensitive in the capture fusion assay), dose response curves were calculated in the monocyte
fusion assay despite the samples being insensitive to telaprevir, although the IC50 was greater than
10µM.
Potential hypotheses regarding the discrepancy between the capture fusion and monocyte fusion
would include technical factors, in particular as three of the discordant samples (B, D and E) had viral
loads below 1x106. Alternatively, in 3 of the samples HCV derived from monocytes appeared to be
sensitive to telaprevir in vitro (D-F) while HCV from the same patient’s serum was not sensitive in-
vitro (and no dose response curve could be calculated). Similarly, in one sample (A) HCV from patient
serum was sensitive in the capture fusion assay but a dose response curve could not be calculated in
the monocyte fusion assay. These findings warranted further investigation, and repeat capture
fusion experiments were performed. Unfortunately, there were insufficient monocytes from trial
participants to repeat the monocyte fusion experiments. This could have provided an opportunity to
undertake next generation sequencing on HCV derived from monocytes and enabled comparison
with HCV from patient serum, to determine if there are different in HCV quasispecies present in
these two different compartments, and whether this would account for the discrepancy noted in the
capture and monocyte fusion results.
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5.4 Capture fusion data: Grazoprevir
During the course of the Telaprevir in genotype 3 clinical trial additional antiviral drugs became
available. In addition to the NS5B inhibiting drug sofosbuvir, new second generation protease
inhibitors also became available which were thought to have greater pan-genotypic activity.
Grazoprevir is one of the first of these pan-genotypic protease inhibitors. In order to evaluate
whether HCV from patients in the TIG 3 trail was sensitive to grazoprevir, preliminary experiments
identifying a dose range which would discriminate between grazoprevir sensitive and insensitive
HCV in vitro were performed.
The s52 (genotype 3) replicon was used to assess the inhibitory effect of grazoprevir (a second
generation pan genotypic protease inhibitor) on HCV RNA replication. Huh 7.5 cells containing the
replicon were seeded in 96 well plates with clear bottoms at 1x104 cells/per well. 24 hours later cells
were exposed to a range of concentrations of grazoprevir and incubated for 72 hours. Cell lysates
were prepared using 1x cell lysis buffer, and firefly luciferase expression was measured with a
luciferase assay system (Promega) and BMG plate reader. The s52 replicon assay results are shown
(fig 5.15) and identified an IC50 value of 0.01µM of Grazoprevir.
Figure 5.15. S52 replicon assay evaluating inhibition of the S52 genotype 3 replicon by
grazoprevir.
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Subsequently capture fusion experiments (using THP-1 monocytes, and Huh 7.5 cells transfected
with SEC14L2 PAd4) were performed using serum from G3 HCV patients who had previously failed
treatment with interferon and ribavirin. A dose-range from 0.001 to 1µM concentration of
grazoprevir was used with four different HCV sera. None of the samples were sensitive to
grazoprevir at this dose range (figure 5.16).
Figure 5.16. Grazoprevir inhibition curves of HCV replication in the capture fusion assay at a
grazoprevir concentration range from (0.001 to 1µM)
Further experiments were performed using a grazoprevir dose range of (0.01 to 10 µM) to evaluate
whether the preliminary results were due to the utilisation of a dose range that was too low to
discriminate between grazoprevir sensitive and insensitive samples. Eight further samples from
patients who had failed treatment with interferon and ribavirin were used and capture fusion data
was obtained from all of these samples (figure 5.17). The results from these eight samples fell into
two distinct groups. Four samples had dose response curves with dose dependent drug inhibition for
which IC50 values could be calculated. These four samples (number 5,6 7 and 10) were designated as
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being sensitive to grazoprevir in vitro. The IC50 values for these samples were 0.005, 0.073, 3.4, and
4.5µM. The remaining four samples were designated as insensitive to grazoprevir as no dose related
drug inhibition was apparent. The pooled grazoprevir dose response curves for samples sensitive to
and insensitive to grazoprevir are shown in figure 5.18.
Figure 5.17. Grazoprevir inhibition curves of HCV replication in the capture fusion assay at a
grazoprevir concentration range from (0.01 to 10µM)
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Figure 5.18. Pooled dose response curves
for samples sensitive to grazoprevir in the
capture fusion assay, and samples
insensitive to grazoprevir in the capture
fusion assay
Figure 5.19. IC50 values for samples
sensitive or insensitive to grazoprevir in
the capture fusion assay
Pooled HCV replication in vitro was significantly different between samples sensitive to grazoprevir
and those insensitive to grazoprevir at concentrations of 1 and 10µM of grazoprevir (p=0.05,
p=0.04). The IC50 values obtained were significantly different for those samples sensitive to
grazoprevir, compared to those insensitive to grazoprevir (p=0.0003) (figure 5.19).
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5.5 Repeat capture fusion experiments
The final group of fusion experiments performed as part of the telaprevir in Genotype 3 Hepatitis C
trial aimed to evaluate whether drug sensitivity at a single concentration could be used to evaluate if
a sample was sensitive to a specific antiviral drug in vitro. The rationale for using a single drug dose
was based on the limited supply of patient serum from the clinical trial, as using a single dose could
potentially facilitate in-vitro testing of several drugs in a single assay without exhausting the stock of
trial participant serum. The experiments were performed using the capture fusion assay (THP-1
monocytes and Huh 7.5 SEC14 PAd4 cells) with blinded HCV containing serum from trial participants
at their baseline visit on the trial used to “infect” the THP-1 cells. The concentration of drugs to be
used were identified as the lowest concentration of an inhibitory drug which achieved a significant
difference in HCV replication values in pooled sensitive and insensitive samples. The inhibitory
concentrations used for each drug were as follows: Peg IFN 1 IU/ml, Ribavirin 1µM, Telaprevir 1µM,
and Grazoprevir 1 µM. Experiments were harvested using the methods previously described, and
results were obtained for all patient samples (figure 5.20a-c). In order to identify which HCV serum
samples were drug sensitive and which were insensitive to the single dose of each drug used
unpaired t tests with Welch’s correction (GraphPad) were calculated comparing the values for the
control sample (with no drug inhibition) against each with drug inhibition. The results of this analysis
are shown in table 5.4. Samples with a value of <0.05 were identified as having a significant
difference between the no drug control and drug inhibited sample. Using this analysis one sample
was noted to be sensitive to Interferon, one sample was sensitive to ribavirin, telaprevir and
grazoprevir, and a third sample was only sensitive to telaprevir.  The samples were unblinded to
enable correlation between clinical outcome and in vitro sensitivity (figure 5.21). The two samples
which were sensitive to telaprevir in-vitro both achieved an SVR, while the sample sensitive to
interferon in-vitro was from a patient who relapsed post treatment. The sensitivity and specificity of
in vitro drug sensitivity predicting SVR or failure to achieve SVR is shown in table 5.5. In vitro drug
sensitivity had a sensitivity of 50% in predicting SVR, and specificity of 90%. in vitro sensitivity was
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Figure 5.20a. Capture fusion experiments using Huh 7.5 SEC14L2 PAd4 cells and single drug
concentration inhibition of HCV replication
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Figure 5.20b. Capture fusion experiments using Huh 7.5 SEC14L2 PAd4 cells and single drug
concentration inhibition of HCV replication.
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Figure 5.20c. Capture fusion experiments using Huh 7.5 SEC14L2 PAd4 cells and single drug
concentration inhibition of HCV replication.
T test p-values for single drug dose capture fusion experiments
Sample no IFN RBV Telaprevir Grazoprevir
1 0.068 0.26 0.24 0.27
2 0.047* 0.089 0.062 0.058
3 0.11 0.45 0.13 0.48
4 0.45 0.18 0.11 0.24
5 0.13 0.27 0.33 0.36
6 0.27 0.064 0.14 0.15
7 0.18 0.041* 0.018* 0.018*
8 0.49 0.15 0.30 0.28
9 0.14 0.28 0.36 0.22
10 0.23 0.10 0.097 0.095
11 0.15 0.28 0.46 0.31
12 0.053 0.073 0.044* 0.060
13 0.086 0.40 0.31 0.28
14 0.48 0.11 0.12 0.49
Table 5.4. P values from t-tests comparing samples with drug inhibition at a single concentration
with samples without drug inhibition (nil samples).
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Figure 5.21. In vitro sensitivity to antiviral drugs in the capture fusion assay with single drug
concentration HCV inhibition and correlation with clinical outcome.
SVR No SVR
Sensitive to any
drug in vitro
2 1 Positive predictive
value (66%)
Insensitive to all
drugs in vitro
2 9 Negative predictive
value (82%)
Sensitivity (50%) Specificity (90%)
Table 5.5 Sensitivity and specificity of in vitro sensitivity to single concentrations of antiviral drugs
and clinical outcome.
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compared with the previous capture and monocyte fusion experiments (table 5.6). Two of the
samples from patients who achieved an SVR were sensitive to telaprevir in both the capture fusion
experiments (original capture fusion assay, and single drug dose capture fusion with Huh 7.5
SEC14L2 cells). The monocyte samples that were sensitive to telaprevir were different samples to
those sensitive in the capture fusion assay.
Treatment
outcome
Sensitive to
telaprevir in
capture
fusion assay
Sensitive to
telaprevir in
monocyte
fusion assay
Sensitive to
telaprevir in
single dose
capture
fusion assay
SVR No Yes No
SVR Yes No Yes
SVR N/A No No
SVR Yes No Yes
Relapse No No No
Relapse No No No
Relapse No Yes No
Relapse No No No
Relapse N/A No No
Breakthrough on
treatment N/A No No
Stopped at Wk4 Yes No No
Stopped at Wk4 N/A No No
Stopped at Wk4 No Yes No
Withdrew No N/A No
Table 5.6. In vitro sensitivity to telaprevir in the capture fusion assay, monocyte fusion assay
and single drug concentration capture fusion assay
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5.6 Discussion
In vitro telaprevir sensitivity was evaluated using the capture fusion and monocyte fusion assays to
evaluate whether in vitro drug sensitivity correlated with clinical response. The capture fusion assay
identified 3 samples as being sensitive to telaprevir, two of those samples were from patients who
subsequently achieved an SVR. Interestingly, there was no significant difference in clinical virological
response from baseline visit to week four between patients sensitive to telaprevir in vitro and those
insensitive to telaprevir in vitro. These findings could potentially be due to several causes. First of all,
they may represent the inability of the capture fusion assay to identify samples that are sensitive to
telaprevir. Secondly, because telaprevir was one drug in a three-drug treatment regimen, patients
with HCV insensitive to telaprevir in vitro may have had a good clinical response to either interferon
or ribavirin. Finally, these findings may be a result of variations in treatment concordance, or
variations in adhering to guidance on how telaprevir should be taken (with fatty meals or snacks to
aid absorption).
The next group of experiments evaluated telaprevir sensitivity in the monocyte fusion assay and
utilised a modified Huh 7.5 cell line (Huh 7.5 SEC14L2 PAd4) which enabled increased HCV
replication in-vitro. In-vitro HCV replication was improved in the monocyte fusion assay with results
obtained for 13 out of 14 samples. Three samples were noted to be telaprevir sensitive in the
monocyte fusion assay, however all three were different samples to those noted to be sensitive to
telaprevir in the capture fusion assay. This could potentially be a result of assay variability, and
therefore repeat capture fusion experiments were planned to assess assay reproducibility.
Monocytes are known to be reservoirs for HCV, and it may be that the specific intracellular
environment in monocytes may exert different selection pressures to that experienced by HCV in
serum. This may result in the selection of HCV quasispecies in different body compartments with
varying sensitivity to antiviral drugs, and may account for the differences in capture fusion and
monocyte fusion telaprevir sensitivity in vitro which were seen in some samples from the same
patient.
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Telaprevir is a first-generation protease inhibitor and has many side effects which would limit its use
as more potent second-generation protease inhibitors become available which also have an
improved side effect profile. One of these second-generation protease inhibitors is grazoprevir. Once
initial dose range finding experiments were completed, eight genotype 3 HCV samples were tested
for grazoprevir sensitivity in vitro. Four (50%) of these samples were sensitive to grazoprevir in vitro.
If these findings were demonstrated at a larger scale grazoprevir would indeed be a more effective
protease inhibitor in genotype 3 HCV, with 50% of individuals having HCV sensitive to grazoprevir in
vitro, compared to 30% having HCV sensitive to telaprevir in vitro.
Finally, the capture fusion results were analysed to evaluate which telaprevir and grazoprevir
concentrations enabled discrimination between drug sensitive and insensitive samples. The lowest
drug concentration in the capture fusion dose response curve which identified a significant
difference between drug sensitive and insensitive groups was used. Single doses of IFN and ribavirin
(based on previous work by our laboratory group) were used to test for multidrug sensitivity in a
single capture fusion experiment. This strategy was used as the volume of serum obtained from trial
participants was limited, and as the trial participants had advanced fibrosis many of them had low
serum HCV viral loads. This necessitated the use of large volumes of HCV containing serum (>1ml per
experiment for certain samples) to achieve a magnitude of infection of 1 (or to achieve a MOI as
close to 1 as possible). This approach enabled repeat capture fusion experiments to assess telaprevir
sensitivity in vitro, whilst allowing concurrent evaluation of grazoprevir sensitivity in HCV serum from
trial participants. The modified Huh 7.5 SEC14L2 PAd4 cells were used in the capture fusion assay
with THP-1 monocytes and dose response data was obtained for all 14 samples. Only two samples
were noted to be sensitive to telaprevir. Both these samples had previously been identified in the
initial capture fusion experiments. Both those individuals achieved an SVR. Only a single HCV sample
was noted to be sensitive to interferon in vitro, and a further sample was noted to be sensitive to
ribavirin. It is unclear whether these findings represent a clinical trial population that had previously
been treated with interferon and ribavirin and had HCV that was not sensitive to interferon or
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ribavirin in vitro, or whether the findings were due to limitations of the assay (with the inter
replicate variability limiting the number of samples where statistically significant differences in HCV
replication). Only one sample was noted to be sensitive to grazoprevir (p<0.05), this sample was also
sensitive to telaprevir. Grazoprevir sensitivity appeared to correlate with telaprevir sensitivity,
although there wasn’t a statistically significant difference between grazoprevir inhibition and the no
drug control samples in the second sample that was telaprevir sensitive. The t test value for this
sample was 0.0598. This finding may have been due to increased variability between replicates with
single dose grazoprevir inhibition compared to telaprevir. Alternatively, the pooled IC50 values for
grazoprevir had a mean of 2.15µM, and it may be that a higher dose of grazoprevir needed to be
used.
The results above also highlight the challenges in evaluating a novel in vitro HCV replication model in
a ‘real world’ environment. The wide error bars in the dose response curves and for single drug
inhibition experiment preclude the use of the assay as a test that could aid clinical decision making in
the choice of treatment regimen. The pooled data however is more suggestive of a difference in
treatment sensitivity between different samples, and the identification of the same two samples as
being sensitive to telaprevir when both sets of experiments were blinded also suggests phenotypic
data can be replicated. One of the key challenges would be decreasing the intra assay variability for
individual replicates, which could potentially be achieved by increasing the number of replicates for
each data point, as four replicates were used for each drug concentration. The limitations to this
strategy are firstly the increase in patient serum likely to be needed and secondly it would make an
already complex assay even more cumbersome (each capture fusion experiment takes
approximately one week including cell preparation, followed by harvesting, RNA extraction and
quantification, then PCR). Using single drug concentrations could potentially aid this but would need
rigorous quality control, and extensive validation of the appropriate drug concentration to use in
order to identify drug sensitivity in-vitro. Finally, it would have been useful to sequence HCV from
samples that were deemed insensitive to telaprevir from both drug inhibited samples and the no
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drug controls, to evaluate whether any particular resistance associated substitutions were selected
by drug inhibition and to compare this to pre and post treatment HCV in patient serum.
To summarise HCV from patients on the telaprevir in genotype 3 hepatitis C was tested for in vitro
telaprevir sensitivity using capture fusion and monocyte fusion assays. A new next generation
protease inhibitor grazoprevir was also evaluated in the capture fusion assay. Finally, a capture
fusion experiment testing HCV inhibition with single concentrations of IFN, Ribavirin, Telaprevir and
grazoprevir was performed. This enabled assessment of in vitro drugs sensitivity for multiple drug
despite many trial samples having a volume of serum with low HCV viral loads. The samples that
were sensitive to telaprevir in the single dose fusion assay were two of the samples identified in the
original capture fusion assay, and both trial participants achieved an SVR. Due to the wide error bars
in this cohort of patients with low HCV viral load, and the lack of correlation between the in-vitro
results and decline in patient viral load over the first four weeks of treatment, the assay is unlikely to
be of clinical utility in predicting patient treatment outcome. Secondly as the assay is laborious and
time consuming it would be impractical for widespread use. Where it may be of use is in patients
who have failed treatment with direct acting antiviral drugs to evaluate whether in-vitro sensitivity
correlates with particular resistance associated variants.
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Chapter 6: Telaprevir in Genotype 3: Sequencing data
6.1 Background
Hepatitis C exists as a variety of quasispecies in infected individuals. The quasispecies with the
greatest replicative fitness form the majority of the viral population, while quasispecies with variants
that have lower replicative fitness form minority species. Selection pressure exerted by the host
immune system, or by external factors such as direct acting antiviral drugs may select for particular
variants. During treatment with direct acting antiviral drugs minority species which confer resistance
to a particular drug may be selected, or drug resistant species that occur de-novo due to the poor
fidelity of the HCV RNA polymerase may be selected. These drug resistant variants may have poor
replicative fitness, as observed by the decline in HCV viral load on treatment, however virological
breakthrough on treatment can occur if a DAA resistant variant with high replicative fitness
develops, and even low-level viral replication can ultimately lead to post treatment relapse. In
addition, certain individuals were noted in early studies to have resistant variants as the dominant
species suggesting that at least some of the variants that conferred virological resistance to DAAs
could exist without a significant loss of replicative fitness169.
The mechanisms by which resistance develops to protease inhibitors are related to the structure and
function of the NS3 protein. The NS3 protein contains two regions: an N-terminal third contains the
region responsible for the protease activity of the protein while the C-terminal two thirds form an
RNA helicase whose function is unclear.  The NS3 protease belongs to the trypsin/chymotrypsin
protease superfamily. The enzyme consists of two β barrel domains, flanked by two short α helices.
The central hydrophobic region of NS4A forms one β strand in one of the β barrels. A zinc ion
stabilises the structure and is essential for its function. The substrate binding site accommodates
amino acid sequences 6-10 amino acids long. The consensus cleavage site has cysteine and serine at
the scissile bond. The catalytic triad of the protease is serine 139, histidine 57 and aspartate 81. The
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oxyanion hole has a backbone of glycine 137 and serine 139170. The NS4A protein contributes to the
proper positioning of the catalytic triad and substrate.
Most protease inhibitors competitively inhibit the substrate binding site.  Initial protease inhibitors
were macrocyclic compounds, which were followed by linear peptide like molecules (telaprevir and
boceprevir).  Many amino acid substitutions contribute to the resistance of NS3 to protease
inhibitors. Selection of variants which are drug resistant and capable of replicating efficiently are
rapidly selected. It is of note that the locations of the amino acid substitutions conferring resistance
to protease inhibitors are often quite far from the substrate binding pocket. One of the hypotheses
for this finding is that the van der Waals surface of the inhibitor molecule has a larger footprint than
the  natural substrate thereby permitting substitutions which are drug resistant without complete
loss of protease action. Additional secondary substitutions could then potentially restore viral
replicative fitness170,171.
Initial DAA resistant variants were identified with first generation protease inhibitors (the first DAAs
evaluated in the treatment of Hepatitis C). HCV resistance associated substitutions were noted in
early in vitro analysis of first generation protease inhibitors172, and in subsequent clinical trials. As
first-generation protease inhibitors were developed using genotype 1 based hepatitis C replicon
systems, and their clinical efficacy was much greater in genotype 1, they were used predominantly in
the treatment of genotype 1 hepatitis C. Subsequently, there is much data on the development of
resistance to protease inhibitors in genotype 1 hepatitis C while data on resistance or sensitivity to
protease inhibitors in genotypes 2 and 3 is limited.
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6.2 Method
200µl of plasma from trial patients was sent to the MRC Virology Unit in Glasgow for sequencing (by
Dr Ana De Silva Felipe and John Mclauchlan). RNA was extracted from plasma using the Agencourt
RNAdvance blood kit (Beckman Coulter), eluted into 11 µl of water. The RNA was then reverse
transcribed using Superscript III (Invitrogen) with random hexamers and a NEB Second Strand
synthesis kit (New England Biolabs) for library preparation using the KAPA library prep kit (KAPA
Biosystems) with index tagging for 16 cycles of PCR using KAPA HiFI Hotstart (KAPA Biosystems) and
NEBNext Multiplex Oligos (oligonucleotides) for Illumina Index primer sets 1 and 2 (New England
Biolabs). Libraries were quantified by Qubit (Thermofisher) and pooled at equimolar concentrations
for sequencing on the Illumina Mi Seq platform (Illumina). Following initial quality assessment of the
sequencing data as Fastq files using FastQC
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), Sam files were created by mapping
against whole genome HCV reference sequences using Tanoti
(http://bioinformatics.cvr.ac.uk/tanoti.php). Sequencing data for individual samples was received in
Fasta format and alignments and phylogenetic analysis was performed by myself using Geneious.
6.3 Results
Initial analysis of the samples was performed by aligning the sequences (of the majority species in
TIG3 trial participants) using Geneious 9.1 along with a reference G3 HCV sequence (accession no
GQ356202). Phylogenetic trees were created using Geneious 9.1. The phylogenetic trees for the
complete HCV RNA sequences for trial participants is shown in figure 6.1, along with the
phylogenetic tree for the complete HCV protein sequence. Although the phylogenetic tree for the
complete HCV RNA sequences demonstrated no clustering of samples based on either clinical
response or in vitro sensitivity to telaprevir, the complete translated protein sequence showed
clustering of sequences from patients who had their treatment terminated at week 4 for insufficient
response and patients who achieved SVR. Regarding in vitro sensitivity samples that were sensitive
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Figure 6.1 Phylogenetic trees of samples in the TIG 3 clinical trial. A) Phylogenetic
tree of RNA sequence. B) Phylogenetic tree of protein sequence. Samples labelled as
per clinical outcome. Those samples sensitive to telaprevir in the capture fusion
assay are labelled as sensitive.
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in vitro did not cluster together in the same sub clade. Subsequently phylogenetic trees were
created for the NS2 and NS3 protein sequences for trial participants (figure 6.2 and 6.3). There was
no clustering of sequences from patients who achieved an SVR, had treatment discontinued at week
4 on treatment or who had HCV sensitive to telaprevir in vitro.
6.3.1 NS2 sequencing data
Although NS2 is not a target of telaprevir several sequence motifs were identified which were
associated with treatment outcome. NS2/3 cleavage has been implicated in viral replication
efficacy15 therefore these findings were analysed further. The translated NS2 sequences from the
majority species of TIG3 trial participants were compared to identify if any amino acid substitutions
were associated with clinical outcome or in vitro sensitivity to telaprevir (based on the capture
fusion assay data). Only two substitutions that were potentially associated with clinical outcome
were identified (figure 6.4). Each substitution was present in two of the patients who achieved SVR.
One was a substitution of threonine for serine at amino acid 2 of the NS2 protein and was present in
two individuals who achieved SVR (one of whom had serum HCV sensitive to telaprevir in the
capture fusion assay). The second substitution was at amino acid 63 with the substitution of alanine
for valine in two patients that achieved SVR. Neither of these samples was sensitive to telaprevir in
vitro. Analysis of minor species was also undertaken, with any substitutions accounting for more
than 1% of the total viral population analysed (see table 6.1). There was no clear correlation
between any of the identified minority species and clinical outcome. Evaluation of the amino acid
sequence of samples did not identify any substitutions associated with in vitro telaprevir sensitivity
in all samples. Finally, on evaluation of significant minority species (>1% of total next generation
reads) no amino acid substitutions associated with in vitro telaprevir sensitivity were noted in
majority or significant minority species (table 6.1).
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Figure 6.2. NS2 protein sequence phylogenetic tree
Figure 6.3. NS3 protein sequence phylogenetic tree
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Figure 6.4. NS2 substitutions associated with clinical outcome (L) S2T and (R) V64A. Both
substitutions were observed in patients who achieved SVR
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Table 6.1. minority species (>1% reads) for any amino acid in NS2
AA No 2 3 6 9 13 15 19 20 28 31 40 46 47 49 52 60
Patient Outcome
Week 4
Sensitive S G98.2:S1.06 S L I A F F H G T A A Q V G88.2:S11.31
Week 4 S G S I V A98.1:V1.3 F F H G A S A Q I S
Week 4 S G S L I V F F97.8:L1.6 H S T A A Q V G
SVR T G S L I A F F Q G T A T Q V G
SVR
Sensitive S G S L V V F F H G T94.2:A4.66 S A Q V S
SVR S G S L I97.4:V1.39 V F F H G T S98.5:A1.02A97.3:V2.01 Q V94.8:I4.6 S79.9:G18.9
SVR
Sensitive T97.9:S1.25 G S L I A F F N97.3:H1.5 G T A A Q V S
Relapse S G S L V A F F H S T A A Q V S
Relapse S G S I81.9:L16.5 I A97.9:V1.13 F96.4:L2.8 F H G T97.2:A1.88 A A Q V S
Relapse S G S L I A98.4:V1.16 F F H G A97.4:T1.93 A A Q98.03:H1 V G
Relapse S G S98.1:R1.13 L97.9:P1.12 I97.4:L1.1 V F F H S97.7:G1.34 T A A Q V S
Relapse S G S L L A F F H G A A A Q V G
Withdrew S G S L V97.1:I2.09 A94.9:V4.7 F F H G94.5:S4.13 T A94.5:S4.9 A Q V
S96.1:R1.87
G1.01
AA No 63 64 65 68 84 86 87 93 95 96 99 100 106 108 110 116
Patient Outcome
Week 4
Sensitive G V I T I V97.14:12.19 L I98.2:L1.26 A S98.2:A1.25 A T A V V V
Week 4 G91.8:S7.4 V I T I L L I A A S T A V V V98.4:A1.34
Week 4 G V I T I V L I98.5:L1.3 A94.8:T4.8 A T T A A V A
SVR G A I T I98.5:L1.03 V L I A A T A A V V V
SVR
Sensitive G V I T I V L I A A T A A V V V
SVR G A96.2:V2.8 I T I V L I A A A T A V V V
SVR
Sensitive G V I T I V L I
S95.1:A1
G2.41 A T T A97.4:S1.1 V V V
Relapse G F I T I V L98.3:F1.24 I A A A T A V V V
Relapse G V I T I V L I A A T T A V V V
Relapse G V I T I V L I A A S97.7:A1.47 S97.1:T1.85 A V V V
Relapse G I I T I V L T94.8:I4.66 A A T97.2:A1.8 A96.2:T3.14 A V I96.3:V2.95 V
Relapse G V I T I V L I A A T T A V V V
Withdrew G V V95.5:I2.98 A93.2:T6.04 I V L I A A97.5:T1.45 A T A V98.4:I1.3 V V
AA No 119 120 123 127 128 129 130 131 132 133 136 140 147 149 150 153
Patient Outcome
Week 4
Sensitive V M97.2:L1.23 K M97.7:L1.13 I I L S I G F L M H W A
Week 4 V T K M60.7:I38.7 V97.8:A1.5 I L S I G F L L H W96.6:C1.21 A
Week 4 V T R96.2:K3.4 M V95.6:A4.0 I L S I G F L98.8:I1.13 M H W T67.9:A31.8
SVR V T89.0:A10.4 K M V I L S V G F L M H W A
SVR
Sensitive V T K M V I L S I G F L M H98.2:Y1.34 W A
SVR V97.6:I1.04 M K M I I L S I G F L M H W A
SVR
Sensitive V97.8:A1.08 V K M97.7:L1.3 V I L S V96.5:12.6 G F L M H W T97.6:A1.34
Relapse V97.7:A1.04
M89.6:L1.7
T7.14 K M98.3:L1.21 I I L S I G F L M H W A
Relapse V97.6:M1.6 A95.0:T3.42 K M I97.4:V1.06 M96.6:I1.9 L98.2:F1.26 S I94.3:V4.2 G97.8:C1.21F97.2:V1.34 L M H W A
Relapse V T97.7:M1.3 K M I I L N97.5:S1.52 V97.7:I1.27 A97.9:G1.22 F L M H W A
Relapse V V96.5:M1.63 K M I97.5:V1.22 I L S I G F L M H W A
Relapse V T K M A I L S I G F L M H W A
WithdrewV97.5:A1.85M97.3:T1.06 K M V97.4:I1.8 I L H96.7:S1.48 I97.9:V1.3 G F96.8:C1.55 L M97.5:L1.6 H W A
AA No 156 168 174 187 194 199 200 209 212 215
Patient Outcome
Week 4
Sensitive N73.7:K24.8 S98.2:R1.11 V I S R E Y M R
Week 4 K S V I S97.0:A1.3 R
E95.8:A1.1
G1.7 Y M R
Week 4 K S V I S R E Y M H
SVR K S V I S H E Y M R
SVR
Sensitive R S V I S H E Y M97.4:L1.05 R
SVR K S V I S R
E96.6:A1.1
G1.27 Y M97.4:L1.15 R
SVR
Sensitive K S97.5:R1.44 V I S H E Y M H97.9:R1.03
Relapse K S I91.5:V6.9 I S H E Y M R
Relapse K S V I S R E96.8:G1.34Y96.2:H2.23 M H97.7:R1.13
Relapse R97.3:K1.26 S V I S R E Y M R
Relapse K S V I S H96.3:R2.01 E Y M R
Relapse R S V I S H E Y M R
Withdrew K S V I98:M1.0 S H95.8:R2.33 E Y M R
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6.3.2 NS3 sequencing data
The translated NS3 sequences from the majority species from TIG3 trial participants were compared
to identify if any particular substitutions were associated with SVR, treatment discontinuation or in
vitro sensitivity to telaprevir. The resistance associated substitutions (RAS) previously identified in
genotype 1 HCV patients receiving protease inhibitors are shown in figure 6.5a. The majority species
from each patient at all those RAS sites are shown in figures 6.5b and 6.5c. At amino acid position 36
of the NS3 protein all trial participants had leucine substituted for valine. This resistance associated
substitution is the reference sequence for Genotype 3 hepatitis C. At positions 41 (glutamine), 43
(phenylalanine), 54 (threonine), 55 (valine), and 56 (tyrosine) all patients had the reference amino
acids which conferred sensitivity of genotype 1 hepatitis C to first generation protease inhibitors. At
position 80 (glutamine) all patients had the reference amino acid apart from one patient who
withdrew from the trial (who had a resistance associated substitution of leucine at this position). At
positions 122 (serine), 155 (arginine), 156 (alanine), 158 (valine), and 170 (isoleucine), the majority
species from all samples was identical to the reference sequence for genotype 1 and genotype 3
hepatitis C. At position 168 all samples expressed glutamine as the majority species, consistent with
the genotype 3 HCV reference sequence. The reference amino acid at position 168 in genotype 1
hepatitis c was aspartic acid, however substitution of glutamine at this position had not been
identified as a resistance associated substitution in genotype 1 hepatitis C. At position 175 isoleucine
was expressed by the majority species in all trial samples. This was consistent with the reference
sequence for genotype 3 hepatitis C, but had been identified as a resistance associated substitution
in genotype 1 hepatitis C (M175L). In summary, analysis of the protein sequence expressed by the
majority species from trial patients did not identify any substitutions correlating with clinical trial
outcome. At V36 and M175 all samples expressed resistance associated substitutions identified in
genotype 1 hepatitis C, but these substitutions were the reference sequence for genotype 3
hepatitis C. At amino acid 168 all trial samples had a substitution (which was consistent with the
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Figure 6.5. A) NS3 Resistance associated substitutions identified in genotype 1a (l) and 1b (r)
Hepatitis C B) Sequencing data for amino acids 31-90 in TIG trial patients with amino acid
locations of G1 RAS highlighted C) Sequencing data for amino acids 121-180 in TIG trial patients
with amino acid locations of G1 RAS highlighted
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reference sequence for genotype 3 hepatitis C) which had not been identified to be a resistance
associated substitution in genotype 1 hepatitis C.
As the translated amino acids (from the majority species of HCV) from trial patients did not
demonstrate any pattern of known resistance associated substitutions pre-treatment affecting
clinical outcome, the minority species at the previously identified resistance associated substitution
sites were also analysed (table 6.2). This demonstrated that no minority species at the previously
identified RAS sites were present at a frequency greater than 1% apart from the presence of L80Q
which was present in 3.71% of reads in a single patient who withdrew from the trial.
Table 6.2 Percentage of next generation sequence reads which identified the majority species and
percentage of reads demonstrating minority species (if total number of reads for a minority
species was >1%) at locations identified as G1 resistance associated substitution sites.
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As there was no association between the previously identified resistance associated substitutions
and clinical outcome, further analysis was performed to evaluate whether other NS3 amino acid
substitutions correlated with clinical outcome (figure 6.6).  Two substitutions were noted to be
present in patients achieving SVR: T477A was present in 3 of the 4 patients who achieved an SVR,
and was not present in any of the patients that didn’t achieve an SVR; S558A was present in 2 of 4
patients achieving an SVR and in one patient who withdrew from the trial at week 2. Similarly,
several substitutions were noted in patients who terminated treatment early due to insufficient
virological response: A67V was present in two patients who stopped treatment at 4 weeks, along
with one patient who relapsed and a patient who withdrew from the trial. T581M was noted in all
patients who stopped treatment at 4 weeks, along with two patients who relapsed, and one who
achieved SVR. At A413 those patients who had the reference G3 sequence included all three patients
who stopped treatment at week 4 due to insufficient response, one patient who relapsed, one
patient who achieved an SVR and one patient who withdrew from the trial.
Minority HCV quasispecies were also evaluated to assess if the was any correlation between the
presence of quasispecies at particular location and treatment outcome (table 6.3). At amino acid 67
samples which did not have alanine as the majority species, or as a minority species with a frequency
above 1% were three samples with valine at amino acid 67. Of these three samples two stopped
treatment at week 4 and one relapsed. At amino acid 125 three individuals had a glycine minority
species with a frequency >1%, and two of these also had an arginine minority species with a
frequency >1%. The two of these patients with the arginine minority species achieved SVR whilst the
other individual relapsed after completing treatment. The HCV samples from the two patients who
achieved SVR were both sensitive to telaprevir in vitro.
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Figure 6.6 Potential NS3 variants that were associated with SVR (T477A), (S558A) (A-B), and
withdrawal of treatment at week 4 due to insufficient response (A67V), (A413T), (T581M) (C-E)
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AA No 7 14 20 28 30 33 39 47 48 66 67 69 74 80 89 91 98
Patient Outcome
Week 4
(sens)
T97.5:A1.
75 L S V T V A T
I96.6:
V1.67 G A
I91.4:R7.
8 M Q P A T
Week 4 A L S V T V A T V G V H M Q P A T
Week4 A L S V T V
T97.7:A1.
56 T V G V H M Q
S79.9:P1
9.5 A T
SVR A M S
M87.4:V1
1.9 T V A T V G A H M Q P A T
SVR
(sens) A L S V T V A T V G A H M Q P A A
SVR A
M97.4:L1.
61
S97.7:G1.
41 V T V A
S97.8:T1.0
1 V G A
H97.8:R
1.4 M Q P A
A83.9:T1
4.8
SVR
(sens) A L S I97.2:V2.1
A97.5:T1.
68 V A
T97.04:A2
.34 V G
V97.4:A1.
75 H M Q P A T
Relapse A L S V T V A T V S A
H88.5:R
9.9 M Q P A A
Relapse
T97.45:A1
.53
L85.7:F13
.6 S V T V A T V G A
H98.2:R
1.3
M97.9:L1.
01 Q P A T
Relapse
T97.6:A1.
74 L S V T
I97.7:V1.
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Table 6.3: NS3 minority species (any amino acid substitutions with a frequency >1% in any
sample)
At amino acid 176 two patients had asparagine as the majority species (the remainder had serine as
the majority species). A further patient had asparagine as a minority species with a frequency of
5.8%. Of the two patients with asparagine as the majority species, one achieved SVR, and the other
relapsed post treatment. The patient with asparagine as a minority species also achieved SVR. At
amino acid 477 all patients who had threonine as the majority species with an absence of any
minority species (>1%) did not achieve SVR (3 stopped treatment at week 4 and two relapsed post
treatment).
The phylogenetic tree of the NS3 amino acid sequence from trial patients showed no clustering of
samples in clades based on in vitro telaprevir sensitivity. Similarly, no amino acid substitutions in
majority species were identified that correlated with in vitro sensitivity to telaprevir. 3 minority
species (with a frequency >1% of total sequencing reads) were identified which could potentially be
associated with in vitro sensitivity to telaprevir: The presence of arginine as a minority species at
amino acid 125 (serine is the majority species)  was noted in two patients with HCV sensitive to
telaprevir in vitro both of whom achieved an SVR (as previously described); at amino acid 274
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(leucine majority species) the presence of a proline minority species (>1%) was noted in two patients
with HCV sensitive to telaprevir in vitro and one sample which was insensitive to telaprevir in vitro.
The clinical outcomes were: one patient sensitive to telaprevir in vitro who stopped treatment at
week 4 due to insufficient response to treatment, one patient with HCV sensitive to telaprevir in
vitro who achieved an SVR, and one patient with HCV insensitive to telaprevir in vitro who relapsed
post treatment. At amino acid 381 (leucine majority species) two samples had arginine (as a minority
species >1%). Both these samples were sensitive to telaprevir in vitro (one patient stopped
treatment after 4 weeks of treatment for insufficient response to treatment, and the other achieved
an SVR).
6.3.3 NS4A sequencing data
The NS 4A protein sequence was also analysed as NS4A is involved in the proteolytic activity of
hepatitis C. There was no clustering of patients based on the amino acid sequence of NS4A that
correlated with clinical outcomes (figure 6.7). No amino acid substitutions (in the majority species)
were identified that were associated with SVR or termination of treatment at week 4. Analysis of
minority species did not yield any association with treatment outcome or in-vitro sensitivity to
telaprevir (table 6.4).
There was no clustering of samples based on the amino acid sequences of NS4B and NS5B that
correlated with treatment outcome. With the NS5A protein sequence, there was also no clustering
of samples based on amino acid sequence (although two samples from patients who achieved SVR
were in adjacent subclades). At amino acid 411 three patients expressed arginine (instead of
glutamate or glycine) as the majority species and two of these patients achieved SVR, and one
withdrew from the trial early. The substitution observed may possibly be related to a potential effect
of NS5A on interferon sensitivity.
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Figure 6.7. Phylogenetic tree for NS4A protein sequence
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Table 6.4. Minority species (>1%) in NS4A
Figure 6.8. NS5A potential sequence variant associated with SVR (E411R)
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6.4 Discussion
Analysis of the phylogenetic tree created based on amino acid sequence homology for trial
participants demonstrated clustering of patients based on clinical outcome. Although this suggested
that similarities in amino acid sequence for the entire HCV genome were likely to predict clinical
outcome, this was not demonstrated for any particular non-structural protein in isolation. Similarly,
no single resistance associated substation was associated with clinical outcome (either relating to
stopping treatment after 4 weeks or achieving SVR). Substitutions present in some of the patients
who either stopped treatment at 4 weeks or who achieved an SVR were noted. Analysis of minority
species (with >1% frequency) did not identify any positions where the presence of a particular amino
acid as either a majority species or a significant minority species correlated with clinical outcome.
This may be indicative of several substitutions which may affect clinical outcome in combination
although the small sample size and lack of post treatment sequencing data limited the ability to
identify amino acid substitutions which were associated with early cessation of treatment or relapse.
Similarly, with the small number of samples that were sensitive to telaprevir in vitro, no single amino
acid substitution was identified which correlated with in vitro telaprevir sensitivity. There were
several amino acid positions where the presence of particular minority species appeared to correlate
with telaprevir sensitivity. These substitutions would be unlikely to result in in-vitro sensitivity to
telaprevir on their own unless they were associated with additional amino acid variants in majority
species that were sensitive to telaprevir.
Although these findings are consistent with previous data which attempted to identify resistance
associated variants in the NS3 sequence for genotype 3 HCV a more recent trial evaluating
grazoprevir in the treatment of genotype 3 HCV identified three resistance associated variants which
had a greater than five-fold effect on in vitro sensitivity to grazoprevir in a genotype 3 HCV chimaeric
replicon system. These were Y56H, A156G and Q168K. None of the TIG3 trial patients had any of
these substitutions at baseline. With the advent of newer protease inhibitors such as glecaprevir and
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voxilaprevir for the treatment of genotype 3 hepatitis C including in patients who have failed
previous direct acting antiviral treatment hopefully further light will be shed on the resistance
associated substitutions that confer resistance of G3 HCV to protease inhibitors and how this pattern
differs to genotype 1 HCV.
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Chapter 7: Discussion and update
The telaprevir in genotype 3 hepatitis C trial demonstrated the possible utility of telaprevir in
treating genotype 3 hepatitis C. Four patients on the trial achieved an SVR, although the rapid
progress in the treatment of hepatitis C has resulted in telaprevir being withdrawn and superseded
by newer protease inhibitors. This undoubtably affected trial recruitment, which was terminated
early once details of the early access programme in England had been finalised. As the cohort of
patients recruited onto the trial was small, we are unable to ascertain if there is any benefit in
adding telaprevir to pegylated interferon and ribavirin. The impact of the trial on the clinical
treatment of hepatitis C will therefore be negligible following the development of multiple all oral
pan-genotypic treatment regimens which have now become the standard of care in the treatment of
hepatitis C, with high SVR rates even in patients with advanced liver disease (including those that
have previously failed treatment). Fortunately, the stringent stopping rules for treatment ensured
that patients with a low likelihood of achieving an SVR had limited exposure to treatment. This was
reflected in the good safety profile of the clinical trial, despite treating patients with advanced
fibrosis and cirrhosis with both telaprevir and interferon.
The process of developing and then managing a clinical trial gave an invaluable insight into
understanding the process by which new clinical treatments are developed. Overseeing the
development of an electronic trial database (and the subsequent data entry from clinical report
forms), along with initiation, monitoring and end of trial visits to participating sites provided
experience in ensuring the trial met regulatory and good clinical practice standards.
The telaprevir in genotype 3 hepatitis C trial also included assessment of a novel in vitro HCV
replication model. This enabled the testing of serum (and monocyte) HCV from trial participants, and
evaluating whether drug inhibition of viral replication was detected in vitro. One of the key
challenges faced was achieving robust viral replication in the capture fusion assay from patients with
low serum HCV titres. The capture fusion assay identified three patients that were sensitive to
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telaprevir in vitro, of whom two achieved an SVR. Due to the low baseline viral load of many patients
on the trial, the capture fusion assay was modified to use SEC14L2 cells, which resulted in enhanced
in vitro replication of HCV. Subsequently, monocyte fusions were undertaken (due to the limited
supply of patient serum) to assess if the modifications to the assay had improved viral replication in
vitro, and to confirm the previous findings. Unfortunately, when the monocyte fusion assay was
performed the results were discordant, with different samples being identified as telaprevir
sensitive. This led to concerns regarding the validity of the assay in identifying samples sensitive to
telaprevir in vitro. Further capture fusion experiments (using a single dose of telaprevir) were
performed with the SEC14L2 cells, and these identified two of three samples (both of which were
from patients who achieved an SVR) previously identified as telaprevir sensitive in the capture fusion
assay. As the samples were all blinded until data analysis had been completed, this suggests
replicability of the capture fusion assay, and that the assay may be of predictive value. A major
limitation of the assay are the wide error bars for individual data points, which preclude the use of
the assay as a clinical test. Secondly, the cumbersome nature of the assay and low throughput would
also limit its utilisation. A more realistic use for the assay could be in assessing in vitro sensitivity of
HCV in patients who have failed direct acting antiviral regimens and correlating this with next
generation sequencing data to potentially identify novel resistance associated substitutions.
Next generation sequencing of HCV from trial participants at baseline did not identify any
substitutions (or minority species) associated with treatment failure. Similarly, no substitutions were
identified which correlated with in vitro sensitivity. This is most likely due to the small sample size of
patients in the trial, however it may also reflect a more complex mechanism of resistance for
genotype 3 HCV to telaprevir (which could potentially involve several different resistance associated
substitutions). In all likelihood, large cohorts of patients who fail treatment would be needed to
identify potential resistance associated substitutions that predict response to treatment with
telaprevir in genotype 3 hepatitis. It is unlikely that these will be identified due to the changes in
hepatitis C treatment since completion of the trial.
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7.1 Advances in hepatitis C treatment since 2014
In the 24 months following the initiation of the Telaprevir in Genotype 3 (TIG3) hepatitis C trial,
there have been significant advances in the treatment of hepatitis C. Following patient recruitment
onto the TIG3 trial compassionate use of sofosbuvir with ledipasvir and daclatasvir was commenced
in 2014 for patients with decompensated liver disease due to hepatitis C in the UK. The ALLY 3 trial
had demonstrated that sofosbuvir and daclatasvir for 12 weeks only achieved SVR rates of 63% in
patients with genotype 3 HCV and liver cirrhosis173. A subsequent trial evaluating sofosbuvir,
daclatasvir and ribavirin for 12 or 16 weeks in patients with liver cirrhosis achieved SVR rates of 83-
89%174. Real world data from the expanded access programme in the UK175 demonstrated that while
the overall rate for SVR was high (for this cohort of patients with predominantly decompensated
liver disease), there was a marked difference between outcomes for genotype 1 HCV and genotype
3. The SVR rates for genotype 1 patients treated on the early access programme was 91% compared
to 69% for genotype 3 patients. In particular, the SVR rate for patients with genotype 3 hepatitis C
treated with sofosbuvir and ledipasvir was only 62% compared to 73% for those treated with
sofosbuvir and daclatasvir.
While the early access programme was underway, second generation NS5A inhibitors were being
evaluated in clinical trials. The ASTRAL-3176 trial used sofosbuvir and velpatasvir (a second generation
NS5A inhibitor) for 12 weeks achieving SVR rates of 97% in patients with genotype 3 HCV without
cirrhosis, with a modest decrease in patients with compensated cirrhosis (91%). The ASTRAL-4177
study also used velpatasvir and sofosbuvir, but demonstrated that patients with genotype 3 hepatitis
C and decompensated liver disease had lower SVR rates than their genotype 1 counterparts (SVR
50% for 12 or 24 weeks sofosbuvir and velpatasvir, SVR 85% for 12 weeks sofosbuvir, velpatasvir and
ribavirin compared to 88%, 93%, and 94% for the equivalent genotype 1a groups). So, although
direct acting antiviral drugs had significantly improved outcome for genotype 3 patients with
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advanced liver disease (with a further small improvement by adding ribavirin) there remained a
significant minority of patients with genotype 3 HCV who did not achieve an SVR.
In order to investigate this variation and to understand the mechanism by which treatment failed for
the small proportion of patients that didn’t achieve an SVR, next generation sequencing of patient
HCV was undertaken as part of the clinical trials evaluating newer direct acting antivirals. It was
noted that particular resistance associated substitutions, especially in the NS5A sequence, resulted
in a decreased SVR12 rate. A30K, L31F/M and Y93H were especially implicated in resistance to NS5A
inhibitors, while the following resistance associated substitutions were noted in NS5B: N142T, L159F,
E237G, L320I, S282 and V321A/IS96T176. Despite the presence of NS5A resistance associated
substitutions in 28% of patients (using a sequencing cut off of 15% of sequencing reads) in the
POLARIS studies using sofosbuvir and velpatasvir, SVR rates of 97-100% were achieved in genotypes
1,2,4,5 or 6. For genotype 3 however, 12% of patients had NS5A resistance associated substitutions
at baseline. In patients with NS5A resistance associated substitutions the SVR rates were lower, 93%
compared to those without those substitutions at baseline (98%). In patients with genotype 3
hepatitis C and the Y93H substitution in the NS5A sequence the SVR12 rate dropped further to
86%178, whilst patients in the ALLY-3 trial (who received 12 weeks of sofosbuvir and daclatasvir) with
the Y93H substitution only achieved an SVR12 of 54%173.
Whilst the NS5A/NS5B combinations achieved excellent SVR rates, in particular for patients with
genotype 1 hepatitis C even with previous treatment failure or advanced liver disease (where SVR
rates still remained above 95%), in genotype 3 hepatitis C the data from the ALLY-3 and POLARIS
studies along with real world data from the expanded access programme demonstrated that an
unmet treatment need still existed for patients with genotype 3 hepatitis C and advanced liver
disease or Y93 resistance associated substitutions.
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Fortunately, additional treatment regimens were also in development at the time, including some
which contained second generation protease inhibitors. Elbasvir (NS5A inhibitor) and grazoprevir
(NS3 inhibitor) were evaluated in the treatment of genotype 3 hepatitis C (in treatment naïve non-
cirrhotic patients). This combination only achieved SVR rates of 45% with 12 weeks of treatment or
57% with 16 weeks of treatment166. Analysis undertaken to determine whether resistance associated
substitutions accounted for virological failure only identified NS3 substitutions (which conferred a >5
fold change in sensitivity) in only 35% of patients with virological failure. NS5A resistance associated
substitutions however occurred more frequently, with the Y93H substitution occurring in 76% of
patients who experienced virological breakthrough.  The C-ISLE study evaluated grazoprevir, elbasvir
and sofosbuvir (with or without ribavirin) in the treatment of patients with genotype 3 hepatitis C
and cirrhosis. Treatment naïve patients treated with elbasvir/grazoprevir, sofosbuvir and ribavirin for
eight weeks achieved an SVR of 91%, whilst treatment with elbasvir/grazoprevir and sofosbuvir for
12 weeks achieved an SVR12 of 96%. In patients who had been treated with interferon and ribavirin
previously, treatment with elbasvir/grazoprevir and sofosbuvir for 12 or 16 weeks resulted in SVR12
rates of 94%. In both the trials above, a high proportion of patients had baseline NS3 resistance
associated substitutions but these were not necessarily associated with clinical outcome. In the C-
ISLE study, despite 50% of patients having detectable NS5A RAS at baseline, the SVR rate was 98% in
participants with or without RAS179.
Another regimen that has subsequently become the standard of care treatment for genotype 3
hepatitis C in the United Kingdom is glecaprevir and pibrentasvir. Glecaprevir (ABT-493) is a pan
genotypic NS3 inhibitor which maintained activity even against substitutions at 155 and 168 (which
conferred resistance against previous generations of NS3 inhibitors). Pibrentasvir (ABT-530) is a
NS5A inhibitor with an improved resistance profile to RAS at M28T, A30K and Y93H. The Surveyor II
study evaluated this combination in patients with genotype 3 HCV and compensated cirrhosis,
achieving SVR rates of 95% in treatment naïve patients following 12 weeks of treatment. In
treatment experienced patients who received 16 weeks of treatment three out of four patients
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achieved an SVR12 (75%). The combination of ABT-493/ABT-530 and ribavirin achieved an SVR12 of
100% in patients with genotype 3 HCV and cirrhosis (irrespective of prior treatment status)167. In the
third phase of the Surveyor II trial, larger numbers of patients were treated with glecaprevir and
pibrentasvir. Treatment naïve cirrhotic genotype 3 patients achieved an SVR12 of 98% following 12
weeks of treatment. Treatment experienced non-cirrhotic genotype 3 patients achieved SVR12 of
91% and 95% with 12 and 16 weeks of treatment respectively. An SVR12 of 96% was achieved in
treatment experienced genotype 3 patients with cirrhosis following 16 weeks of treatment. Patients
with previous sofosbuvir experience achieved an SVR12 of 98%180.
Initial trials evaluating treatment duration with sofosbuvir/velpatasvir and voxilaprevir (a pan
genotypic NS3 inhibitor) achieved SVR12 rates of 94% following eight weeks of treatment in
treatment naïve genotype 3 HCV patients with cirrhosis. Treatment experienced genotype 3 HCV
patients with cirrhosis were given 12 weeks of treatment and also achieved SVR rates of 94%181.
Subsequent trials evaluated this combination for 12 weeks in NS5A experienced patients (POLARIS-
1), and also in patients exposed to any DAA except NS5A inhibitors (POLARIS-4). In POLARIS-1
genotype 3 NS5A experienced patients achieved an SVR12 of 95%, with an SVR12 rate of 93% in
patients with cirrhosis. In POLARIS-4 an SVR rate of 96% was achieved in genotype 3 patients treated
with a non-NS5A DAA regimen (predominantly sofosbuvir based treatment)182. In POLARIS-3 SVR12
rates of 96% were achieved with both 12 weeks of sofosbuvir/velpatasvir and eight weeks of
sofosbuvir/velpatasvir and voxilaprevir in DAA naive patients with genotype 3 hepatitis C and liver
cirrhosis168.
As these newer, pangenotypic (and better tolerated) protease inhibitors became available, first
generation protease inhibitors were superseded and therefore withdrawn from usage.  As a result
telaprevir was withdrawn from use in Europe in September 2016. Some of the challenges faced in
the Telaprevir in Genotype 3 clinical trial still remain, however. The limited efficacy of
grazoprevir/elbasvir in genotype 3 further demonstrated that protease inhibitors appeared to only
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confer benefit in a proportion of patients. Interestingly, there were no significant NS3 RAS that were
identified that conferred resistance to treatment in patients with genotype 3 HCV. This contrasts
with the NS5A resistance associated substitutions which are well documented with both initial NS5A
inhibitors (daclatasvir, ledipasvir and elbasvir) along with newer NS5A inhibitors (velpatasvir and
pibrentasvir). With the most recent NS3 containing regimens, the high efficacy of treatment results
in a small number of patients who have virological failure or relapse post treatment. Subsequently,
predicting patients who may fail treatment or identifying combinations of RAS that confer resistance
is challenging. As the sequencing data from the telaprevir in genotype 3 trial demonstrated, in a
small cohort of samples the likelihood of identifying RAS which confer NS3 resistance in genotype 3
is limited. Whilst there may be certain RAS which appear to correlate with clinical outcome, it is
difficult to extrapolate firm conclusions when other variables may be present (such as sensitivity to
additional drugs in a treatment regimen, pharmacokinetic variables and treatment adherence). This
highlights the need for an effective in vitro system to enable accurate phenotyping of patient
derived genotype 3 HCV to direct acting antiviral drugs. This data then allows a greater number of
samples to be tested and may improve the ability to detect RAS which confer resistance to a single
DAA (which may not be apparent when patients are treated with multi-DAA combinations).
7.2 Advances in cell culture HCV replication systems
Whilst the rapid development of multiple new and effective direct acting antiviral drugs continued,
research was being undertaken to improve the in vitro models available to evaluate genotype 3
hepatitis C in vitro. The aim was to move away from the existing in vitro replication systems that
were either based on genotype 1 (Con1) or 2 (JFH-1) to those that would facilitate improved
understanding of drug sensitivity in-vitro for genotype 3 hepatitis C.
Saeed et al.183 created a sub-genomic replicon from a genotype 3 hepatitis C isolate (S310). S310 was
derived from patient serum (from a genotype 3 patient with post-transplant recurrence of HCV)
which demonstrated infectivity of primary human hepatocytes. A sub-genomic replicon was then
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created based on this isolate which replicated in vitro. Those clones that demonstrated in vitro
replication developed cell culture adaptive mutations. Kim et al.184 subsequently developed an in
vitro genotype 3 replication system based on the S310 replicon, this system enabled viral replication
and the production of viral particles in cell culture. The infectivity of the genotype 3 S310 was
approximately 10% of JFH-1. Interestingly, in vitro infection with S310 resulted in increased
intracellular lipid droplet formation, in keeping with the increased incidence of steatosis in patients
infected with genotype 3 hepatitis C. Unfortunately, the S52 and S310 subgenomic replicons did not
replicate well (even in modified hepatoma cells) when reporter genes (e.g. luciferase) were added to
enable testing of drug sensitivity185.
In addition to attempting to develop a genotype 3 replicon, research was undertaken to evaluate
why clinical isolates of HCV replicated poorly in cultured hepatoma cells. Huh 7.5 cells were
transfected with human cDNA and then transfected with subgenomic replicons lacking adaptive
mutations. This enabled the identification of specific cDNA which augmented in vitro replication162.
The SEC14L2 cDNA permitted replication of subgenomic replicons without adaptive mutations.
SEC14L2 was postulated to increase in vitro HCV replication by enhancing vitamin E mediated
inhibition of lipid peroxidation. SEC14L2 also enabled replication of HCV from patient serum in Huh
7.5 cells, although high viral loads were needed to achieve this (5.98x106 to 3.2x107).
Despite these advances, there is still no readily available cell culture system which permits patient
derived HCV replication in vitro. In order to assess patient derived genotype 3 HCV sensitivity to
specific drugs a chimeric replicon would need to be created with the majority and significant
minority species from a particular patient. The capture fusion model allowed an efficient method of
assessing patient derived HCV sensitivity to particular antiviral drugs. With the addition of SEC14L2,
which augmented in vitro HCV replication, this enabled genotype 3 HCV from patients with low viral
loads to replicate in vitro. This was of particular relevance to the telaprevir in genotype 3 hepatitis C
trial. As patients recruited to the trial had advanced fibrosis or cirrhosis, their viral loads were
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generally lower than those than would be expected in non-cirrhotic HCV patients (and lower than
the patient HCV viral loads which replicated in SEC14L2 cells). The capture fusion assay permitted in
vitro viral replication of HCV from multiple different patients in the telaprevir in genotype 3 trial, and
enabled phenotypic testing of HCV sensitivity to telaprevir.
The capture fusion assay has been used since the completion of the telaprevir in genotype 3 study to
evaluate the in vitro sensitivity of patient derived HCV to a novel antiviral compound (SB9200)186.
Further work undertaken by our group used the capture fusion assay to assess in vitro sensitivity of
patient derived HCV to sofosbuvir in patients who had either achieved SVR or relapsed post
treatment with sofosbuvir. This enabled identification of the A150V substitution in the NS5B protein
which was associated with a decreased SVR rate.
As the number of patients who fail treatment has decreased, identifying the mechanisms of
treatment failure becomes more challenging. The capture fusion assay remains a useful tool in
assessing in vitro sensitivity of patient derived HCV to antiviral drugs. As the current first line
treatment for genotype 3 HCV in the UK is glecaprevir (a NS3 inhibitor) and pibrentasvir, the capture
fusion assay could be used to evaluate HCV sensitivity from patients who have failed this regimen to
other protease inhibitors such as voxilaprevir which forms part of the “rescue” treatment
(voxilaprevir/sofosbuvir/velpatasvir) for patients that have had treatment failures. In addition to
assessing in vitro drug sensitivity, this may allow the assay to be used prospectively to potentially
predict treatment outcome, and furthermore enable identification of the resistance associated
substitutions and mechanisms which confer HCV genotype 3 resistance to protease inhibitors.
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7.3 Summary
Whilst telaprevir may be of use in the treatment of genotype 3 hepatitis C, the rapid progress in
hepatitis C treatment over the last four years has rendered it obsolete, resulting in it being
withdrawn from clinical use (as more potent pan-genotypic protease inhibitors have become
available). The small number of patients who enrolled onto the trial had limited treatment options
available to them at the time of trial recruitment, and strict stopping rules minimised exposure to
treatment in patients where SVR was unlikely. The capture fusion assay was investigated as a tool
which could predict treatment response. Low patient HCV viral load posed a challenge in achieving
robust in vitro viral replication. The capture fusion assay was modified to enhance viral replication,
using SEC14L2 cells and the PAd4 construct. Despite this, intra-assay variability precludes its use as a
clinical tool. It may have a utility in identifying drug sensitivity and correlation with next generation
sequencing data may help identify resistance associated substitutions. The next generation
sequencing undertaken on trial participants’ baseline HCV did not identify any substitutions
associated with treatment response. There were no substitutions identified which directly correlated
with in vitro sensitivity to telaprevir either. This is unsurprising due to the small patient cohort
involved in the trial.
7.4 Future work
As telaprevir has been withdrawn from use, further clinical work using it will not be undertaken. The
focus of research would shift to newer protease inhibitors used in genotype 3 hepatitis C such as
glecaprevir and voxilaprevir. The capture fusion assay may be of use in assessing patient derived HCV
sensitivity to either (or both) of these drugs, and correlating in vitro sensitivity to treatment
outcome and next generation sequencing to identify relevant resistance associated substitutions
which may affect treatment outcome for genotype 3 patients treated with regimens containing a
protease inhibitor.
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STUDY SUMMARY/SYNOPSIS
TITLE Telaprevir in patients with genotype 3 HCV: pilot
clinical study to evaluate efficacy and predictability of
therapy in patients who have failed to respond to
pegylated interferon and ribavirin
SHORT TITLE Telaprevir In Genotype 3 HCV
Protocol Version
Number and Date Version 3.4 dated  06 June 2016
Methodology Multi-site, pilot study evaluating the impact of Telaprevir in
patients with genotype 3 HCV who have failed to respond
to pegylated interferon and ribavirin therapy
Study Duration 18 months – 24 weeks therapy, 24 weeks follow up, 24
weeks recruitment
Sponsor Queen Mary University of London
Objectives To determine whether a proportion of patients with
genotype 3 HCV who have failed to respond to pegylated
interferon and ribavirin respond to re-treatment with a
telaprevir containing regime
Phase of the Trial 4
Number of
Subjects/Patients Approximately 30
Main Inclusion Criteria People with genotype 3 HCV who have advanced fibrosis
and who have failed to respond to therapy with pegylated
interferon and ribavirin.
Statistical
Methodology and
Analysis
The primary outcome will be sustained virological
response as determined by undetectable HCV RNA 12
weeks after cessation of therapy.
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Glossary of Terms and Abbreviations
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CA Competent Authority
CI Chief Investigator
CRF Case Report Form
CRO Contract Research Organisation
CTA Clinical Trial Authorisation
CTIMP Clinical Trial of Investigational Medicinal Product
DMC Data Monitoring Committee
EC European Commission
EMEA European Medicines Agency
EU European Union
EUCTD European Clinical Trials Directive
EudraCT European Union Drug Regulating Authorities Clinical Trials
EudraVIGILANCE European Union Drug Regulating Authorities Pharmacovigilance
GAfREC Governance Arrangements for NHS Research Ethics Committees
GCP Good Clinical Practice
GMP Good Manufacturing Practice
IB Investigator Brochure
ICF Informed Consent Form
IMP Investigational Medicinal Product
IMPD Investigational Medicinal Product Dossier
ISRCTN International Standard Randomised Controlled Trial Number
JRO Joint Research and Development Office
MA Marketing Authorisation
MHRA Medicines and Healthcare products Regulatory Agency
MS Member State
Main REC Main Research Ethics Committee
NHS R&D National Health Service Research & Development
PI Principal Investigator
QA Quality Assurance
QC Quality Control
QP Qualified Person for release of trial drug
Participant An individual who takes part in a clinical trial
RCT Randomised Controlled Trial
REC Research Ethics Committee
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SAE Serious Adverse Event
SAR Serious Adverse Reaction
SDV Source Document Verification
SmPC Summary of Product Characteristics
SOP Standard Operating Procedure
SSA Site Specific Assessment
SUSAR Suspected Unexpected Serious Adverse Reaction
TMG Trial Management Group
TSC Trial Steering Committee
214
Index
1. Introduction
1.1 Background
1.2 Investigational Medicinal Products
1.3 Pre-Clinical Data
1.4 Clinical Data
1.5 Rationale and Risks/Benefits
2. Trial Objectives and Design
2.1    Trial Objectives
2.2 Trial Design and Study Scheme Diagram
3.      Subject Selection
3.1 Number of Subjects and Subject Selection
3.2    Inclusion Criteria
3.3 Exclusion Criteria
3.4 Criteria for Premature Withdrawal
4.      Investigational Medicinal Product
4.1 Definition of IMP
4.2    IMP Supply
4.3    Prescription of IMP
4.4    Preparation and Administration of IMP
4.5 Packaging and Labeling of IMPs
4.6    Accountability/Receipt /Storage and Handling of IMP
4.7    Dispensing of IMP
4.8    Prior and Concomitant Therapies
4.9    Dose modification/reduction/ delay
4.10  Return of IMP
4.11  Recall or Destruction of IMP
5.      Study Procedures
5.1 Informed Consent Procedures
5.2 Screening Procedures
5.3    Enrolment Procedures
5.4 Schedule of Treatment for each visit
5.5 Schedule of Assessment
5.6    Follow up Procedures
5.7 Laboratory Assessments
5.8 End of Study Definition
5.9 Patient Support
5.10  Patient Withdrawal and Early Termination
5.11 Data Collection and Follow up for Withdrawn Subjects 5.12
6.      Laboratories
6.1 Central/Local Laboratories
6.2 Sample Collection, Processing and Analysis
7.      Pharmacovigilance
7.1 General Definitions
7.2    Investigators Assessment
7.3 Notification and Reporting of Serious Adverse Events/SUSAR
7.4 Urgent Safety Measures
215
7.5 Annual Safety Reporting
7.6 Overview of the Safety Reporting Process/Pharmacovigilance Responsibilities
7.7 Pregnancy
8.      Statistical Considerations
8.1 Primary Endpoint Efficacy Analysis
8.2    Secondary Endpoint Efficacy Analysis
8.3 Sample Size
8.4 Statistical Analysis
9.      Data Handling & Record Keeping
9.1    Confidentiality
9.2    Study Documents
9.3 Case Report Form
9.4    Record Retention and Archiving
9.5    Compliance
9.6 Clinical Governance Issues
9.7    Quality Control and Quality Assurance
9.8    Serious Breaches in GCP or the Trial Protocol
10.    Trial Committees
11.    Publication Policy
12.    References
216
1. Introduction
1.1    Background
Chronic infection with genotype 3 hepatitis C virus (HCV) is common [1]. The majority of
those who are infected respond to therapy with current anti-viral agents (pegylated interferon
(PegIFN) and ribavirin (RBV)) [1]. However, in patients with genotype 3 HCV and cirrhosis,
response rates are less than 60%, with many patients relapsing when therapy is withdrawn
[1]. Patients with genotype 3 HCV and cirrhosis who have failed to respond to antiviral
therapy are at high risk of complications of HCV (chiefly hepatocellular carcinoma) [2] and
there are no effective treatments.  In patients with genotype 1 HCV the protease inhibitor
telaprevir improves the response to therapy [3] and in patients who have relapsed following
pegylated interferon and ribavirin the response to therapy with telaprevir, pegylated
interferon and ribavirin is impressive, with sustained virological response rates of >80% [4].
Clinical trials with telaprevir monotherapy in patients with genotype 3 HCV show a relatively
poor response with a mean reduction in viral load of 0.5 log (compared to 3-4 log in patients
with genotype 1 HCV) [5]. However, within the cohort of patients treated with telaprevir
monotherapy a proportion (approximately 30%) showed a significant response with a
reduction of HCV RNA of >2 logs. Given that patients with genotype 1 HCV who have
relapsed after pegylated interferon and ribavirin therapy are very sensitive to re-treatment
with telaprevir containing regimes we speculate that the modest antiviral effect of telaprevir
in patients with genotype 3 HCV may be sufficient to induce a response in a proportion of
subjects. We have recently developed a viral replication model which allows virus from
patients with HCV to be cultured in vitro and its sensitivity to anti-viral agents assessed. We
have shown that different genotype 3 isolates have differing sensitivity to telaprevir and we
speculate that the probability of response may be determined by pre-treatment assessment
of viral sensitivity to telaprevir. We now propose to examine these possibilities in a clinical
trial.
1.2    Investigational Medicinal Products
This trial involves 3 licensed medications:
IMP1 – Telaprevir (INCIVO) 375 mg film coated tablets to be taken orally.
IMP2 - 40 Kd Pegylated interferon alfa 2a (Pegasys) 180 µg in pre-filled syringe/pen for sub-
cutaneous injection
IMP3 - Ribavirin (Copegus) 200 mg tablets to be taken orally.
1.3 Pre-Clinical Data
Telaprevir
Animal toxicology and/or pharmacology
In rats and dogs, telaprevir was associated with a reversible reduction of red blood cell
parameters accompanied by a regenerative response. In both rats and dogs, AST/ALT
elevations were observed in most studies, of which the increase in ALT in rats was not
normalised after recovery. Histopathological findings in the liver were similar in both rat and
dog studies, of which not all were fully resolved after recovery. In rats (but not in dogs),
telaprevir caused degenerative changes in testes which were reversible and did not affect
fertility. In general, exposure levels in relation to human values were low in animal
pharmacology and toxicology studies.
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Carcinogenesis and mutagenesis
Telaprevir has not been tested for its carcinogenic potential. Neither telaprevir nor its major
metabolite caused damage to DNA when tested in the standard battery of mutagenesis
assays, in the presence and absence of metabolic activation.
Impairment of fertility
Telaprevir had no effects on fertility or fecundity when evaluated in rats.
Embryo-foetal development
Telaprevir readily crosses the placenta in both rat and mouse giving a foetal: maternal
exposure of 19 - 50%. Telaprevir did not have any teratogenic potential in rat or mouse. In a
fertility and early embryonic development study in rats, an increase in non-viable
conceptuses was observed. Dosing of the animals did not result in any exposure-margin
when compared to human exposure.
Excretion into milk
When administered to lactating rats, levels of telaprevir and its major metabolite were higher
in milk compared to those observed in plasma. Rat offspring exposed to telaprevir in utero
showed normal body weight at birth. However, when fed via milk from telaprevir-treated
dams, body weight gain of rat pups was lower than normal (likely due to taste aversion).
After weaning, rat pup body weight gain returned to normal.
Pegylated interferon alfa 2a
The non-clinical toxicity studies conducted with Pegasys were limited due to species
specificity of interferons. Acute and chronic toxicity studies have been carried out in
cynomolgus monkeys, and the findings observed in peginterferon dosed animals were
similar in nature to those produced by interferon alfa-2a.
Reproductive toxicity studies have not been performed with Pegasys. As with other alpha
interferons, prolongation of the menstrual cycle was observed following administration of
peginterferon alfa-2a to female monkeys. Treatment with interferon alfa-2a resulted in a
statistically significant increase in abortifacient activity in rhesus monkeys. Although no
teratogenic effects were seen in the offspring delivered at term, adverse effects in humans
cannot be excluded.
Pegasys plus ribavirin
When used in combination with ribavirin, Pegasys did not cause any effects in monkeys not
previously seen with either active substance alone. The major treatment-related change was
reversible mild to moderate anaemia, the severity of which was greater than that produced
by either active substance alone.
Ribavirin
Ribavirin is embryotoxic and/or teratogenic at doses well below the recommended human
dose in all animal species in which adequate studies have been conducted. Malformations of
the skull, palate, eye, jaw, limbs, skeleton and gastrointestinal tract were noted. The
incidence and severity of teratogenic effects increased with escalation of the dose. Survival
of foetuses and offspring is reduced.
Erythrocytes are a primary target of toxicity for ribavirin in animal studies, including studies in
dogs and monkeys. Anaemia occurs shortly after initiation of dosing, but is rapidly reversible
upon cessation of treatment. Hypoplastic anaemia was observed only in rats at the high
dose of 160 mg/kg/day in the subchronic study.
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Reduced leucocyte and/or lymphocyte counts were consistently noted in the repeat-dose
rodent and dog toxicity studies with ribavirin and transiently in monkeys administered
ribavirin in the subchronic study. Repeat-dose rat toxicity studies showed thymic lymphoid
depletion and/or depletion of thymus-dependent areas of the spleen (periarteriolar lymphoid
sheaths, white pulp) and mesenteric lymph node. Following repeat-dosing of dogs with
ribavirin, increased dilatation/necrosis of the intestinal crypts of the duodenum was noted, as
well as chronic inflammation of the small intestine and erosion of the ileum.
In repeat dose studies in mice to investigate ribavirin-induced testicular and sperm effects,
abnormalities in sperm occurred at doses in animals well below therapeutic doses. Upon
cessation of treatment, essentially total recovery from ribavirin induced testicular toxicity
occurred within one or two spermatogenic cycles.
Genotoxicity studies have demonstrated that ribavirin does exert some genotoxic activity.
Ribavirin was active in an in vitro Transformation Assay. Genotoxic activity was observed in
in vivo mouse micronucleus assays. A dominant lethal assay in rats was negative, indicating
that if mutations occurred in rats they were not transmitted through male gametes. Ribavirin
is a possible human carcinogen.
Administration of ribavirin and peginterferon alfa-2a in combination did not produce any
unexpected toxicity in monkeys. The major treatment-related change was reversible mild to
moderate anaemia, the severity of which was greater than that produced by either active
substance alone.
1.4    Clinical Data
These medications are licensed and NICE approved for the treatment of genotype 1 HCV.
Telaprevir, in combination with peginterferon alfa and ribavirin, is indicated for the treatment
of genotype 1 chronic hepatitis C in adult patients with compensated liver disease (including
cirrhosis):
- Who are treatment-naïve;
- Who have previously been treated with interferon alfa (pegylated or non-pegylated) alone
or in combination with ribavirin, including relapsers, partial responders and null responders
(see sections 4.4 and 5.1).
In the Phase 3 studies, none of the patients with HCV RNA > 1,000 IU/ml at either week 4 or
week 12 achieved SVR with continued peginterferon alfa and ribavirin treatment. In
treatment-naïve patients in the Phase 3 studies, 4/16 (25%) patients with HCV RNA levels
between 100 IU/ml and 1,000 IU/ml at week 4 achieved SVR. In patients with HCV RNA
between 100 IU/ml and 1,000 IU/ml at week 12, 2/8 (25%) achieved an SVR.
Special populations
Renal impairment
There are no clinical data on the use of INCIVO in HCV patients with moderate or severe
renal impairment (CrCl ≤ 50 ml/min). In HCV-negative patients with severe renal impairment,
no clinically relevant change in telaprevir exposure was observed. Therefore, no dose
adjustment is recommended for telaprevir in HCV patients with renal impairment.
There are no clinical data on the use of telaprevir in patients on hemodialysis.
Hepatic impairment
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Telaprevir is not recommended in patients with moderate to severe hepatic impairment
(Child-Pugh B or C, score ≥ 7) or decompensated liver disease. Dose modification of
telaprevir is not required when administered to hepatitis
C patients with mild hepatic impairment (Child-Pugh A, score 5-6).
Severe rash
Severe rashes have been reported with telaprevir combination treatment. In placebo-
controlled Phase 2 and 3 trials, severe rash (primarily eczematous, pruritic and involving
more than 50% body surface area) was reported in 4.8% of patients who received telaprevir
combination treatment compared to 0.4% receiving peginterferon alfa and ribavirin. 5.8% of
patients discontinued telaprevir alone due to rash events and 2.6% of patients discontinued
telaprevir combination treatment for rash events compared to none of those receiving
peginterferon alfa and ribavirin.
In placebo-controlled Phase 2 and 3 trials, 0.4% of patients had suspected Drug Rash with
Eosinophilia and Systemic Symptoms (DRESS). In telaprevir clinical experience, less than
0.1% of patients had Stevens - Johnson syndrome. All of these reactions resolved with
treatment discontinuation. DRESS presents as a rash with eosinophilia associated with one
or more of the following features: fever, lymphadenopathy, facial oedema, and internal organ
involvement (hepatic, renal, pulmonary). It may appear at any time after start of treatment,
although the majority of cases appeared between six and ten weeks after the start of
treatment with telaprevir.
Anaemia
In placebo-controlled Phase 2 and 3 clinical trials, the overall incidence and severity of
anaemia increased with telaprevir combination treatment compared to peginterferon alfa and
ribavirin alone. Haemoglobin values of < 10 g/dl were observed in 34% of patients who
received telaprevir combination treatment and in 14% of patients who received peginterferon
alfa and ribavirin. Haemoglobin values of < 8.5 g/dl were observed in 8% of telaprevir
combination treatment compared to 2% of patients receiving peginterferon alfa and ribavirin.
A decrease in haemoglobin levels occurs during the first 4 weeks of treatment, with lowest
values reached at the end of telaprevir dosing. Haemoglobin values gradually improve after
completion of telaprevir dosing.
Cardiovascular
Results of a study conducted in healthy volunteers demonstrated a modest effect of
telaprevir at a dose of 1,875 mg every 8 hours on the QTcF interval with a placebo-adjusted
maximum mean increase of 8.0 msec (90% CI: 5.1-10.9). Exposure at this dose was
comparable to the exposure in HCV-infected patients receiving a dose of 750 mg telaprevir
every 8 hours plus peginterferon alfa and ribavirin. The potential clinical significance of these
findings is uncertain.
The use of telaprevir in combination with peginterferon alfa-2b
The Phase 3 studies were all conducted with peginterferon alfa-2a in combination with
telaprevir and ribavirin. There is no data using telaprevir in combination with peginterferon
alfa-2b in treatment-experienced patients and limited data in treatment-naïve patients. Naïve
patients treated with either peginterferon alfa-2a/ribavirin (n = 80) or peginterferon alfa-
2b/ribavirin (n = 81) in combination with telaprevir, in an open label study, had comparable
SVR rates. However, patients treated with peginterferon alfa-2b experienced more frequent
viral breakthrough, and were less likely to meet the criteria for shortened total treatment
duration.
One published study Foster et al (5) has shown limited activity in patients with Genotype 3
HCV and the purpose of this pilot study is to determine whether or not this activity is
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sufficient to justify further clinical trials in a subset of patients with minimal alternative
treatment options.
Hepatic impairment
Telaprevir has not been studied in patients with severe hepatic impairment (Child-Pugh C,
score ≥ 10) or decompensated liver disease and is not recommended in these populations.
Telaprevir has not been studied in HCV-infected patients with moderate hepatic impairment
(Child-Pugh B, score 7-9). In HCV negative patients with moderate hepatic impairment,
reduced exposure to telaprevir was observed.
Summary of the safety profile
The overall safety profile of telaprevir is based on all available pooled Phase 2 and 3 clinical
trial data (both controlled and uncontrolled) containing 2,641 patients who received telaprevir
combination treatment.
The incidence of adverse drug reactions (ADRs) of at least moderate intensity (≥ Grade 2)
was higher in the telaprevir group than in the placebo group. During the telaprevir /placebo
treatment phase, the most frequently reported ADRs of at least Grade 2 in severity in the
telaprevir group (incidence ≥ 5.0%) were anaemia, rash, pruritus, nausea, and diarrhoea.
During the telaprevir/placebo treatment phase, the most frequently reported ADRs of at least
Grade 3 in the telaprevir group (incidence ≥ 1.0%) were anaemia, rash, thrombocytopenia,
lymphopenia, pruritus, and nausea.
Clinical virology studies
In Phase 2 and 3 clinical trials of telaprevir, treatment-naïve and prior treatment-failure
patients with predominant telaprevir resistant variants at baseline (pre-treatment) were rare
(V36M, T54A and R155K < 1% and T54S 2.7%). Predominant baseline resistant variants at
baseline (pre-treatment) were rare (V36M, T54A and R155K < 1% and T54S 2.7%).
Predominant baseline resistance to telaprevir does not preclude successful treatment with
telaprevir, peginterferon alfa, and ribavirin. The impact of predominant telaprevir-resistant
variants at baseline is likely greatest in patients with a poor interferon response, such as
prior null responders.
A total of 215 of 1,169 patients treated with a T12/PR regimen in a Phase 3 clinical trial had
on-treatment virologic failure (n = 125) or relapse (n = 90). Based on population sequencing
analyses of HCV in these 215 patients, the emergence of telaprevir-resistant HCV variants
was detected in 105 (84%) virologic failures and in 55 (61%) relapsers, and wild-type virus
was detected in 15 (12%) virologic failures and in 24 (27%) relapsers. HCV sequencing data
were not available for 16 (7%) patients. Sequence analyses of the telaprevir-resistant
variants identified substitutions at 4 positions in the NS3-4A protease region, consistent with
the mechanism of action for telaprevir (V36A/M, T54A/S, R155K/T, and A156S/T/V). On-
treatment virologic failure during telaprevir treatment was predominantly associated with
higher-level resistant variants, and relapse was predominantly associated with lower-level
resistant variants or wild-type virus.
Patients with HCV genotype 1a predominately had V36M and R155K single and combination
variants, while patients with HCV genotype 1b predominately had V36A, T54A/S, and
A156S/T/V variants. This difference is likely due to the higher genetic barrier for the V36M
and R155K substitutions for genotype 1b than genotype 1a. Among patients treated with
telaprevir, on treatment virologic failure was more frequent in patients with genotype 1a than
with genotype 1b and more frequent in prior null responders than in other populations
(treatment-naïve, prior relapsers, prior partial responders; see section 5.1, Clinical
Experience, Efficacy in Previously Treated Adults).
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Follow-up analysis of INCIVO-treated patients who did not achieve an SVR showed that the
population of wild-type virus increased and the population of telaprevir-resistant variants
became undetectable over time after the end of telaprevir treatment. Of a combined 255
treatment-naïve and previously treated patients from Phase 3 studies 108, 111, and C216 in
whom telaprevir-resistant variants had emerged during treatment, 152 (60%) patients no
longer had resistant variants detected by population sequencing (median follow-up of 10
months). Of the 393 resistant variants detected in the 255 patients, 68% of NS3-36, 84% of
NS3-54, 59% of NS3-155, 86% of NS3-156, and 52% of NS3-36M+NS3-155K variants were
no longer detected.
In a follow-up study of 98 treatment-naïve and prior treatment-failure patients who were
treated with a INCIVO regimen in a Phase 2 or Phase 3study and did not achieve SVR,
telaprevir-resistant variants were no longer detected in 85% (83/98) of patients (median
follow-up of 27.5 months). Clonal sequencing analysis of a subset of patients who had wild-
type HCV by population sequencing (n=20), comparing the frequency of resistant variants
before the start of telaprevir treatment and at follow-up, showed that the HCV variant
population in all patients had returned to pre-treatment levels. The median time for
telaprevir-resistant variants to become undetectable by population sequencing was longer
for variants NS3-36 (6 months), NS3-155 (9 months) and NS3-36M+NS3-155K (12 months)
predominantly observed in patients with genotype 1a than for variants NS3-54 (2 months)
and NS3-156 (3 months) predominantly observed in patients with genotype 1b.
Clinical efficacy and safety
The efficacy and safety of INCIVO in patients with genotype 1 chronic hepatitis C were
evaluated in three Phase 3 studies: 2 in treatment-naïve patients and 1 in previously treated
patients (relapsers, partial responders, and null responders). Patients in these studies, 108,
111 and C216, had compensated liver disease, detectable HCV RNA, and liver
histopathology consistent with chronic hepatitis C. Unless otherwise indicated, INCIVO was
administered at a dosage of 750 mg every 8 hours; the peginterferon alfa-2a dose was 180
μg/week, and the ribavirin dose was 1,000 mg/day (patients weighing < 75 kg) or 1,200
mg/day (patients weighing ≥ 75 kg). Plasma HCV RNA values were measured using the
COBAS® TaqMan® HCV test (version 2.0), for use with the High Pure System. The assay
had a lower limit of quantification of 25 IU/ml. In the description of  Phase 3 study outcomes
below, SVR, considered virologic cure, was defined based on the HCV RNA assessment in
the study week 72 visit window, using the last measurement in the window. In the case of
missing data within the week 72 window, the last HCV RNA data point from week 12 of
follow-up onwards was used. In addition, the limit of quantification of 25 IU/ml was used to
determine SVR.
Efficacy in treatment-naïve adults
Study 108 (ADVANCE)
Study 108 was a randomised, double-blind, parallel-group, placebo-controlled, Phase 3
study conducted in treatment-naïve patients. INCIVO was given for the first 8 weeks of
treatment (T8/PR regimen) or the first 12 weeks of treatment (T12/PR regimen) in
combination with peginterferon alfa-2a and ribavirin for either 24 or 48 weeks. Patients who
had undetectable HCV RNA at weeks 4 and 12 received 24 weeks of peginterferon alfa-2a
and ribavirin treatment, and patients who did not have undetectable HCV RNA at week 4
and week 12 received 48 weeks of peginterferon alfa-2a and ribavirin treatment. The control
regimen (Pbo/PR) had a fixed treatment duration of 48 weeks, with telaprevir-matching
placebo for the first 12 weeks and peginterferon alfa-2a and ribavirin for 48 weeks.
The 1,088 enrolled patients had a median age of 49 years (range: 18 to 69); 58% of the
patients were male; 23% had a body mass index ≥ 30 kg/m2; 9% were Black; 11% were
Hispanic or Latino; 77% had baseline HCV RNA levels ≥ 800,000 IU/ml 15% had bridging
fibrosis; 6% had cirrhosis; 59% had HCV genotype 1a; and 40% had HCV genotype 1b. The
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SVR rate for the T8/PR group was 72% (261/364) (P < 0.0001 compared to Pbo/PR48
group)
Study 111 (ILLUMINATE)
Study 111 was a Phase 3, randomised, open label study conducted in treatment-naïve
patients. The study was designed to compare SVR rates in patients with undetectable HCV
RNA at weeks 4 and 12 who were treated with INCIVO for 12 weeks in combination with
peginterferon alfa-2a and ribavirin for either 24 weeks (T12/PR24 regimen) or 48 weeks
(T12/PR48 regimen). Patients with undetectable HCV RNA at weeks 4 and 12 were
randomised at week 20 to receive either 24 weeks or 48 weeks of peginterferon alfa-2a and
ribavirin treatment. The primary assessment was an evaluation of non-inferiority, using a
margin of -10.5% of the 24-week regimen compared to the 48-week regimen in patients with
undetectable HCV RNA at weeks 4 and 12. The 540 enrolled patients had a median age of
51 years (range: 19 to 70); 60% of the patients were male; 32% had a body mass index ≥ 30
kg/m2; 14% were Black; 10% were Hispanic or Latino; 82% had baseline HCV RNA levels >
800,000 IU/ml; 16% had bridging fibrosis; 11% had cirrhosis; 72% had HCV genotype 1a;
and 27% had HCV genotype 1b.
A total of 352 (65%) patients had undetectable HCV RNA at weeks 4 and 12. In patients who
had undetectable HCV RNA at weeks 4 and 12, there was no additional benefit to extending
peginterferon alfa-2a and ribavirin treatment to 48 weeks (difference in SVR rates of 2%;
95% confidence interval: -4%, 8%).
Study 110
Study 110 was a phase II randomised, double-blind, placebo-controlled study conducted in
patients with chronic genotype 1 HCV/HIV co-infection who were treatment-naïve for
hepatitis C. Patients were either not on antiretroviral therapy (CD4 count ≥ 500 cells/mm3),
or had stable controlled HIV (HIV RNA < 50 copies/ml, CD4 count ≥ 300 cells/mm3) being
treated with efavirenz or atazanavir/ritonavir in combination with tenofovir disoproxil fumarate
and emtricitabine or lamivudine. Patients were randomised to 12 weeks of INCIVO (750 mg
every 8 hours if taken in combination with atazanavir/ritonavir, tenofovir disoproxil fumarate,
and emtricitabine or lamivudine OR 1125 mg every 8 hours if taken in combination with
efavirenz, tenofovir disoproxil fumarate, and emtricitabine) or placebo. All patients received
peginterferon alfa-2a and ribavirin for 48 weeks. Fifty-five out of 60 patients received ribavirin
at a fixed dose of 800 mg/day and the remaining 5 patients received a weight-based ribavirin
dose. At baseline, 3 (8%) subjects had bridging fibrosis and 2 (5%) subjects had cirrhosis in
the T12/PR48 arm. In the Pbo/PR arm, 2 (9%) subjects had baseline bridging fibrosis and no
subjects had baseline cirrhosis. The response rate in the Pbo/PR arm was higher than that
seen in other clinical studies of peginterferon bitherapy (historical SVR rates < 36%).
Efficacy in previously treated adults
Study C216 (REALIZE)
Study C216 was a randomised, double-blind, placebo-controlled, Phase 3 study conducted
in patients who did not achieve SVR with prior treatment with peginterferon alfa-2a and
ribavirin or peginterferon alfa-2b and ribavirin. The study enrolled prior relapsers (patients
with HCV RNA undetectable at end of treatment with a pegylated interferon-based regimen,
but HCV RNA detectable within 24 weeks of treatment follow-up) and prior non-responders
(patients who did not have undetectable HCV RNA levels during or at the end of a prior
course of at least 12 weeks of treatment). The non-responder-population was comprised of 2
subgroups: prior partial responders (greater than or equal to 2 log10 reduction in HCV RNA
at week 12, but not achieving HCV RNA undetectable at end of treatment with a
peginterferon and ribavirin) and prior null responders (less than 2 log10 reduction in HCV
RNA at week 12 of prior treatment with peginterferon and ribavirin).
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Patients were randomised in a 2:2:1 ratio to one of three treatment groups: simultaneous
start (T12/PR48): INCIVO from day 1 through week 12; delayed start (T12(DS)/PR48):
INCIVO from week 5 through week 16; Pbo/PR48: placebo through week 16. All treatment
regimens had a 48-week duration of peginterferon alfa-2a and ribavirin treatment.
The 662 enrolled patients had a median age of 51 years (range: 21 to 70); 70% of the
patients were male; 26% had a body mass index ≥ 30 kg/m2; 5% were Black; 11% were
Hispanic or Latino; 89% had baseline HCV RNA levels > 800,000 IU/ml; 22% had bridging
fibrosis; 26% had cirrhosis; 54% had HCV genotype 1a; and 46% had HCV genotype 1b.
SVR rates for the T12(DS)/PR group were 88% (124/141) for prior relapsers, 56% (27/48)
for prior partial responders, and 33% (25/75) for prior null responders. For all populations in
the study (prior relapsers, prior partial responders, and prior null responders), SVR rates
were higher for the T12/PR group than for the Pbo/PR48 group across subgroups by sex,
age, race, ethnicity, body mass index, HCV genotype subtype, baseline HCV RNA level, and
extent of liver fibrosis.
Study 106 and Study 107
Study 106 was a randomised, double-blind, placebo-controlled, Phase 2 study that enrolled
patients who had failed prior treatment with peginterferon alfa-2a and ribavirin or
peginterferon alfa-2b and ribavirin. Among prior relapsers in the T12/PR24 treatment group
who had undetectable HCV RNA at weeks 4 and 12 of treatment, the SVR rate was 89%
(25/28) and the relapse rate was 7%.
Study 107 was an open label, rollover study for patients who were treated in the control
group (placebo, peginterferon alfa-2a, and ribavirin) of a Phase 2 study of telaprevir and who
did not achieve SVR in the Phase 2 study. Among prior relapsers in the T12/PR24 treatment
group who had undetectable HCV RNA at week 4 and 12 of treatment, the SVR rate was
100% (24/24).
Use of peginterferon alfa 2a or 2b
Two types of peginterferon alfa (2a and 2b) were studied in the Phase 2a open label,
randomised study C208 in treatment naïve patients.
All patients received 12 weeks of INCIVO in combination with the peginterferon alfa/ribavirin
standard therapy. Patients were randomised to 1 of 4 treatment groups:
- INCIVO 750 mg every 8 hours with peginterferon alfa-2a 180 μg/week and ribavirin 1,000
or 1,200 mg/day
- INCIVO 750 mg every 8 hours with peginterferon alfa-2b 1.5 μg/kg/week and ribavirin 800
or 1,200 mg/day
- INCIVO 1,125 mg every 12 hours with peginterferon alfa-2a 180 μg/week and ribavirin
1,000 or 1,200 mg/day
- INCIVO 1,125 mg every 12 hours with peginterferon alfa-2b 1.5 μg/kg/week and ribavirin
800 or 1,200 mg/day
Peginterferon alfa-2a/peginterferon alfa-2b and ribavirin were used according to their
relevant Summary of Product Characteristics. At week 12, INCIVO dosing ended and
patients continued on standard therapy only. 73.8% (59/80) of patients in the pooled
peginterferon alfa-2a group met the criteria (undetectable HCV RNA at week 4 through week
20) for the shortened 24 week peginterferon/ribavirin treatment duration versus 61.7%
(50/81) of patients in the pooled peginterferon alfa-2b group.
Side effects observed when telaprevir was taken in combination with Peg-IFN and RBV
An analysis of the safety data from all completed studies in HCV-infected subjects through
31 October 2011 has been conducted to identify adverse events considered to be related to
the combination of telaprevir and Peg-IFN/RBV, and these side effects are listed below. The
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frequency rate is given for clinically important adverse reactions of moderate severity or
more.
 Very common side effects (reported by more than 10% of subjects):
Anemia, Itching skin, Rash.
 Common side effects (reported by 1 – 10 % of subjects): Nausea, Diarrhoea,
Haemorrhoids (painful swelling of a vein in the region of the anus), Vomiting, Anal
and/or rectal pain, Itching anus, Abnormal taste, Fainting.
 Uncommon side effects (reported by less than 1% of subjects): Fungal infection in
the mouth, Bleeding from the anus or rectum, Anal fissure (a crack or tear in the skin
of the anus), Face swelling, Swelling of the arms or legs, Hypothyroidism (reduced
function of the thyroid gland), Drug Rash with Eosinophilia and Systemic Symptoms
(DRESS, a severe type of rash), Stevens-Johnson syndrome (SJS, a severe type of
rash), Hives, Proctitis (inflammation of the anus or rectum), Retinopathy (damage to
the retina in the back of the eye), Gout (painful joint swelling most commonly in the
foot).
Significant changes in the following blood tests in addition to anemia already mentioned
above are also considered side effects of telaprevir/Peg-IFN/RBV combination therapy. The
frequency rate is given for changes in blood tests of moderate severity or more.
 Very common side effects (observed in 10% of subjects or more): reduced
Lymphocytes (a type of white blood cells), reduced Platelets (a type of blood cell),
increased blood Uric Acid (a substance produced by the body), increased blood
Bilirubin (a substance produced by the liver), increase in Cholesterol (a type of blood
fat).
 Common side effects (reported by 1% of subjects or more but less than 10% of
subjects): decreased blood Potassium (a salt in the blood), increased blood
Creatinine (a substance produced by the body and removed by the kidneys).
Overall, rashes were reported in 55% of subjects (all grades of severity). More than 90% of
rashes have been mild to moderate in severity. Approximately 5% of subjects experienced
severe rash during treatment with telaprevir in combination with Peg-IFN and RBV, and
approximately 3% of subjects discontinued telaprevir, Peg-IFN and RBV because of rashes.
Rashes are usually itchy and have features similar to eczema.
Some of the severe rashes observed with telaprevir combination therapy were suspected as
being specific skin reactions: Drug Rash with Eosinophilia and Systemic Symptoms in 0.4%
(4 out of a thousand subjects), or Stevens-Johnson syndrome in less than 0.1% (less than 1
out of a thousand subjects). In addition to a widespread rash, these specific drug reactions
can include one or more of the following symptoms: fever, skin blistering and peeling,
swollen lymph glands, swelling of the face or the area of the rash, blisters in the mouth, or
eyes or genitals.
The rashes may be improved by skin treatments such as ointments or creams or other
medicines, and in case of more severe rashes after stopping one or all of the study drugs.
Improvement and clearing of the rash is observed over varying periods of time.
More than 50,000 patients have received telaprevir in combination with Peg-IFN and RBV
since approval by regulatory authorities.  Rare fatal (deadly) and non-fatal serious skin
reactions, including a specific severe rash disorder called toxic epidermal necrolysis (TEN),
have been reported since telaprevir was approved by regulatory authorities.
Anemia (a decrease in the oxygen-carrying cells of the blood) was reported in 32% of
subjects (all grades of severity). Approximately 22% of subjects who experienced anemia
during treatment with telaprevir in combination with Peg-IFN and RBV required a reduction in
the dose of RBV.
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Approximately 3% of subjects received blood transfusion, 3% of subjects discontinued
telaprevir and less than 1% of subjects discontinued telaprevir, Peg-IFN and RBV
combination therapy because of anemia.
Anorectal disorders were reported in 26% of subjects (all grades of severity). In clinical trials,
the majority of these events (e.g., haemorrhoids, anorectal discomfort, anal pruritus, and
rectal burning) were mild to moderate; very few led to treatment discontinuation and resolved
after completion of telaprevir dosing.
The effect of telaprevir on the QTc interval was studied in a clinical trial in healthy subjects;
the QTc interval is a measurement of part of the electrical activity of the heart seen on the
electrocardiogram (ECG/EKG). A modest increase in the QTc interval has been observed
with telaprevir at a higher dose than used in this trial. There is a very small chance that
increases in the QTc interval may lead to serious heart problems such as abnormal heart
rhythms (arrhythmias) that may result in a very fast heartbeat and fainting. Very rarely such
arrhythmias may lead to the heart stopping and sudden death. The risks of abnormal heart
rhythms may be higher when telaprevir is combined with certain other drugs or when used in
patients who already have heart conditions or have a low level of potassium in the blood. No
such arrhythmias or sudden deaths have been seen in any clinical study with telaprevir.
Side effects commonly attributed to Pegasys® and Copegus®
Possible, serious side effects (which in some cases could be life threatening or fatal)
associated with the use of these drugs include:
 Autoimmune problems: conditions where the body’s own immune system begins to
attack itself; these conditions include psoriasis and thyroid problems.
 Heart problems, including irregular heart beat (arrhythmia), chest pain and very rarely
heart attack.
 Worsening of liver function, including liver failure.
 Psychiatric symptoms: depression (including suicidal thoughts), anxiety, insomnia,
irritability, relapse of drug abuse, and drug overdose.
 Severe infections which could be life-threatening or fatal.
 Risk to pregnancy (i.e. birth defects); see below for more information.
 Low blood counts: including anemia (drop in red blood cell count; this can be
especially dangerous in patients with heart or breathing problems); drop in certain
white blood cells (this can increase your risk of infection) and low platelet count (this
can increase risk of bleeding).
 Inflammation of the pancreas.
 Bleeding in the brain (cerebral haemorrhage), blood clot in the lungs (pulmonary
embolism).
 Vision changes and problems in the blood vessels in the back of the eye, sore on the
cornea (corneal ulcer).
 Skin rash: When rashes occur due to the use of Pegasys/PegIntron, with or without
Copegus/Rebetol, they are usually mild. However, rare but serious skin reactions
(including a type called Stevens Johnson Syndrome) have been reported.
Common, but less serious side effects include:
 Flu-like symptoms, such as headache, tiredness, muscle aches, fever and chills.
 Itching skin (pruritus), skin reaction at the place where the injection is given.
 Digestive symptoms such as diarrhoea, vomiting, lack of appetite; taste changes and
nausea.
 Problems controlling blood sugar, including diabetes.
 Hair loss (alopecia).
Potential risks based on non-clinical studies
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The safety of telaprevir has also been evaluated in laboratory tests and studies involving
animals. An early test using mouse lymphoma tumour cells to assess effects on genetic
material was conducted with lower grade (less pure) telaprevir and showed a risk of damage
to genetic material. Similar tests conducted with higher grade (highly pure) telaprevir like that
used in clinical trials have not shown any potential genetic damage.
When telaprevir is manufactured, very small amounts of other chemicals may remain in the
pills as leftover ingredients, or side products. These other chemicals are called
"impurities". Laboratory tests conducted separately with individual impurities present in the
telaprevir tablets showed risks of damage to the genetic material. However, the amount of
these impurities present in the telaprevir tablets is very low.
Reproductive Risks
At this time it is not understood how telaprevir affects an unborn baby or sperm. Telaprevir
has shown no teratogenic potential in animal studies. Ribavirin is known to cause birth
defects, and has very specific instructions regarding birth control and pregnancy which
should be adhered to during participation to this study.
1.5    Rationale and Risks/Benefits
The current recommended first line treatment for patients with chronic hepatitis C is the
combination of pegylated interferon alfa (PEG-IFN) and ribavirin (RBV). In 2002, Pegasys
(Peginterferon alfa-2a, PEG-IFN alfa-2a) and Copegus (ribavirin) were approved for
marketing in the United States, Europe and several other countries for the treatment of
chronic hepatitis C. This medication has a well-established safety profile. Telaprevir is a new
drug that is licensed to treat genotype 1 hepatitis C and which works very well in these
patients. Additional side effects to standard treatment regime of pegylated interferon alfa
(PegIFN) and ribavirin (RBV) include skin reactions that may (very rarely) be severe and
may include life threatening disorders such as Stevens-Johnson syndrome.
In clinical trials in patients with advanced liver disease severe sequelae including hepatic
decompensation and even death have been seen. It should be noted that in patients with
advanced liver disease the rate of significant, life threatening complications is 5% per year
and therefore without therapy a significant proportion of patients with advanced liver disease
will die.
To minimise the risks of therapy in these patients we will select experienced investigators
with the support services required to manage and minimise the risks of therapy.
Patients at high risk of decompensation (those with ascites) have been excluded from the
study and the regular clinical review will reduce the risk of serious adverse events to an
acceptable level.
The study involves a population of patients who are not normally considered eligible for
treatment with interferon and ribavirin containing regimes – specifically patients with low
haemoglobin levels, low neutrophil counts and low platelet counts will be included. This is
because current ‘standard of care’ therapy for patients with genotype 3 HCV (Pegylated
interferon and ribavirin) leads to a sustained virological response in >80% in patients with
early disease. However in patients with cirrhosis (invariably associated with low
haemoglobins, low platelet counts and low neutrophil counts) the response is much reduced
(<50%). Hence there is an unmet medical need for treatments for patients with cirrhosis and
associated cytopaenias.
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The SmPC for Pegasys and ribavirin was based on early clinical studies with very
conservative inclusion criteria. Multiple studies since then have shown the safety of this
combination in patients with advanced cirrhosis and cytopaenias and it is now standard
clinical practice to treat such patients with ribavirin containing regimes.
Thus the inclusion criteria of haemoglobin, platelet and neutrophil counts for this study are
based on current clinical practice not the SmPC guidance which has been shown to be safe
in published clinical studies and the inclusion criteria specifically address an unmet clinical
need.
2. Trial Objectives and Design
2.1    Trial Objectives
Primary Objective
 To determine whether patients with genotype 3 HCV and cirrhosis who have  failed to
achieve a sustained virological response (SVR) with PegIFN and RBV will achieve a
SVR if treated with telaprevir, PegIFN and RBV
Secondary objective
 To determine whether viral phenotyping predicts the response to therapy with
telaprevir in patients with G3 HCV and cirrhosis
Primary outcomes
 The primary outcome is the proportion of patients with a sustained virological
response (SVR) 12 weeks after end of treatment (SVR12). SVR 12 is defined as
undetectable HCV RNA on a blood sample taken between 12 and 18 weeks after the
end of treatment measured using a sensitive, validated polymerase chain reaction
(PCR) assay with a lower limit of quantification of at least 30IU/ml. End of treatment
is defined as date of final dose of IMP 1, 2 or 3 (whichever is the latest date).
Secondary outcomes
 The proportion of patients who are phenotypically poorly responsive to telaprevir
(defined as virus with a poor response to telaprevir in vitro i.e. an IC50 of <0.1Mol in
an in vitro assay) who achieve early and late virological clearance.
 The proportion of patients with a sustained virological response 24 weeks after the
last dose of PegIFN and RBV (SVR24). SVR 24 is defined as undetectable HCV
RNA on a blood sample taken between 24 and 30 weeks after the final dose of
PegIFN and ribavirin measured using a sensitive, validated polymerase chain
reaction (PCR) assay with a lower limit of quantification of at least 30IU/ml.
 The proportion of patients who have undetectable HCV RNA (measured using a
sensitive, validated polymerase chain reaction (PCR) assay with a lower limit of
quantification of at least 30IU/ml) after 1,2,3 and 4 weeks of therapy with PegIFN,
RBV and telaprevir.
2.2 Trial Design and Study Scheme Diagram
Open trial design in which all patients who are fulfil the entry criteria are treated for 24 weeks
with PegIFN, RBV and 12 weeks with telaprevir as outlined in the treatment procedure. Prior
to treatment all patients will have samples taken for viral phenotyping.
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Patient with G3 HCV, advanced
fibrosis and failure to respond to
pegylated interferon and ribavirin
Viral sensitivity
assessed in vitro
Screen failures:
i.e. Not eligible or
Eligible not recruited
Treated for 12 weeks with
telaprevir alongside a 24
week course of PegIFN
and RBV
Entered into
screening log
SVR12 assessed
(12-18 weeks
post-treatment)
SVR24 assessed
(24-30 weeks
post-treatment)
Eligible and
recruited
Patients withdrawn from
treatment
1. Patients removed as non-
responders to therapy will
be referred back to their
clinical team for follow-up
as appropriate
2. Patients withdrawn due to
other clinical reasons (e.g.
SAEs) will be followed up
appropriately and referred
to a relevant service
provider.
229
3.      Subject Selection
3.1    Number of Subjects and Subject Selection
The study involves a population of patients who are not normally considered eligible for
treatment with interferon and ribavirin containing regimes – specifically patients with low
haemoglobin levels, low neutrophil counts and low platelet counts will be included. This is
because current ‘standard of care’ therapy for patients with genotype 3 HCV (Pegylated
interferon and ribavirin) leads to a sustained virological response in >80% in patients with
early disease. However in patients with cirrhosis (invariably associated with low
haemoglobins, low platelet counts and low neutrophil counts) the response is much reduced
(<50%). Hence there is an unmet medical need for treatments for patients with cirrhosis and
associated cytopaenias. This study is specifically aiming to investigate this unmet need.
Patients attending the out-patient clinic at the participating sites who are deemed suitable for
the study by their consultant will be contacted and asked if they wish to consider
participating in the study. Those who are willing to consider the study will be provided with
the patient information sheet and asked to consider this at their leisure. Subjects will be
given a minimum of 24 hours to review the information. Those who agree to participate will
then be asked to sign the consent form and enrolled in the study.
A total of approximately 30 patients will be enrolled on the trial spread over the trial sites.
This study will be competitive recruitment therefore once the total number of patients
enrolled on the study reaches 30 recruitment to the study will be closed even if some sites
have not recruited any participants.
3.2    Inclusion Criteria
 Age ≥18 years of age and ≤ 70 years old
 Advanced fibrosis - defined as a liver biopsy within 2 years showing an Ishak fibrosis
score of >4 OR radiological evidence of cirrhosis (ultrasound scan or fibroscan reading
>10.6)
 Previous therapy with pegylated interferon and ribavirin with detectable HCV RNA six
months after treatment cessation
 Chronic genotype 3 HCV infection, RNA positivity with genotype 3 infection confirmed at
a local laboratory.
 HBsAg negative  and no clinical evidence of co-infection with HIV
 Platelet count >50,000 cells/mm3 (support with eltrombopag is permitted) Neutrophil
count > 600 cells/mm3
 All female patients of childbearing potential and all males with female partners of
childbearing potential must be prepared to use two forms of effective contraception*
(combined) during treatment and 6 months after treatment end
 Able and willing to give informed consent and able to comply with study requirements
NOTE: Subjects are considered not of child bearing potential if they are surgically sterile (they have undergone a
hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.
* Effective contraceptive methods include an intrauterine device, a male OR female condom [not both
simultaneously as friction between the two can result in damage or breakage of either product], or diaphragm
with spermicidal jelly, or cervical cap with spermicidal jelly.
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3.3    Exclusion Criteria
 Evidence of other cause of significant liver disease – serum ferritin > 1000, biochemical
evidence of Wilson’s disease, autoantibody titres in excess of 1:160
 Poorly controlled diabetes that, in the investigators opinion, precludes therapy
 Severe retinopathy that, in the opinion of the investigator, precludes therapy
 Evidence of ascites seen on previous liver ultrasound
 Haemoglobin concentration <11 g/dL in females or <12 g/dL in males or any patient with
an increased risk for anaemia (e.g., thalassemia, sickle cell anaemia, spherocytosis,
history of gastrointestinal bleeding) or for whom anaemia would be medically problematic
 Albumin levels <35 G/L
 Females who are pregnant or breast-feeding
 History of severe psychiatric disease, including psychosis and/or depression,
characterized by a suicide attempt, hospitalization for psychiatric disease, or a period of
disability as a result of psychiatric disease within the last 2 years
 History of immunologically mediated disease (e.g., inflammatory bowel disease,
idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune haemolytic
anaemia, scleroderma, severe psoriasis (defined as affecting >10% of the body, where
the palm of one hand equals 1%, or if the hands and feet are affected), rheumatoid
arthritis requiring more than intermittent nonsteroidal anti-inflammatory medications for
management
 Other on-going serious medical condition in the opinion of the investigator that would
prohibit treatment
 Poorly controlled thyroid dysfunction that, in the investigators opinion, precludes therapy
 History of major organ transplantation with an existing functional graft
 History of severe pre-existing cardiac disease, including unstable or uncontrolled cardiac
disease in the previous 6 months
 History or laboratory testing showing evidence of a haemoglobinopathy
 Concomitant administration with active substances that are highly dependent on CYP3A
for clearance and for which elevated plasma concentrations are associated with serious
and/or life-threatening events. These active substances include alfuzosin, amiodarone,
bepridil, quinidine, astemizole, terfenadine, cisapride, pimozide, ergot derivatives
(dihydroergotamine, ergonovine, ergotamine, methylergonovine), lovastatin, simvastatin,
atorvastatin, sildenafil or tadalafil (only when used for treatment of pulmonary arterial
hypertension) and orally administered midazolam or triazolam.
 Concomitant administration with Class Ia or III antiarrhythmics, except for intravenous
lidocaine (see section 4.5).
 Concomitant administration of INCIVO with active substances that strongly induce
CYP3A e.g. rifampicin, St John's wort (Hypericum perforatum), carbamazepine,
phenytoin and phenobarbital and thus may lead to lower exposure and loss of efficacy of
INCIVO.
3.4    Criteria for Premature Withdrawal
1. To avoid unnecessary exposure to therapy that has a low probability of success the
following pre-defined ‘stopping rules’ will apply.
 If the viral load after 4 weeks of therapy with PegIFN, Ribavirin and telaprevir is >1000
IU/ml, therapy will be abandoned and the patient will be deemed a non-responder to
therapy.
 If the viral load at week 8 is greater than 1000 IU/ml OR the viral load has not declined
by more than 3 logs from the pre-treatment viral load, therapy will be abandoned and
the patient deemed a non-responder to therapy.
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2. Patients will be withdrawn from the study if there is evidence of systemic drug toxicity
which, in the opinion of the investigator, modifies the risk: benefit ratio in favour of harm*.
3. Request of the participant or discretion of the investigator
4. Inability or participant’s failure to comply with the protocol requirements
5. Pregnancy
* If there is evidence of telaprevir intolerance the drug may be discontinued and the patient will remain in the
study and will continue to receive pegylated interferon and ribavirin.
4.      Investigational Medicinal Product
Patients will receive standard of care 24 week treatment with a weekly injection of 180 µg 40
Kd Pegylated interferon alfa 2a combined with oral ribavirin 800mg per day given in two
divided doses. In addition, patients will be administered IMP which consists of 1125mg (3 x
375mg tablets) of oral telaprevir administered twice a day for the first 12 weeks of the study.
The dose of pegylated interferon and the dose of ribavirin may be reduced at the discretion
of the prescribing physician but the dose of telaprevir must not be reduced. If there is
evidence of telaprevir intolerance the drug may be discontinued and the patient will remain in
the study and will continue to receive pegylated interferon and ribavirin.
Patients should be reminded that telaprevir should be taken with food.
4.1  Definition of IMP
IMP1 – Telaprevir (INCIVO) 375 mg film coated tablets to be taken orally. Yellow caplet
shaped tablets of approximately 20 mm in length, marked with “T375” on one side.
IMP2 - 40 Kd Pegylated interferon alfa 2a (Pegasys) 180 µg in pre-filled syringe/pen for sub-
cutaneous injection
IMP3 - Ribavirin (Copegus) 200 mg tablets to be taken orally.
4.2  IMP Supply
Telaprevir IMP 1 will be sourced as commercial stock provided and manufactured by
Janssen. It will be packaged and delivered by B&C to each site according to contract and
technical agreement.
Pegasys IMP2 and Copegus IMP3 will be sourced as commercial stock, and provided by the
site per standard of care.
4.3  Prescription of IMPs
The IMPs will be prescribed by the PI or delegated sub-investigator at each site once
enrollment has been confirmed. A template prescription will be provided to sites which will
allow for IMPs to be prescribed per standard prescribing timelines and procedures at each
site. If the PegIFN or RBV are dose reduced the prescription is to clearly identify this.
4.4 Preparation and Administration of IMPs
IMPs will be provided as per manufacturing licence and SmPC.  IMPs will be administered
by the patient and IMP administration training will be provided according to local standard
procedures at each site. IMPs will be administered at the doses outlined below.
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 A weekly injection of 180 µg 40 Kd Pegylated interferon alfa 2a (Pegasys) (given by
self-administration).
 Oral ribavirin, two 200mg tablets to be taken twice a day (total 800mg per day).
 Oral telaprevir, three 375 mg tablets to be taken twice a day (total 2250mg a day).
The dose of pegylated interferon and the dose of ribavirin may be reduced at the discretion
of the prescribing physician in line with clinical practice but the dose of telaprevir must not
be reduced. If there is evidence of telaprevir intolerance the drug may be discontinued and
the patient will remain in the study and will continue to receive pegylated interferon and
ribavirin.
4.5 Packaging and Labeling of IMPs
The IMPs will be labeled at study site with approved clinical trial labels in accordance with
Annex 13. The labels will include participants’ study details, dosing instructions and contact
details for study investigators in case of adverse reactions or questions regarding
medication.
Patients should be reminded that telaprevir should be taken with food.
4.6  Accountability/Receipt /Storage and Handling of IMPs
Telaprevir will be sourced as commercial stock provided and manufactured by Janssen. It
will be packaged and delivered by B&C to each site according to contract.  This will be
stored as separate clinical trials stock and labeled appropriately.
All study drugs will be stored according to the SmPC and labelling guidelines. Records of
storage will be maintained by the delegated site pharmacy team and any excursions from
the storage instructions will be documented.
The pharmacy is responsible for dispensing in line with local dispensing procedures and
excursion management normal practices. If the IMP does experience an excursion outside
the ranges as stipulated by the manufacturer, the product will be discarded and humanely
destroyed.
Accountability will be managed by the site. Missed doses will be recorded on the relevant
CRF pages. The site pharmacy team will keep a record of the study medication received,
stored, dispensed and destroyed per local SOPs.
.
4.7 Dispensing of IMP
All investigational product supplies that will be used in the study must be maintained
securely according to local regulations under the direct responsibility of the delegated site
pharmacist. Dispensing of IMP should not be completed without a correctly completed
prescription signed by a delegated Investigator. All drugs shall be dispensed in accordance
with the Investigator’s prescription.
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The site pharmacy team will keep a record of the study medication dispensed and the
participant details to which the study medication is dispensed. The quantity dispensed to
each participant will be documented. The investigational product must be dispensed only
from official study sites by authorized personnel according to local regulations.
4.8 Prior and Concomitant Therapies
Subjects must not consume drugs metabolized by CyP3A4 during the period of use of
telaprevir. It is the responsibility of the prescribing physician to ensure that such drugs are
not consumed.
Females of childbearing potential and males must be willing to use (or ask their partners to
use) two effective* methods of contraception (non-hormonal methods of birth control must be
used as telaprevir may interfere with the metabolism of hormone based contraceptives
rendering them less effective) from the time consent is signed until 6 weeks after treatment
discontinuation.
Patients should be reminded that telaprevir should be taken with food.
4.9 Dose modification/reduction
The dose of pegylated interferon and the dose of ribavirin may be reduced at the discretion
of the prescribing physician in line with clinical practice but the dose of telaprevir must not
be reduced. If there is evidence of telaprevir intolerance the drug may be discontinued and
the patient will remain in the study and will continue to receive pegylated interferon and
ribavirin.
All dose reductions should be recorded on the CRF.
4.10 Return of IMP
Any returned unused, partially used, or empty primary containers of the study medication
should be returned to the study site. Missing study medication must be accounted for in
writing by the investigator. Drug accountability will be recorded by a delegated member of
the site study team. All discrepancies must be explained in writing. Any returned unused,
partially used, or empty primary containers will be checked, destroyed and documented by
the site pharmacy and records will be kept for accountability.
Upon completion or termination of the study, all partially and/or completely used
investigational product should be disposed of at the study site according to the sites local
SOPs.
4.11 Recall or Destruction of IMP
Drug recall should be managed in line with the agreements between sponsor and IMP
providers. If an IMP is recalled sponsor will notify sites to recall all relevant IMPs/batches.
All IMP that is to be destroyed will be done so in line with standard procedures for the
humane destruction of unwanted pharmaceuticals. Pharmacy will be responsible for the drug
destruction on site.
5.      Study Procedures
5.1    Informed Consent Procedures
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Patients attending the out-patient clinic at the participating sites who are deemed suitable for
the study by their consultant will be contacted and asked if they wish to consider
participating in the study. Those who are willing to consider the study will be provided with
the patient information sheet and asked to consider this at their leisure. Subjects will be
given a minimum of 24 hours to review the information. Those who agree to participate will
then be asked to sign the consent form and enrolled in the study.
Patients who have read the information sheet and who wish to enroll in the study will meet
with a member of the study team to sign the consent form. . It is the responsibility of the
Investigator, or a person delegated by the Investigator to obtain written informed consent
from each participant prior to participation in this study. The delegation log must include
individuals authorized to take consent. Only GCP trained individuals will be allowed to take
consent. Consent should only be taken following adequate explanation of the aims,
methods, anticipated benefits and potential hazards of the study. The Investigator should be
available to answer any questions or concerns the patient may have before consent is
signed. The Investigator or designee must explain the participants are completely free to
refuse to enter the study or to withdraw at any time during the study, for any reason.
If new safety information results in significant changes in the risk/benefit assessment, the
consent form should be reviewed and updated if necessary. All participants, including those
already being treated, should be informed of the new information, giving a copy of the
revised form and give their consent to continue in the study.
For patients who do not speak or read English an independent translator will be provided
and the translator will read through the patient information leaflet with the patient and ensure
that the patient comprehends the information. The patient and the interpreter will sign the
informed consent form
5.2    Screening Procedures
After signing the informed consent form, patients will be assessed for the inclusion exclusion
criteria for the study. This includes a review by a trial physician who will complete a physical
examination (including eye examination), collect relevant medical history, record and current
medication the patient is taking. . Blood samples will be taken to check for inclusion and
exclusion criteria. These will be requested and analyzed at site local laboratory. Female
patients will also be asked to give a urine sample for pregnancy test.
5.3 Enrolment Procedures
This is an open label single arm study and no randomisation will be performed.
Enrolment will be determined as start date of treatment. A total of approximately 30 patients
will be enrolled on the trial spread over the trial sites. This study will be competitive
recruitment therefore once the total number of patients enrolled on the study reaches 30
recruitment to the study will be closed even if some sites have not recruited any participants.
Prior to starting patients on treatment sites must confirm eligibility to Sponsor who will then
assign an enrolment number to the patient. No patients should be started on study treatment
without an enrolment number. This will be detailed further in study specific enrolment SOP.
5.4 Schedule of Treatment for each visit
All females of child bearing potential on the study must have a negative urine pregnancy test
result documented within the 24-hour period prior to the first dose of study drugs.
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IMP will be administered at the doses outlined below.
 A weekly injection of 180 µg 40 Kd Pegylated interferon alfa 2a (Pegasys) (given by
self-administration).
 oral ribavirin, two 200mg tablets to be taken twice a day (total 800mg per day).
 oral telaprevir, three 375 mg tablets to be taken twice a day (total 2250mg a day).
The dose of pegylated interferon and the dose of ribavirin may be reduced at the discretion
of the prescribing physician in line with clinical practice but the dose of telaprevir must not
be reduced.
IMP will be dispensed to patients at study visits according to local clinical practice.
5.5   Schedule of Assessment
Patients will be reviewed regularly – weekly for the first 4 weeks of the study and then
monthly (or more often if clinically indicated). At each visit the following assessments will be
carried out:
 a limited physical examination with eye and skin examination will be performed
 blood samples taken for safety follow up and assessment of primary and secondary
endpoints.
 Female patients will be required to give a urine sample for pregnancy test.
At each visit compliance with medication will be assessed by direct questioning.
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Visit Windows
≤
6weeks
+/- 1
day
+/- 1
day
+/- 1
day
+/- 1
day
+/- 1
day
+/- 1
day
+/- 1
day
+/- 1
day
+/- 1
day +6 weeks +6 weeks
Assessment Details of Requirements Screen Wk0 Wk 1 Wk 2 Wk 3 Wk 4 Wk 8
Wk
12
Wk
16
Wk
20
Wk
24 Wk 36 Wk 48
Informed Consent ✓
Review of Inclusion and Exclusion Criteria ✓ ✓
Recording Demographics
Age ✓
Ethnicity ✓
Sex ✓
Drug Administration
Telaprevir administered ✓ ✓ ✓ ✓ ✓ ✓
PegIFN & RBV administered ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Drug Accountability Record of reported missed doses ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Physical examination
Eye examination/Fundoscopy ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Skin ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Respiratory ✓
CVS ✓
Gastrointestinal ✓
Neurological ✓
Vital Signs Blood Pressure, Heart Rate,Respiration Rate ✓
Review of Concomitant Medications ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Adverse Events Recording ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Safety Lab Samples
FBC (blood) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
LFTs (blood) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Creatinine (Blood) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
U&Es (Blood) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
HIV & HBV ✓
Serum ferritin ✓
Autoantibodies ✓
Pregnancy Test (urine) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Study Outcome lab samples
HCV RNA ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Viral Phenotyping (* At Week 8 the
sample could be taken at a later
visit instead)
✓ ✓
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5.6    Follow up Procedures
At the completion of the study (patients will be referred back to their clinical care team for
follow-up as appropriate.
Completion of the study is defined as one of the following:
Patients who are defined as non-responders to therapy or who are removed due to
one of the other withdrawal criteria will be removed from the study immediately. There
will be no other follow up visits on the study following withdrawal.
 after the final blood test performed 24 weeks (+6 weeks) after treatment has been
completed per protocol (last dose of 24 weeks treatment)
5.7 Laboratory Assessments
Laboratory assessments will be performed as indicated in the table of study assessments.
Initial assessments to assess inclusion and exclusion criteria will be performed at site local
laboratories. All safety labs and viral loads will also be performed at site local laboratories.
Extra blood will be taken for viral phenotyping and storage for future research. These
samples will be shipped to the lab at Queen Mary University of London. Viral phenotyping
will be carried out at the virology laboratory at Barts Health NHS Trust and the blood
collected for future research will be processed and stored at the Blizard Institute Labs and
Queen Mary University of London. The lab work will be carried out in accordance with GCP.
Further information about the sample collection and shipping can be found in the study lab
manual.
5.8 End of Study Definition
The end of the study will be defined as the day of completion of the last patient final study
visit plus 12 months.
5.9 Patient support
All patients will be provided with a card containing details of the clinical trial and a contact
number
5.10 Patient Withdrawal and Early termination
Subjects have the right to withdraw consent at any time. Data collected will be analysed but
no further information will be collected.
Patients who experience intolerable toxicity will be withdrawn.
To avoid unnecessary exposure to therapy that has a low probability of success the following
pre-defined ‘stopping rules’ will apply and patient will be defined as a non-responder to
therapy.
 If the viral load after 4 weeks of therapy with PegIFN, Ribavirin and telaprevir is
>1000 IU/ml, therapy will be abandoned and the patient will be deemed a non-
responder to therapy.
 If the viral load at week 8 is greater than 1000 IU/ml
 If the viral load has not declined by more than 3 logs from the pre-treatment viral load
by week 8.
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 If return of viraemia during the study after a period when HCV RNA is undetectable.
If any female participant becomes pregnant, she will be withdrawn from the study.
Pregnancy will be followed up to determine outcome, including spontaneous or voluntary
termination, details of the birth, and the presence or absence of any birth defects, congenital
abnormalities, or maternal and/or newborn complications
5.11 Data Collection and Follow up for Withdrawn Subjects
Data from withdrawn participants will be included in the analysis of the study unless the
patient specifically requests the deletion of their data.
6.      Laboratories
6.1 Central/Local Laboratories
The screening samples for reviewing inclusion and exclusion criteria and the blood samples
for safety review will be performed at the sites local laboratory. Details of the labs, their
accreditation and reference ranges should be provided to Sponsor. .
The viral load determination at every visit will be performed locally at each site. The hospital
labs will use a validated assay within their CPA accreditation with a lower limit of detection of
<30 IU/ml. All accreditation documentation and reference ranges for each lab will be
provided to Sponsor and Sponsor will carry out an assessment before the first samples are
sent to the lab.
The viral phenotyping assay will be performed in the virology laboratory at Barts Health NHS
Trust. All accreditation documentation and reference ranges will be provided to Sponsor and
Sponsor will carry out an assessment before the first samples are sent to the lab.
6.2    Sample Collection, Processing and Analysis.
Patient samples will be taken by study staff appropriately trained in phlebotomy Samples
will be handled in line with good laboratory practice and study specific SOPs and guidelines.
Upon receipt of the samples, the laboratory will ensure that the physical integrity of the
samples has not been compromised in transit. If it has, it is important that the study team, as
well as the sponsor, will be informed of this.
7.      Pharmacovigilance
7.1   General Definitions
7.1.1 Adverse Event (AE)
An AE is any untoward medical occurrence in a subject to whom a medicinal product has
been administered, including occurrences which are not necessarily caused by or related to
that product.  An AE can therefore be any unfavourable and unintended sign (including an
abnormal laboratory finding), symptom or disease temporally associated with the use of an
Investigational Medicinal Product (IMP), whether or not considered related to the IMP.
7.1.2 Adverse Reaction (AR)
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An AR is any untoward and unintended response in a subject to an Investigational Medicinal
Product (IMP), which is related to any dose administered to that subject.  All adverse events
judged by either the reporting investigator or the Sponsor as having a reasonable causal
relationship to a medicinal product qualify as adverse reactions. The expression reasonable
causal relationship means to convey in general that there is evidence or argument to
suggest a causal relationship.
7.1.3       Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR)
An SAE fulfils at least one of the following criteria:
 Is fatal – results in death (NOTE: death is an outcome, not an event)
 Is life-threatening
 Requires inpatient hospitalisation or prolongation of existing hospitalisation
 Results in persistent or significant disability/incapacity
 Is a congenital anomaly/birth defect
Serious Adverse Reaction (SAR)
An SAR is an adverse reaction that is classed as serious and which is consistent with the
information about the medicinal product as set out in the Summary of Product Characteristics
(SmPC) or Investigator’s Brochure (IB) for that product.
7.1.4 Suspected Unexpected Serious Adverse Reaction (SUSAR)
The definition of a SUSAR is any serious adverse event related to an IMP that is both
suspected to be related to the IMP and unexpected. In this case the event is not outlined in
the Summary of Product Characteristics (SmPC)
7.2    Investigators Assessment
7.2.1 Seriousness
The Chief/Principal Investigator responsible for the care of the patient, or in his absence an
authorised medic within the research team, is responsible for assessing whether the event is
serious according to the definitions given in section 7.1.
7.2.2       Causality
The Investigator must assess the causality of all serious adverse events/reactions in relation
to the trial treatment according to the definition given. If the SAE is assessed as having a
reasonable causal relationship, then it is defined as a SAR.
7.2.3       Expectedness
The investigator must assess the expectedness of all SARs according to the definition given.
If the SAR is unexpected, then it is a SUSAR.
7.2.4       Severity
The Investigator must assess the severity of the event according to the following terms and
assessments. The intensity of an event should not be confused with the term “serious” which
is a regulatory definition based on patient/event outcome criteria.
Mild: Some discomfort noted but without disruption of daily life
Moderate: Discomfort enough to affect/reduce normal activity
Severe: Complete inability to perform daily activities and lead a normal life
7.3    Notification and Reporting of Serious Adverse Events/SUSAR
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7.3.1 All Serious Adverse Event (SAEs) will be recorded in the subjects’ notes, the CRF,
the sponsor SAE form and reported to the Joint Research management  Office (JRMO)/ and
Janssen UK IMP  within 24 hours of the CI or PI or co-investigators becoming aware of the
event.  Nominated co-investigators will be authorised to sign the SAE forms in the absence
of the CI at the co-ordinating site or the PI at the participating sites.
7.3.2       Suspected Unexpected Serious Adverse Reactions (SUSARs) that occur during
the trial will be reported to the JRO/ main REC/IMP provider (if applicable) within 24 hours of
the CI or co-investigator becoming aware of the event. SUSARs should be reported to the
sponsor (JRO Office) within 24 hours as the sponsor has a legal obligation to report this to
the MHRA within 7 days (for fatal or life-threatening SUSARs) or 15 days for all other
SUSARs. In the case of multicentre studies, the PI or the co-investigators at the participating
site must inform the CI within 24 hours of the event. The CI or co-investigators at the co-
ordinating site must inform the sponsor (JRO) immediately to allow reporting to the MHRA
within the allocated timelines.  The CI will need to complete the CIOMS form in conjunction
with the sponsor SAE form to be sent to the MHRA by the sponsor. If warranted, an
investigator alert may be issued, to inform all investigators involved in any study with the
same drug (or therapy) that this serious adverse event has been reported.
The original and any subsequent follow up of Serious Adverse Event Forms and CIOMS
forms (where applicable), together with the fax confirmation sheet must be kept with the TMF
at the study site.
7.3.3 Notifications to the company
As the sponsor of the Study, Queen Mary, University of London (QMUL) and Professor GR Foster
shall be responsible for complying, within the required timelines, with any safety reporting
obligation towards the competent Health Authorities, the Ethics Committee(s) and all participating
investigators, as defined in the applicable laws and regulations, or elsewhere.
This includes:
 the retrieval and assessment of all serious adverse events originating from all clinical sites
and all  participating  investigators in the concerned study;
 submission of expedited serious single case reports to Health Authorities (by electronic
means where applicable), the Ethics committee(s) and where applicable to the distribution
of these to all participating  investigators in the concerned study;
 the preparation and submission of annual safety reports  (ASR) of the concerned study;
 the submission of periodic listings of expedited serious unexpected adverse events as
appropriate;
 and the submission of any updated documents as required.
QMUL and GR Foster will submit to the Janssen UK Representative using forms provided, the
following safety information:
- all Serious Adverse Events and pregnancy reports in the study (including reports unblinded
as to treatment for blinded studies) involving the Study Drug regardless of whether
causality with the administration of the Study Drug is suspected by the investigator as well
as transmission of an infectious agent and medication errors.  QMUL and GR Foster will
transmit these SAE reports by facsimile in English within 24 hours of becoming aware
of the event(s).  Follow-up information will be transmitted within the same timelines;
- copies of all expedited serious single case reports sent to the Health Authorities and Ethics
Committees (following causality and expectedness assessments made as applicable for
the current study sponsored by the institution and/or principal investigator);
QMUL and GR Foster shall notify Janssen UK immediately in case of a suspension of recruitment
or premature cessation of the concerned clinical study because of a safety concern; preferably
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by means of a telephone contact with the Company Representative, alternatively by fax within
24 hours of the decision;
- at the end of the treatment phase (= “last patient off treatment”) as well as the end of any
follow-up phase (= ”last patient out”) of the Study, QMUL and GR Foster  shall provide all
Adverse Events, both serious and non-serious, in report format within 90 days after
completion of the treatment or follow-up respectively.
7.4 Urgent Safety Measures
The CI may take urgent safety measures to ensure the safety and protection of the clinical
trial subjects from any immediate hazard to their health and safety, in accordance with
Regulation 30. The measures should be taken immediately. In this instance, the approval of
the Licensing Authority Approval prior to implementing these safety measures is not
required. However, it is the responsibility of the CI to inform the sponsor, Main Research
Ethics Committee (via telephone) and the MHRA (via telephone for discussion with the
medical assessor at the clinical trials unit) of this event immediately.
The CI has an obligation to inform both the MHRA and Main Ethics Committee in writing
within 3 days, in the form of a substantial amendment. The sponsor (JRO) must be sent a
copy of the correspondence with regards to this matter.
7.5 Annual Safety Reporting
The Annual Safety Reports (ASR) will be sent by the CI to the sponsor, the MREC and
MHRA (the date of the anniversary is the date on the “notice of acceptance letter” from the
MHRA) using the sponsor DSUR form template. The CI will carry out a risk benefit analysis
of the IMPs encompassing all events having arisen on the trial.
The CI will send the Annual Progress Report to the main REC using the NRES template (the
anniversary date is the date on the MREC “favourable opinion” letter from the MREC) and to
the sponsor.
7.6 Overview of the Safety Reporting Process/Pharmacovigilance Responsibilities
The CI/PI has the overall Pharmacovigilance oversight responsibility. The CI/PI has a duty to
ensure that Pharmacovigilance monitoring and reporting is conducted in accordance with the
sponsor’s requirements.
7.8    Pregnancy
Identification of
SAE/SUSAR by member
of the study team
Fax to Trial Office
Professor Foster to fax
report to sponsor (within
24 hours) and Janssen
UK
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If a patient becomes pregnant whilst involved in this trial, it is not considered to be an SAE or
an AE. However, it is an event that requires monitoring and follow up. If a patient, or his
partner, becomes pregnant whilst enrolled in this study and whilst taking medication or within
24 weeks of discontinuing medication immediate reporting to the sponsor is required (within
one working day of the PI/CI becoming aware of the event) using a JRO pregnancy template
form. The CI/PI has the responsibility to ensure that the pregnancy form is completed and
sent to the sponsor within the agreed timelines. Patients who become pregnant whilst
enrolled in this study will be prematurely withdrawn from the study.
The PI/CI will follow up the pregnancy until delivery (or termination) as well as monitoring the
development of the newborn for 6 months after birth. Any events that occur during this time
that could be considered to be a SAE must be reported to the sponsor in line with section
7.4.1, utilising the sponsor SAE reporting form.
8. Statistical Considerations
8.1 Primary Endpoint Efficacy Analysis
The proportion of patients receiving telaprevir who achieve a sustained virological response
at 12 weeks post end of treatment.
8.2    Secondary Endpoint Efficacy Analysis
The proportion of patients receiving telaprevir who are phenotypically ‘telaprevir sensitive’ and
who achieve an SVR.
The proportion of patients receiving telaprevir who are phenotypically ‘telaprevir insensitive’
and who achieve an SVR.
The proportion of patients who are phenotypically poor responsive to telaprevir who achieve
early and late virological response.
8.3    Sample Size
This is a pilot study designed to test the hypothesis that patients with telaprevir sensitivity
may achieve a sustained virological response when treated with telaprevir plus pegylated
interferon and ribavirin. We estimate that overall 20% of patients will respond (90% CI of 8 –
32%) and we estimate that 30% of patients (10) will show pre-treatment viral sensitivity to
telaprevir. We speculate that 60% of these patients (CI – 35-85%) will respond compared to
10% (0-20%) in those who are insensitive to telaprevir. The trial is therefore appropriately
powered to detect a difference in response between telaprevir ‘sensitive’ and telaprevir
‘insensitive’ patients.
8.5    Statistical Analysis
Non transformed data will be analysed using a Chi square analysis. Additional post-hoc
analysis may be carried out if appropriate following the initial analysis.
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9. Data Handling & Record Keeping
9.1 Confidentiality
The Principal Investigator at each site has a responsibility to ensure that participant
anonymity is protected and maintained. They must also ensure that their identities are
protected from any unauthorised parties. Information with regards to study participants will
be kept confidential and managed in accordance with the Data Protection Act, NHS Caldicott
Guardian, The Research Governance Framework for Health and Social Care and Research
Ethics Committee Approval. The confidentiality of records that could identify participants
must be protected, respecting the privacy and confidentiality rules in accordance with the
applicable regulatory requirement(s).
The study will use participant initials and participant number to refer to participant on all
study related documentation. These pseudo-anonymised details will also be used for study
correspondence with third parties (central labs, sponsor and study funder).
A main participant ID log will be kept in the Investigator Site File that can be located by the
Principal Investigator and study team only at that site only it will be packaged and delivered
by B&C to each site according to contract.  .
The Chief Investigator is the ‘Custodian’ of the data. Subjects have the right to revoke their
authorisation for the use of their private health information. The patients will be anonymised
with regards to any future publications relating to this study.
This study is subject to audit as part of the Sponsor SOPs and policies. In addition regulatory
authorities, the REC and/or the Funder Janssen UK may request access to all source
documents, data capture records, informed consent forms, and other study documentation
for on-site audit or inspection. The patient consent form includes information that this will
happen and patients are asked to give to coesent for these 3rd parties to have supervised
access to their patient identifiable data. This should only be access for the purposes of audit
and inspection and cannot be copied or removed from the study site.
9.2 Study Documents
All essential documents and study approved documents must be in place before each site is
fully initiated and given the green light to recruit.
9.3   Case Report Form
Data will be entered to an electronic CRF (eCRF) which will be designed and managed by
the study management team. The eCRF is on a system which has been commissioned by
the Chief Investigators site. It will be hosted on a secure server managed by Cerner. The
eCRF will be pseudo-anonymised with the identification list held by each study site team.
This will not be accessed by the sponsor.
Data reported on the CRF, will be derived from source documents as outlined in study
specific SOPs. The data must be consistent with the source documents or the discrepancies
must be explained.
The source must be completed legibly in ink. Participants are to be identified by initials, birth
date and participant number, if applicable. All requested information must be collected on
source and entered into the eCRF in the spaces provided. If an item is not available or is not
applicable, it must be documented as such; do not leave a space blank. The completed
source documents must be promptly reviewed, signed, and dated by a qualified physician
who is an Investigator or Sub-investigator.
244
The Investigator will maintain a Signature Sheet to document signatures and initials of all
persons authorized to make entries and/or corrections on the eCRFs.
9.4 Record Retention and Archiving
The records are kept for a further 20 years. The main trial files and sponsor records for this
study will be archived according to sponsor SOPs. Patient data and site data will be archived
according to local site policies. Sponsor should be provided with details of this archiving
policy and address of where the records will be stored.
9.5    Compliance
The CI will ensure that the trial is conducted in compliance with the principles of the
Declaration of Helsinki (1996), and in accordance with all applicable regulatory requirements
including but not limited to the Research Governance Framework, Trust and Research Office
policies and procedures and any subsequent amendments.
9.6 Clinical Governance Issues
This protocol and any subsequent amendments, along with any accompanying material
provided to the patient in addition to any advertising material will be submitted by the
Investigator to an Independent Research Ethics Committee. Written Approval from the
Committee must be obtained and subsequently submitted to the JRMO to obtain Final R&D
approval.
9.6.1       Ethical Considerations
The study involves a population of patients who are not normally considered eligible for
treatment with interferon and ribavirin containing regimes – specifically patients with low
haemoglobin levels, low neutrophil counts and low platelet counts will be included. This is
because current ‘standard of care’ therapy for patients with genotype 3 HCV (Pegylated
interferon and ribavirin) leads to a sustained virological response in >80% in patients with
early disease. However in patients with cirrhosis (invariably associated with low
haemoglobins, low platelet counts and low neutrophil counts) the response is much reduced
(<50%). Hence there is an unmet medical need for treatments for patients with cirrhosis and
associated cytopaenias. This study is specifically aiming to investigate this unmet need.
This study is predicting a high rate of non-responders to treatment (60%). To avoid
unnecessary exposure to therapy that has a low probability of success the following pre-
defined ‘stopping rules’ will apply and patient will be defined as a non-responder to therapy.
 If the viral load after 4 weeks of therapy with PegIFN, Ribavirin and telaprevir is
>1000 IU/ml, therapy will be abandoned and the patient will be deemed a non-
responder to therapy.
 If the viral load at week 8 is greater than 1000 IU/ml
 If the viral load has not declined by more than 3 logs from the pre-treatment viral load
by week 8.
 If return of viraemia during the study after a period when HCV RNA is undetectable.
The study schedule and treatment regime are in line with current clinical practice for the
administration of interferon, ribavirin and telaprevir. Other than the blood tests for the
endpoint analysis patients are not being asked to take part in an additional assessments
from what the Chief Investigator feels is good clinical practice with these treatment.
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This protocol and any subsequent amendments, along with any accompanying material
provided to the patient in addition to any advertising material will be submitted by the
Investigator to an Independent Research Ethics Committee. Written Approval from the
Committee must be obtained and subsequently submitted to the JRO to obtain Final R&D
approval.
9.7    Quality Control and Quality Assurance
9.7.1       Summary Monitoring Plan
This Study will be monitored as per sponsors SOPs and study specific monitoring plan which
is outlined in a separate document.
In summary on site visits will be used to ensure safety of Patients, Integrity of data and
compliance with the Protocol and regulations.
9.7.2      Audit and Inspection
This study is subject to audit as part of the Sponsor SOPs and policies. In addition regulatory
authorities, the REC and/or the Funder Janssen UK may request access to all source
documents, data capture records, informed consent forms, and other study documentation for
on-site audit or inspection. Direct access to these documents must be guaranteed by the
investigator, who must provide support at all times for these activities. In addition the study
may be audited as part of the Sites Quality Management requirements.
9.8    Breaches in GCP or the Trial Protocol
The study shall be conducted as described in this protocol. All revisions to the protocol must
be discussed with, and be prepared by, the Chief Investigator. The Investigator should not
implement any deviation or change to the protocol without prior review and documented
approval/favorable opinion from the REC of an Amendment, except where necessary to
eliminate an immediate hazard(s) to study participants. Any significant deviation must be
documented in the CRF.
The sponsor of the Clinical Trial is responsible for notifying the licensing authority in writing
of any serious breach of:
 The conditions and principles of GCP in connection with that trial; or
 The protocol relating to the trial, as amended from time to time in accordance with
regulations 22 to 25, within 7 days of becoming aware of that breach.
For the purposes of this regulation, a ‘serious breach’, is a breach which is likely to effect to
a significant degree:
 The safety or physical or mental integrity of the subjects of the trials; or
 The scientific value of the trial.
The CI is responsible for reporting any serious breaches to the sponsor (JRO) within 24
hours. The sponsor will notify and report to the MHRA within 7 working days of becoming
aware of the serious breach.
A deviation or change to a protocol may be implemented for urgent safety measures prior to
obtaining REC approval/favorable opinion, as soon as possible the deviation or change will
be submitted to:
 REC for review and approval/favorable opinion;
 Regulatory Authorities, if required by local regulations.
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 Documentation of approval signed by the chairperson or designee of the
IRB(s)/IEC(s) must be sent to the Sponsor and Chief Investigator
 If the revision is an Administrative Letter, Investigators must inform their
IRB(s)/IEC(s).
10.    Trial Committees
The trial will be managed by a Trial Steering committee consisting Principal
Investigators taking part in the study, the study management team and 2 independent
medical peers. The committee will review the safety data and trial progress and will have
the authority to terminate the study if they believe that its continuation poses unacceptable
risks to patients. The committee will have a charter agreed by sponsor, CI and committee
members. This charter outlines the roles and responsibilities of the committee, frequency of
meetings, the documentation and dissemination of the meeting records and any decisions
made.
11.    Publication Policy
All publications from the study will be published with joint authorship which will include all
members of the study teams at the multiple sites. No member of the study team may publish
any data from the study without the express consent of the management committee and any
publications will be co-authored by all members of the study teams.
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